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Follicular lymphoma is a common B cell malignancy which usually follows an indolent course but it is 
a heterogeneous disease and there are no biomarkers that can accurately predict outcome or 
prognosis at the time of diagnosis. There is now clear evidence that the microenvironment plays an 
important role in the pathogenesis of this disease and the composition of the microenvironment has 
been linked to prognosis with variable results. The biological basis for the influence of the 
microenvironment and the contribution of individual cell types remain unclear. In this research we 
focus on CD4+ T cell subsets, in particular T follicular helper cells and characterise their number, 
phenotype and distribution in follicular lymphoma with comparisons to normal germinal centres in 
reactive lymph nodes. We also investigate if T follicular helper cells have a role in promoting B cell 
proliferation, and induction of AID, whether B and T cells form immunological synapses in follicular 
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Chapter 1 Introduction 
1.1 Follicular Lymphoma 
1.1.1 Introduction to follicular lymphoma 
Follicular lymphoma (FL) is the second commonest subtype of non-Hodgkin lymphoma (NHL) 
worldwide accounting for approximately 20% of all lymphoma diagnoses (Harris, Swerdlow et al. 2008) 
with an annual incidence of approximately 1800 new cases in the UK per year (Haematological 
Malignancy Research Network 2014). FL is a neoplasm of germinal centre (GC) B-cells typically 
characterised by the presence of the chromosomal translocation t(14;18)(q32;q21) which leads to 
deregulation of the proto-ongogene BCL-2 (Rowley 1988, Harris, Swerdlow et al. 2008). The disease is 
described as indolent but it is has a highly variable course; whilst some patients never require 
treatment, rapid progression and the development of refractory disease or histological transformation 
are all also well recognised and it is difficult to predict outcome or prognosis at the time of diagnosis 
(Smith 2013). Despite improvements in treatment over recent years, FL remains a largely incurable 
malignancy. It is increasingly apparent that the driving force for the survival and proliferation of the 
malignant B cells in FL is not limited to intrinsic events within the tumour cells but is also dependent 
on signals from, and interactions with non-malignant cells infiltrating the tumour microenvironment.  
It is hoped that better understanding of the role of the microenvironment in the pathogenesis of FL 
will lead to better prognostic markers and ultimately, new targets for therapy. 
1.1.2 Pathology, immunophenotype, and cytogenetics of follicular lymphoma 
FL is a malignancy of GC B cells, it predominantly affects the lymph nodes but the spleen, bone 
marrow, peripheral blood and other extra-nodal sites can also be involved. The lymph node 
architecture is typically effaced by enlarged follicles which resemble normal GCs although, in contrast 
to GCs, the mantle zones are reduced or absent, and the demarcation between highly proliferative 
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dark zones containing many centroblasts and less proliferative light zones composed mainly of 
centrocytes is lost and there are fewer tingible body macrophages in FL than in normal GCs (Harris, 
Swerdlow et al. 2008, Leich, Ott et al. 2011, Kridel, Sehn et al. 2012, Victora and Nussenzweig 2012).  
The number of centroblasts – large round cells with prominent nucleoli - counted per high power field 
(x40 objective) within follicles forms the basis of the histological grading of FL in the World Health 
Organisation (WHO) classification of tumours of haematopoietic and lymphoid tissues (Table 1-1) 
(Harris, Swerdlow et al. 2008). Grades 1-2 are considered the same in terms of clinical outcome and 
are treated identically; accordingly there is no distinction between grade 1 and 2 disease in the current 
classification system. Grade 3 FL is separated into grade 3a and grade 3b, in grade 3b FL the FDC 
network is absent and there are solid sheets of centroblasts with no centrocytes present, whereas in 
grade 3a disease, the FDC networks are disrupted and occasional centrocytes are retained. Clinical 
evidence suggests that the outcome of grade 3a FL is similar to that of grade 1-2 disease and it is 
managed in the same way (Wahlin, Yri et al. 2012). Grade 3b FL, however, has an aggressive course 
analogous to DLBCL and is clinically treated as such (Salaverria and Siebert 2011). 80-90% of all cases 
of FL are grade 1-2. The bone marrow is involved in approximately 50% of patients and the pattern of 
infiltration is characteristically paratrabecular (Solal-Celigny, Roy et al. 2004).  
Table 1-1 World Health Organisation Grading of Follicular Lymphoma 
Grading Definition 
Grade 1-2 (low grade)* 
- Grade 1 
- Grade 2 
0-15 centroblasts per hpf 
- 0-5 centroblasts per hpf 
- 6-15 centroblasts per hpf 
Grade 3  
- Grade 3a 
- Grade 3b 
>15 centroblasts per hpf 
- Centrocytes present 
- Solid sheets of centroblasts 
*Grade 1 and 2 usually reported as “Grade 1-2” 
If diffuse areas containing >15 centroblasts per HPF are present, the diagnosis is reported as DLBCL 
with follicular lymphoma.  




The malignant B-cells express the B-cell antigens CD19, CD20, CD22, and CD79a and surface 
immunoglobulin is usually present, typically IgM. The immunoglobulin heavy chain variable genes 
(IgVH) show ongoing somatic hypermutation reflecting the GC origin of the malignant cells (Leich, Ott 
et al. 2011). BCL-2 (as a result of the t(14:18) translocation), BCL-6, and CD10 are usually positive. CD5, 
which is aberrantly expressed on the surface of CLL and mantle cell lymphoma B cells, is not expressed 
in FL. Of note, BCL-2 is not expressed in the B-cells of normal GCs.  The expression of CD10 is variable; 
expression is stronger in the malignant cells of the follicles than the interfollicular, bone marrow, or 
peripheral blood malignant cells, similarly, BCL-6 is often low in interfollicular malignant cells (Harris, 
Swerdlow et al. 2008). Follicular dendritic cells (FDCs) forming meshworks within the follicles can be 
identified by CD21 or CD23 staining which highlights the follicular structure (Harris, Swerdlow et al. 
2008, Kridel, Sehn et al. 2012). The proliferation index, measured by Ki67 staining reflects the 
histological grade and is typically <20% in grade I-2 FL and >20% in grade 3 disease (Samols, Smith et 
al. 2013, Kedmi, Hedvat et al. 2014).   
The characteristic cytogenetic abnormality in FL is the chromosomal translocation t(14;18) resulting 
in over-expression of the anti-apoptotic proto-oncogene, BCL-2 (B-cell lymphoma-2) by bringing it into 
proximity with the immunoglobulin heavy chain gene on chromosome 14. BCL-2 is over-expressed in 
approximately 80-90% of grade 1-2 FL but is less commonly identified in grade 3 disease where other 
translocations are more often found (Harris, Swerdlow et al. 2008, Leich, Ott et al. 2011). There is 
considerable variation in the reported incidence of BCL-2 negative FL. The difference in reported rates 
of BCL-2 negativity is in part explained by different mutations in the BCL-2 gene leading to loss of the 
epitopes to which the most commonly used immunohistochemistry BCL-2 antibodies react, and when 
antibodies to alternative epitopes are used, expression can be identified in 20% of cases that were 
negative with the first antibody (Marafioti, Copie-Bergman et al. 2013).  Nevertheless, there remains 
a small proportion of FL cases in which BCL-2 is not over expressed as there is no translocation 
involving this gene. Fluorescence in-situ hybridisation (FISH) can be used to confirm t(14;18) status 
although this is not routinely performed in most cases. In some BCL-2 negative cases, 3q27 BCL-6 
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translocations can instead be identified (Marafioti, Copie-Bergman et al. 2013). Further genetic events 
that have been identified in FL include mutations in the epigenetic modifiers EZH2, CREBBP and MLL2, 
loss of function mutations in TNFRSF14, and mutations in the apoptosis regulator FAS (Kridel, Sehn et 
al. 2012, Shaffer, Young et al. 2012).  
1.1.3 Pathogenesis of follicular lymphoma 
The malignant cells of FL are B cells that form follicles resembling GCs, express the GC markers CD10 
and BCL-6, have somatically mutated immunoglobulin variable genes and a gene expression profile of 
centrocytes or centroblasts. Taken together, these findings demonstrate that FL arises through the 
malignant transformation of GC-derived B cells (Kuppers 2005, Kridel, Sehn et al. 2012, Shaffer, Young 
et al. 2012).   
The translocation t(14;18) leads to deregulated, constitutive expression of BCL-2 which gives a strong 
anti-apoptotic signal to the B cells so promoting their survival. This occurs as a result of defective RAG-
mediated VDJ recombination leading to a double stranded break at the immunoglobulin heavy chain 
gene (IGH) on chromosome 14 and a break in the BCL-2 locus on chromosome 18. Given that VDJ 
recombination occurs early in normal B cell development in the bone marrow, it is thought that this 
first step in the development of FL occurs at an early phase of naïve B cell development in the bone 
marrow (Kuppers 2005, Kridel, Sehn et al. 2012). It is proposed that naïve B cells carrying the t(14;18) 
translocation and therefore over-expressing BCL-2, leave the bone marrow and migrate to secondary 
lymphoid organs where they are able to undergo the GC reaction in the same way as normal B cells. 
Normal GC B cells do not express BCL-2, and die by apoptosis if their B cell receptor (BCR) is non-
functional. B cells with t(14;18) fail to undergo apoptosis and therefore have a survival advantage over 
normal B cells (Roulland, Faroudi et al. 2011).  
Although the t(14;18) translocation leads to failure of apoptosis of B-cells, there is evidence that this 
alone is not sufficient to lead to the development of FL. Firstly, circulating peripheral blood 
mononuclear cells (PBMCs) carrying the t(14;18) translocation with the same breakpoints as seen in 
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FL can be identified in healthy individuals who have no evidence of FL (Limpens, Stad et al. 1995, 
Schuler, Dolken et al. 2009, Roulland, Kelly et al. 2014). The reported incidence is between 50% and 
70% of normal populations with the translocation identified by PCR in approximately 1 in 105 
circulating PBMCs, the frequency of this increases with age (Rabkin, Hirt et al. 2008, Schuler, Dolken 
et al. 2009, Hirt, Weitmann et al. 2013). Evidence from transgenic mouse models also indicates that 
the t(14;18) translocation is insufficient to cause FL. In mice with the IgH-BLC-2 fusion onco-gene, B 
cell expansion and lymphoid hyperplasia were seen, but overt FL did not develop. Some mice did 
however develop high grade NHL but additional cytogenetic abnormalities such as c-myc 
translocations were identified in these mice, suggesting  that a second ‘hit’ after t(14:18) is required 
for the development of lymphoma (McDonnell and Korsmeyer 1991). Further evidence that the 
t(14;18) translocation is in itself insufficient to lead to the development of FL comes from the 
observation that over-expression of BCL-2 cannot be identified in some cases of FL, even when 
different antibodies and FISH studies are used, see section 1.1.2 above.  
Until recently, an increased pre-disposition to FL was not described in healthy individuals with 
circulating t(14;18) cells but a recent study involving 520,000 healthy subjects revealed that people 
with a high frequency of circulating t(14;18) cells (greater than 1 in 104) had a 23-fold increased risk 
of subsequently developing FL, sometimes many years later (Roulland, Kelly et al. 2014). The other 
key observation that emerged from this important study is that the same IGH-BCL-2 break points were 
present in the original peripheral blood samples of circulating t(14;18) cells and the tumour biopsies 
of individuals who subsequently developed FL many years later, so indicating the presence of a 
‘founder clone’ of pre-malignant B cells. The clinical significance of this finding is not yet known and 
screening for people carrying t(14;18) is neither practical or desirable at present, but these findings 
clearly support the notion that the t(14;18) translocation is an early step in the complex pathogenesis 
of FL but that further events or influences are required for the disease to develop. 
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It has recently been demonstrated that normal B cells undergo multiple cycles of entry and egress to 
and from GCs (Victora and Nussenzweig 2012). This has led to the suggestion that circulating t(14;18) 
cells similarly undergo multiple GC cycles and it is during these repeated cycles that they acquire 
further genetic alterations and mutations leading to the development of FL under the influence of 
activation induced cytidine deaminase (AID), the enzyme required for class switch recombination and 
somatic hypermutation (Roulland, Sungalee et al. 2013, Sungalee, Mamessier et al. 2014). AID has 
previously been shown in a mouse model to be important for the development of GC derived 
lymphomas and has also been implicated in the transformation of FL to high grade disease  indicating 
that it plays an important role in disease development (Pasqualucci, Bhagat et al. 2008, Pasqualucci, 
Khiabanian et al. 2014).  See section 1.2 below.  
The pathophysiology of histological transformation is poorly understood but is likely to involve genetic 
and epi-genetic events as well as involvement of the microenvironment. In many cases, 
transformation involves the accumulation of additional cytogenetic mutations through clonal 
evolution. Additional mutations in transformed disease typically involve cell cycle regulation or DNA 
damage responses and include upregulation of MYC, mutation of TP53, genetic or epigenetic 
inactivation of the CDKN2A/p16 tumour suppressor gene, or additional translocations involving BCL-6  
(Pasqualucci, Khiabanian et al. 2014). There is also evidence to support a role for the 
microenvironment in inducing transformation, for example, a predominantly follicular location of 
FOXP3+ T regulatory cells has been identified as a risk factor for the development of transformed 
disease in one study (Farinha, Al-Tourah et al. 2010). Furthermore, aberrant somatic hypermutation, 
mediated by AID has been implicated in some cases of transformation (Pasqualucci, Khiabanian et al. 
2014).  
As with some other forms of lymphoma e.g. mucosa associated lymphoid tissue (MALT) lymphomas, 
there is indirect evidence that chronic infection may play a role in the development of FL. The evidence 
for antigenic activation includes the identification of auto-reactive BCRs in some patients with FL, 
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somatic hypermutation with a pattern consistent with antigenic selection, and the generation of 
carbohydrate-linking motifs (Coelho, Krysov et al. 2010, Ame-Thomas and Tarte 2014).     
There is now a large body of evidence that supports the hypothesis that the tumour microenvironment 
has an important role in the pathophysiology of FL. This is discussed in detail in section 1.6 below.  
1.1.4 Epidemiology  
The median age at time of diagnosis of FL is 64 years and it is rare in childhood, it has an approximately 
equal sex distribution (Harris, Swerdlow et al. 2008). There is considerable geographical variation in 
incidence; in Europe and North America, FL is the 2nd commonest lymphoma after DLBCL but in Asia 
the incidence is up to 10 times lower. There are approximately 1800 new cases per year (or 3.1 per 
100,000 population) in the UK (Haematological Malignancy Research Network 2014). The long natural 
history of the disease, and increasing survival give rise to a high prevalence which is likely to increase 
further as outcomes continue to improve and as the population ages (Sant, Minicozzi et al. 2014).  
1.1.5 Clinical features 
FL is often described as ‘indolent’, or ‘low-grade’. This reflects the slow rate of progression observed 
in the majority of cases and the fact that some patients do not require treatment for many years after 
diagnosis. It is known from studies of untreated asymptomatic patients that up to 19% of patients with 
asymptomatic advanced stage disease never require therapy and spontaneous remissions in 
untreated patients are also well recognised (Horning and Rosenberg 1984, Ardeshna, Smith et al. 
2003). However, the indolent label can be misleading as the disease progresses rapidly in some 
patients and it belies the fact that, for most patients, FL is an incurable condition characterised by 
responses to initial therapy but with inevitable relapses. Both the response rate and length of 
remissions are observed to decline with subsequent lines of therapy and in many cases the disease 
ultimately becomes refractory to further therapy or transforms to high grade disease (Johnson, 
Rohatiner et al. 1995).  
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Presentation of FL is most commonly with lymphadenopathy which may be asymptomatic or may 
cause local symptoms or rarely (compared to high grade disease) organ compromise. In the largest 
retrospective review of patients which included 4167 patients enrolled in clinical trials, 78% had 
advanced stage, 22% early stage, 19% had constitutional ‘B’ symptoms (weight loss, night sweats or 
fever), 52% had bone marrow involvement, and 38% had areas of extranodal disease (other than bone 
marrow) (Solal-Celigny, Roy et al. 2004). These clinical characteristics were broadly verified in a 
prospective review of 942 patients (Federico, Bellei et al. 2009). It should be noted that these 
characteristics are not wholly representative of all patients presenting with FL as they only included 
patients who required active treatment and were enrolled in clinical trials.  
There is an associated risk of transformation to high grade lymphoma, most commonly DLBCL but 
occasionally Burkitt Lymphoma. The risk is approximately 3% per year or 15-28% at 10 years (Montoto, 
Davies et al. 2007). There is considerable variation in the reported rates of transformation in part due 
to differences in the definition of transformation (whether histologically confirmed or clinically 
suspected) and variations in clinical practice with regard to performing biopsies to histologically verify 
transformation. Transformation has a very poor prognosis with a median time from histological 
transformation to death of 1.2 years in one retrospective study although the outcome for patients 
treated with contemporary immunochemotherapy is likely to be better than this (Montoto, Davies et 
al. 2007).  
1.1.6 Clinical staging and baseline investigations 
FL is clinically staged according to the Ann Arbor staging system which was originally devised for the 
staging of Hodgkin Lymphoma (Lister, Crowther et al. 1989). Stage is determined by the number and 
distribution of involved lymph nodes, the involvement of extranodal sites of disease and the presence 
or absence of a number of modifying factors (Table 1-2). Stage I-IIA is early stage disease while IIB-IV is 
classified as advanced stage.  Approximately 80-90% of patients present with advance stage disease; 
accordingly, early stage disease is infrequently seen.  
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Accurate staging is of vital importance for prognostication and also for planning treatment, especially 
for determining whether patients with apparent early stage disease are truly early stage, or whether 
there are any distant lymph nodes or extranodal sites of disease that would lead to upstaging. Staging 
routinely involves bone marrow biopsy and cross-sectional imaging of the neck, chest, abdomen, and 
pelvis. Functional imaging by [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) is 
increasingly being used, especially in the staging of early stage disease where it has been shown to up-
stage (i.e. identify advanced stage disease) 18-30% of patients (Meignan, Barrington et al. 2014). 
Table 1-2 The Ann Arbor Staging system for Lymphoma 
Stage Definition 
I Involvement of one lymph node region only 
II Involvement of 2 or more lymph node regions on the same side of the diaphragm 
III Involvement of lymph node regions on both sides of the diaphragm 
IV Extranodal involvement beyond that indicated by the subscript ‘E’ 
Subscripts/modifying factors: 
A Absence of ‘B’ symptoms 
B ‘B’ symptoms present (weight loss of >10% body weight over 6 months, fever >380C, or 
night sweats) 
E Direct extranodal spread from an adjacent lymph node that is limited in extent 
X Disease bulk (>10cm in maximal diameter, or mediastinal mass >1/3 thoracic diameter) 
 
1.1.7 Predicting prognosis in FL 
Determining prognosis in FL is currently based on a number of clinical and laboratory parameters. The 
most commonly used scoring system is the Follicular Lymphoma International Prognostic Index (FLIPI) 
which incorporates age (>60 vs. ≤60 years), stage (III-IV vs. I-II), number of involved nodal groups (>4 
vs. ≤4), anaemia (Haemoglobin <120g/l vs. ≥120g/l), and serum LDH (>upper limit of normal vs. ≤ upper 
limit of normal range), see Table 1-3, and Figure 1-1. The FLIPI score was developed from retrospective 
analysis of data and uses overall survival (OS) as its end point. Patients are divided into 3 risk groups, 
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low risk (FLIPI 0-1) with 10 year OS of 71%, intermediate risk (FLIPI 2) with 10 year OS 51%, and high 
risk (FLIPI 3-5) with 10 year OS 36% (Solal-Celigny, Roy et al. 2004). Despite a number of drawbacks, 
including the fact that the FLIPI score was developed from retrospective data from patients treated 
before the introduction of rituximab, it remains the most widely used prognostic tool and is useful in 
clinical trials for describing the distribution of high risk and low risk patients in the population, and 
therefore allowing comparison of trials in this heterogeneous disease.  
Table 1-3 Overall survival by group defined by the follicular lymphoma international prognostic index (FLIPI).  
FLIPI Score Risk Group  Proportion of 
patients (%) 
5 year overall 
survival (%)  
10 year overall 
survival (5%) 
0-1 Low 36 90.6 70.7 
2 Intermediate 37 77.6 50.9 
3-5 High 27 52.5 35.5 
 
 
Figure 1-1 Diagram detailing the number of nodal areas used to calculate the FLIPI score (Figure reproduced 
from Solal-Celigny, Roy et al. 2004). 
An updated prognostic score, The FLIPI 2, has been developed prospectively using PFS as the primary 
outcome measure. The FLIPI2 score determines risk according to age (>60 vs. ≤60 years), haemoglobin 
(<120g/l vs. ≥120g/l), bone marrow infiltration (present vs. absent), β2MCG (>upper limit of normal 
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(ULN) vs. ≤ULN), and greatest diameter of largest involved lymph node (>6cm vs. ≤6cm). Patients with 
a FLIPI2 score of 0 are low risk and have a 3-year PFS of 91%, score 1-2 is intermediate risk with a 3-
year PFS of 69%, and score 3-5 is high risk with a 3-year PFS of 51% (Federico, Bellei et al. 2009).  
It is likely that the mutational status of genes implicated in the pathogenesis of FL will be incorporated 
into risk stratification systems in the near future. One such approach that has already been proposed 
is the M7 FLIPI score. In this risk stratification score, the mutational status of 7 genes, 
EZH2, ARID1A, MEF2B, EP300, FOXO1, CREBBP and CARD11 are added to a prognostic model that also 
incorporates the FLIPI score and the patient’s performance status. This has been shown to be highly 
predictive of 5-year failure free survival and overall survival but is not yet in standard clinical practice 
(Pastore, Jurinovic et al. 2015).  
Depth of response to treatment has also been used to provide prognostic information with evidence 
to show that patients achieving a complete remission (CR) to treatment have significantly longer 
duration of response than patients achieving only partial remission (PR) (Marcus, Imrie et al. 2008, 
Bachy, Brice et al. 2010). It is possible that new techniques for determining response including FDG-
PET and determining the level of molecular response by quantifying the burden of circulating t(14;18) 
cells will prove useful in assessing response to treatment and provide prognostic information after 
first line treatment. However such methods would not provide baseline information at the time of 
diagnosis to guide initial management decisions. 
Therefore there is a need for better predictors of prognosis, to date there are few biological 
parameters that are useful in this regard (with the exception of haemoglobin, LDH, and β2MCG which 
are incorporated into the FLIPI and FLIPI2 scores) and it is hoped that better understanding of the 
tumour microenvironment will allow improved identification of good and poor risk groups; factors in 




1.1.8 Current clinical management of FL 
Choosing the optimal management for patients with newly diagnosed FL depends on accurate 
determination of clinical stage and assessing the requirement for active treatment.  
1.1.8.1 Treatment of early stage disease 
Early stage FL represents only about 20% of all new FL diagnoses.  It is important to identify this group 
of patients because the treatment intent and treatment modality are different to advanced stage 
disease; whereas it is anticipated that most treatments in advanced stage FL will not be curative, true 
early stage FL can be cured with radiotherapy alone. The current standard of care for early stage FL is 
24 Gray involved field radiotherapy (Hoskin, Kirkwood et al. 2014, Specht 2014). This approach leads 
to excellent outcomes with 49% PFS at 10 years. If relapse does occur, it typically occurs outside of 
the original radiotherapy field suggesting that the disease was in fact disseminated at time of 
treatment but was not detectable, and it is therefore likely that patients with stage I-II disease 
confirmed by FDG-PET may have better PFS with localised radiotherapy although there is no 
prospective data to support this. Late relapses beyond 10 years are extremely rare in early stage FL 
treated with this approach (Campbell, Voss et al. 2010).  
1.1.8.2 Treatment of advanced stage asymptomatic disease 
For patients with advanced stage disease (stage IIb-IV) who are asymptomatic, there is no proven 
benefit of early initiation of chemotherapy over observation alone (Ardeshna, Smith et al. 2003). A 
period of observation or ‘watchful waiting’ is often employed in asymptomatic patients, withholding 
treatment until such a time as it is required due to progressive disease, increasing symptoms, or falling 
peripheral blood counts. Interestingly, when this approach is followed, 19% of patients never require 
therapy.  
The approach of not treating asymptomatic patients was originally adopted due to the failure of 
treatments to prolong survival and to delay exposure to potentially toxic chemotherapy but, in the 
modern treatment era where survival is improving and treatments are becoming less toxic (leading to 
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fewer treatment-related deaths and secondary malignancies) this paradigm is being challenged. In a 
recent trial, patients with advanced stage, asymptomatic disease were randomised to receive no 
treatment or the anti-CD20 monoclonal antibody, rituximab alone with no cytotoxic chemotherapy. 
This demonstrated, perhaps unsurprisingly, that patients receiving single-agent rituximab had a longer 
time to initiation of next treatment than the observed cohort but longer follow up is required to 
determine the effect of this on response to subsequent therapies, survival, and other long term 
outcome measures (Ardeshna, Qian et al. 2014).  
1.1.8.3 Treatment of symptomatic advanced stage follicular lymphoma 
To determine whether a patient with advanced stage disease needs to start treatment, the GELF 
(Groupe d’Etude des Lymphomes Folliculaires) criteria are widely used. According to these criteria, 
patients with any site of disease >7cm in maximal diameter, ≥3 nodal sites each ≥3cm in diameter, B 
symptoms, splenic enlargement, or cytopenias should be considered for active treatment, whereas 
patients with none of these factors can often be managed with ‘watchful waiting’. These criteria are 
also frequently used as inclusion criteria in clinical trials of induction therapy to ensure that all patients 
have a clinical indication to start treatment.  
Until 2005, there were no advances in the treatment of advanced stage symptomatic FL that improved 
overall survival. In 2005 a trial was published that demonstrated a significant improvement in overall 
survival through the addition of the anti-CD20 monoclonal antibody rituximab to combination 
chemotherapy. Rituximab has subsequently revolutionised the treatment of FL and other CD20 
positive NHLs (Marcus, Imrie et al. 2005).  
Rituximab was first demonstrated to have activity in FL when used as a single-agent in the relapsed or 
refractory setting (Maloney, Grillo-Lopez et al. 1997) and was also found to be highly active as a single 
agent in the front-line setting where 4 x weekly doses of 375mg/m2 gave an overall response rate of 
73% (Colombat, Salles et al. 2001). Subsequent trials assessed the addition of rituximab to existing 
chemotherapy regimens. Marcus et al demonstrated that the addition of rituximab to CVP 
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(cyclophosphamide, vincristine and prednisolone) combination chemotherapy in the first-line 
treatment of advanced stage FL led to significant improvements in all outcome measures assessed 
including longer time to treatment failure (TTF), CR rate, time to progression (TTP), response duration 
and OS. The 4-year OS in the R-CVP arm was 83% compared to 77% in the CVP arm (P = 0.029) and this 
represents a landmark in the treatment of FL, Figure 1-2 (Marcus, Imrie et al. 2005, Marcus, Imrie et 
al. 2008). 
 
Figure 1-2 Outcomes from the CVP versus R-CVP trial. (A) Time to disease progression. (B) Overall survival 
showing improvement in outcome with the addition of rituximab (Marcus, Imrie et al. 2005, Marcus, Imrie et al. 
2008) 
Several further studies have conclusively demonstrated the benefit of adding rituximab to 
chemotherapy with significant improvement in both PFS and OS (Hiddemann, Kneba et al. 2005) 
(Herold, Haas et al. 2007) (Salles, Mounier et al. 2008). The optimal chemotherapy regimen to use in 
conjunction with rituximab has until recently been open to debate with little evidence to suggest the 
superiority of any particular regimen. However, evidence is emerging that treatment with more 
intensive regimens such as R-CHOP delivers better outcomes than R-CVP and there is data from one 
randomised trial suggesting that bendamustine in combination with rituximab (BR) may be superior 
even to CHOP with lower toxicity too. Accordingly, BR has been widely adopted as first line therapy 
although it should be noted that there is little data on BR followed by rituximab maintenance  
(Morschhauser, Seymour et al. 2011) (Federico, Luminari et al. 2011, Rummel, Niederle et al. 2013).  
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As described above, FL is largely incurable with a disease course characterised by recurrent relapses 
and progressively shorter remissions (Johnson, Rohatiner et al. 1995). This has led to searches for 
effective ways of maintaining remission in patients who respond to treatment. Previously, 
maintenance therapy with interferon was found to be partially effective but poorly tolerated and 
difficult to administer (Baldo, Rupolo et al. 2010). Given its proven efficacy in induction and its 
favourable toxicity profile, the role of rituximab as maintenance therapy was investigated. It has now 
been demonstrated that rituximab maintenance is effective at prolonging remissions after initial single 
agent rituximab (Ghielmini, Schmitz et al. 2004, Martinelli, Schmitz et al. 2010), after CVP 
chemotherapy (Hochster, Weller et al. 2009), after rituximab-containing chemotherapy (R-CHOP) in 
the relapsed setting (van Oers, Van Glabbeke et al. 2010), and after rituximab-containing 
chemotherapy in previously untreated patients (Salles, Seymour et al. 2011).  
The landmark trial for rituximab maintenance as part of first line therapy was conducted by the French 
study group GELA (Group d’Etude des Lymphomes de l’Adulte). In the PRIMA study, 1217 previously 
untreated patients with advanced stage FL received 1 of 3 rituximab-containing induction regimens 
with responding patients (1019, 84%) randomised to maintenance rituximab (every 2 months for 2 
years) or observation only. At a median of 36 months follow-up, the rate of progression was 
significantly lower in the maintenance arm, PFS 74.9% vs. 57.6%, HR 0.55 (95% CI 0.44-0.68, p<0.0001) 
Figure 1-3. More patients in the maintenance arm have achieved CR than the observation arm but no 
difference in OS has been identified to date (Salles, Seymour et al. 2011). This trial has led to the 




Figure 1-3 Results of the PRIMA trial. Improvement in PFS with maintenance rituximab versus observation alone 
(Salles, Seymour et al. 2011) 
High dose therapy followed by autologous stem cell transplantation or allogeneic haematopoietic 
stem cell transplant are not typically used in first line therapy but are reserved for relapsing patients 
with aggressive disease who are fit enough (and young enough) to tolerate these intensive treatment 
strategies (Montoto, Corradini et al. 2013).  
1.1.8.4 Novel agents and future treatment strategies 
Attempts to improve on the results achieved with rituximab plus chemotherapy followed by rituximab 
maintenance are ongoing and the aims are twofold; to improve outcome through prolonged PFS and 
to reduce exposure to cytotoxic agents so reducing short and long term toxicity.  
Novel agents that may be added to the rituximab plus chemotherapy backbone include the 
immunomodulatory agent lenalidomide which may have a role in maintenance, and the proteasome 
inhibitor bortezomib although the precise place of these agents in the treatment of patients with 
newly diagnosed FL have not been formally demonstrated at present (Merli, Ferrario et al. 2013, 
Wang, Fowler et al. 2013, Craig, Hanna et al. 2014, Evens, Smith et al. 2014, Tuscano, Dutia et al. 2014). 
There are several new anti CD20 monoclonal antibodies that are being assessed in clinical trials 
including ofatumumab and GA101 (obinutuzumab). Obinutuzumab is a glycoengineered anti CD20 
monocloncal antibody, with a different mechanism of action to rituximab; it induces lower levels of 
complement-dependent cytotoxicity, but greater antibody-dependent cellular cytotoxicity and 
31 
 
phagocytosis, and higher levels of direct B-cell killing. Emerging clinical trial data in low grade NHL and 
CLL appear to demonstrate superior outcomes with obinutuzumab compared to rituximab although 
longer follow up will be required to see whether an early PFS advantage translates into an overall 
survival benefit (Mossner, Brunker et al. 2010, Czuczman, Fayad et al. 2012, Czuczman, Hess et al. 
2012, Radford, Davies et al. 2013, Salles, Morschhauser et al. 2013, Cartron, de Guibert et al. 2014, 
Marcus, Davies et al. 2017).  
Exciting results are being achieved in various B cell malignancies by targeting the downstream 
signalling of the BCR with agents such as the PI3K inhibitor idelalisib or the BTK inhibitor ibrutinib and 
results from early stage clinical trials of these agents in low grade NHL are very promising (Gopal, Kahl 
et al. 2014). Inhibition of BCL-2 with compounds such as the small molecule inhibitor Venetoclax (ABT-
199) also shows great promise (Advani, Buggy et al. 2013, Fowler and Davis 2013, Gopal, Kahl et al. 
2014, Ng and Davids 2014).  
In addition, there are some emerging therapies that directly influence the microenvironment; most 
applicable to this research is the development of anti-PD1 antibodies such as nivolumab, 
pembrolizumab, and pidilizumab. Pidilizumab was shown to have considerable clinical efficacy when 
used in combination with rituximab in patients with relapsed FL perhaps through restoration of the 
anti-tumour immune response (Westin, Chu et al. 2014). However development of this compound has 
recently been halted after it was disclosed that its mechanism of action may after all not be through 
PD-1 inhibition; there is at time of writing uncertainty about this and the implications for the trials 
already performed using this drug in FL are unclear. The response of FL to PD-1 inhibition with 
nivolumab is less marked than in classical Hodgkin Lymphoma (Ansell, Lesokhin et al. 2015).  
It is highly likely that in the near future, treatment for advanced stage FL will comprise of 
immunotherapy (rituximab or another anti-CD20 antibody) and novel, non-chemotherapy agents 
alone or in combination but numerous clinical trials with long follow-up will be required to determine 
the optimal combinations, doses and duration of these agents in induction and maintenance therapy.   
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1.2 The normal germinal centre reaction 
As described in section 1.1.2 above, there are a number of similarities between the physical structure 
of the malignant follicles found within the involved lymph nodes of patients with FL and normal GCs 
in reactive lymph nodes and there is good evidence that FL arises from GC-derived B cells.  
One of the aims of this research is to investigate to what extent the interactions between malignant 
B cells and T cells in the FL microenvironment recapitulate the interactions between normal B and T 
cells in the GC reaction in reactive lymph nodes.  
GCs are the site of VDJ recombination, somatic hypermutation (SHM), class switch recombination 
(CSR), and B cell selection and clonal expansion in response to antigenic stimulation. These are the 
processes by which the human adaptive immune system is able to produce immunoglobulins highly 
specific to an almost infinite number of possible antigens. The diversity generated through these 
mechanisms are far in excess of what would be expected with a relatively limited genome (Victora and 
Nussenzweig 2012). 
In the normal GC reaction, naïve B cells are exposed to antigen by follicular dendritic cells (FDCs) in 
the secondary lymphoid tissue. On engaging antigen via their BCR, the B cells are activated and the 
antigen is internalised before being expressed on the cell surface in conjunction with Major 
Histocompatibility Complex (MHC) class II. GC B cells are critically dependent on specific T cell help for 





Figure 1-4 Schematic representation of key events in the germinal centre reaction. Figure made by W. 
Townsend, adapted from figures in: Victora 2012 and Kuppers 2005. 
1. B cells with the highest affinity for T cells are permitted entry to the GC 
2. B cells not expressing a BCR or with low affinity do not enter the GC and undergo apoptosis 
3. In the dark zone, B cells rapidly proliferate and undergo somatic hypermutation under the influence 
of AID 
4. B cells with low or absent BCR expression undergo apoptosis 
5. Upregulation of the chemokine receptor CXCR5 permits entry to the light zone 
6. B cells interact with antigen presented on the surface of follicular dendritic cells 
7. B cells with low antigen affinity undergo apoptosis 
8. B cells present antigen to a limiting number of CD4+ helper T cells. B cells with the highest antigen 
affinity react preferentially at the expense of B cells with lower affinity in a rate limiting step 
(competitive selection) 
9. B cells not receiving T cell help undergo apoptosis 
10. B cells with high affinity and receiving T cell help have 3 potential fates: 
a. Upregulation of CXCR4 permits re-entry to the dark zone where they undergo further rounds 
of proliferation, mutation and selection 
b. Exit from the GC to a plasma cell fate 
c. Exit from the GC to a memory B cell fate 
 
 Note that these processes in the GC reaction are not linear, some B cells undergo many cycles of 
selection in the light zone and cycling back to the dark zone for further proliferation and mutation 




    
Within the GC, T helper cells with a specific T cell receptor (TCR) engage B cells via their TCR which 
recognises the MHC-linked antigenic peptide on the B cell surface. Interaction of the tumour necrosis 
factor family member CD40 on B-cells with its ligand CD40L expressed on CD4+ T cells provides one of 
the vital co-stimulatory signals that the B cells require. The importance of T cells to the GC reaction 
and therefore to the generation of high affinity antibody in response to antigen is highlighted by the 
observations from mouse models that athymic mice are unable to produce GCs and that blockade of 
CD40-CD40L interaction leads to termination of the GC reaction (Victora and Nussenzweig 2012). In 
humans, loss-of-function mutations in CD40 or CD40L lead to failure of GC reactions and low-affinity, 
non-class-switched antibody responses with accompanying high susceptibility to infections (Allen, 
Armitage et al. 1993, Ferrari, Giliani et al. 2001, Victora and Nussenzweig 2012).  
The interaction of antigen-expressing B cells with a specific subset of CD4+ helper T cells, T follicular 
helper cells (TFH) promotes B cell survival, proliferation, SHM, and CSR to generate the high-affinity 
response to the antigenic stimulus.   
Central to the process of generating a repertoire of B cells with a vast range of BCR specificities are 
the processes by which the genes encoding the BCR of naïve B cells in the GC undergo rearrangement. 
The key regions to the genes encoding the BCR are the Variable, Diversity, and Joining regions (V,D, 
and J). Initial diversity of the BCR is generated through the multitude of different combinations of 
these regions under the control of recombination activation genes (RAG), but this leads only to a 
relatively limited repertoire of BCRs, limited by the number of genes encoding each V,D, and J regions. 
Further diversity is generated through somatic hypermutation (SHM) of those B cells with the highest 
affinity after VDJ recombination in a process called affinity maturation. SHM, and class switch 
recombination occur under the influence of the DNA modifying enzyme AID in the dark zone of GCs. 
AID deaminates cytidine residues to uracyl in single strand DNA in the variable region at a very high 
frequency. This unique process leads to the generation of a vast number of different BCRs so that, by 
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chance it is likely that some BCRs with very high affinity for the antigen will be generated, the B cells 
expressing the highest affinity BCRs are then selected to proliferate.  
Because AID leads to breaks in DNA, its’ off-target action has been proposed to lead to mutations in 
genes other than immunoglobulin variable regions or double stranded breaks leading to 
translocations, both of which have been implicated in lymphomagenesis (Pasqualucci, Bhagat et al. 
2008, Nussenzweig and Nussenzweig 2010).   
GCs can be clearly identified on conventional histology of secondary lymphoid tissue and it is possible 
to visually distinguish two discrete zones within the GC on haematoxylin and eosin stained sections; a 
dark zone where B cells undergo rapid proliferation and expansion and a light zone composed mainly 
of non-proliferating centrocytes and antigen-presenting FDCs.  
It is now apparent that GCs are dynamic structures and the GC B cells migrate between the dark and 
light zones, furthermore there is also evidence that the GC T cells are able to migrate both within and 
between GCs (Shulman, Gitlin et al. 2013). In the light zone, they bind antigen and present it together 
with MHC class II to TFH cells (see below). GC B cells with high-affinity BCRs receive help signals from 
TFH cells and migrate from the light zone to the dark zone of the GC where they proliferate and undergo 
SHM and CSR under the influence of AID. After undergoing SHM and CSR, the GC B cells then migrate 
back to the light zone for further interaction with TFH cells, to select those B cells with highest affinity 
BCRs. The B cells with highest affinity BCRs receive further ‘help’ from TFH cells to undergo further 
proliferation, mutation and additional selection to continually ensure that only the highest affinity B 
cells are selected, Figure 1-4.  
Through these repeated rounds of selection, proliferation and mutation under TFH cell help and 
control, a high affinity antibody response is generated (Victora and Nussenzweig 2012, Shulman, Gitlin 
et al. 2013).   
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1.3 T follicular helper cells 
The ability to mount a rapid and effective immune response on exposure to a novel or previously 
identified antigen is pivotal to the human adaptive immune system (Crotty 2014).   
As described above, GCs are essential structures at the centre of the adaptive immune system where 
B cells undergo somatic hypermutation, class switch recombination, selection and ultimately 
proliferation. Central to this process is interaction between B cells and CD4+ T cells, and without T cell 
help, the GC reaction would fail, antibody production would be non-specific and there would be 
heightened susceptibility to infection (Allen, Armitage et al. 1993, Ferrari, Giliani et al. 2001, Victora 
and Nussenzweig 2012, Crotty 2014).     
Follicular helper T cells (TFH) are highly specialised CD4+ T cells usually restricted to the follicles of 
secondary lymphoid tissue, they are essential for providing B cell help and for propagating the GC 
reaction.  
Differentiation of naïve T cells to TFH is dependent on cognate interaction with B cells and there is 
evidence that the quality of this interaction determines differentiation of naïve CD4+ T cells into TFH 
with only those T cells with highest antigen affinity developing into TFH (Fazilleau, Mark et al. 2009). 
The differentiation of naïve T cells remains only partially understood and much remains to be 
elucidated to fully understand this complex process (King 2009, Crotty 2014). 
It is increasingly apparent that the relationship between TFH cells and GC B cells is mutually beneficial; 
without GC B cells presenting antigen in conjunction with MHC class II, naïve T cells would not receive 
signals for differentiation to a TFH phenotype. Likewise, without TFH cell help, GC B cells would not 
survive and proliferate. It has been shown that GC size is correlated with the availability of TFH cell 
help, and the amount of TFH cell help may therefore be a critical rate-limiting step in the GC reaction 
(Rolf, Bell et al. 2010, Victora and Nussenzweig 2012).    
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1.3.1 TFH phenotype 
There is no single antigen or transcription factor that identifies TFH cells, instead they can only be 
identified by the presence or absence of a combination of cell surface proteins and transcription 
factors. They have a complex phenotype and are characterized by very high surface expression of the 
T cell inhibitory protein, programmed cell death 1 (PD1, PDCD1, CD279), the CD28 family member 
ICOS (T-cell inducible costimulatory molecule), the chemokine receptor CXCR5, and the transcription 
factor B cell lymphoma 6 (BCL6). Additionally they express the chemokine CXCL13, and the growth 
factors IL-21 and IL-4.  
The reason for, or cause of the very high level of surface expression of programmed cell death 1 (PD1 
- CD279), an immunoreceptor tyrosine-based inhibitory motif (ITIM) - containing inhibitory molecule 
on TFH cells is not fully understood at present (King 2009). One theory for the high level expression of 
this immunomodulatory protein is that it may regulate and slow the rate of TFH cell proliferation in 
GCs upon TCR signalling (Crotty 2014). T cells within the GC are constantly exposed to antigen and 
would ordinarily proliferate on TCR activation but since one of the primary functions of GCs is to 
promote B cells to rapidly proliferate, the TFH cells present within the GCs may express high levels of 
PD1 to slow their own rate of proliferation. Without PD1 expression, TFH cells would potentially 
proliferate uncontrollably which could have a detrimental effect on the ability to mount an effective 
adaptive immune response to antigen challenge (Crotty 2014).  
PD1 expression is not unique to TFH cells and has previously been suggested to be a marker of 
exhausted T cells; whilst this appears to be the case for cytotoxic T cells, it remains unclear if the same 
is true for CD4+ T helper cells (Haynes, Allen et al. 2007).  
The chemokine receptor CXCR5 is also highly expressed by TFH cells which, together with their lack of 
chemokine receptor 7 (CCR7) expression – the main chemotactic receptor for the T cell zone - 
facilitates their egress from the T cell rich zone of the lymph node and permits their entry into the 
CXCL13-rich B cell follicles and GCs along a CXCL13 gradient (King 2009). CXCR5 expression is not 
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limited to TFH cells, it is expressed by many cells within the GC and so is not helpful on its own for 
defining this cellular subset within a GC. Unlike other subsets in which CXCR5 is only transiently 
expressed, TFH cells maintain a persistently high level of CXCR5 expression (King 2009).  
Expression of the T cell co-stimulatory molecule ICOS is essential for TFH cell differentiation. Upon 
ligation with ICOS-ligand which is highly expressed on GC B cells, naïve T cells receive further signals 
to differentiate to TFH cells. Signalling through ICOS is also required for TFH cell survival and, in its 
absence in ICOS-/- mice, GC formation is grossly diminished (Fazilleau, Mark et al. 2009, Nutt and 
Tarlinton 2011, Linterman, Liston et al. 2012). Continued signalling through ICOS may be essential for 
perpetuating BCL6 expression and therefore maintaining the TFH phenotype and function (Kroenke, 
Eto et al. 2012, Crotty 2014). It has also been demonstrated that ICOS-mediated PI3 kinase signalling 
is a vital step in regulating the number of TFH cells and their production of cytokines (Gigoux, Shang et 
al. 2009, Rolf, Bell et al. 2010).  
1.3.2 TFH differentiation 
A further key feature of TFH cells is their expression of the repressive transcription factor BCL6 which 
has been shown to be essential for TFH differentiation (Johnston, Poholek et al. 2009, Crotty 2014). It 
is interesting to note that whilst it appears that TFH cells and GC B cells have an absolute requirement 
for each other to survive, they share a common transcription factor in BCL6.   
T helper cell differentiation is determined largely by the expression of transcription factors with each 
T helper lineage having a ‘master controller’ or lineage specific transcriptional factor programme. For 
example expression of the forkhead box protein 3 transcription factor (FOXP3) leads to differentiation 
to a T regulatory cell phenotype and function, GATA-binding protein 3 (GATA3) expression leads to a 
TH2 phenotype, T-bet (TBX21) leads to TH1 differentiation, and retinoic acid receptor - RORƳt leads to 
TH17 differentiation. Rather than being a definitive, ‘one-way’ process, T helper cell differentiation is 
now increasingly thought of as a ‘plastic’ process reliant on the continued expression of transcription 
39 
 
factors and other proteins but changes in expression of these may lead to a change in phenotype, 
function and lineage (King 2009).  
TFH cell differentiation is dependent on the transcription factor BCL6. BCL6 is also present in GC B cells 
in secondary lymphoid tissue as well as in GC-derived B cell lymphomas such as FL and many cases of 
DLBCL. BCL6 expression in TFH cells is thought to lead to suppression of other transcription factors such 
as RORƳt, T-bet, and Blimp-1 preventing differentiation to TH2 and TH17 and other T helper cell fates 
whilst also promoting the development of TFH characteristics such as CXCR5 expression (Johnston, 
Poholek et al. 2009, King 2009). MAF is another transcription factor which, together with BCL6 is 
essential for TFH differentiation (King 2009, Kroenke, Eto et al. 2012).    
1.3.3 TFH cell function 
As described above in section 1.2 on the normal GC reaction, TFH cells are absolutely essential for GCs 
to develop and function. They supply the essential signals required for the survival and proliferation 
of GC B-cells and may trigger expression of AID, which initiates somatic hypermutation (SHM) and 
class switch recombination (CSR) leading to the development of a class-switched, high affinity 
antibody response.  
TFH are able to regulate GC size, limit the ability of B cells with low affinity BCRs from entering the GC, 
and stimulate the survival and proliferation of GC B cells with the highest affinity BCRs and highest 
amount of antigen expressed on their surface with MHC class II. Thereby TFH cells ensure that the GC 
reaction leads to the generation and selection of B cells with the highest possible antigen specificity 
(Johnston, Poholek et al. 2009, Good-Jacobson, Szumilas et al. 2010, Victora and Nussenzweig 2012, 
Crotty 2014).  
The signals that TFH cells provide to GC B cells come from both cell surface receptors and via cytokines. 
For example, TFH cells have high expression of CD40 ligand (CD40L), interleukin 21 (IL-21), and 
interleukin 4 (IL-4) which provide key ‘help’ signals to GC B cells to survive and to promote B cell 
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proliferation. Upon ligation of ICOS, TFH cells are stimulated to produce IL-21 and IL-4 which are 
important in inducing IgG1 class switch recombination.  
Since TFH cells have such a pronounced ability to stimulate GC B cell expansion, it is important that 
they only select the GC B cells with the highest affinity BCRs. Accordingly, negative regulatory checks 
are in place to prevent uncontrolled ‘help’ being given to GC B cells with low affinity BCRs which, if 
allowed to proceed unchecked would lead to the generation of ineffective, low affinity antibody 
production. One such regulatory check is the signalling lymphocyte activation molecule SLAMF6, 
which is upregulated in TFH cells and signalling through which leads to loss of TFH-GC B cell adhesion 
and abrogation of TFH help (Crotty 2014). The high surface expression of PD1 on TFH cells may also 
serve as a further inhibitory process by limiting the proliferation of the TFH cells themselves (Crotty 
2014). Further regulation of TFH cells is achieved through the action of T follicular regulatory cells (TFR) 
which are thought to attenuate the immune response either by interacting with and suppressing the 
TFH cells or by directly inhibiting GC B cells with an autoreactive BCR (Linterman, Pierson et al. 2011, 
Crotty 2014), TFR are further discussed in sections 1.3.4 and 1.6.2.1 below.  
1.3.4 T follicular regulatory cells 
T follicular regulatory cells (TFR) are a subset of CD4+ T cells that have a similar phenotype to TFH but 
are distinct from TFH and have a role in controlling the GC response.  
TFR are CD4+, CXCR5+, PD1Hi cells and like TFH they are positive for the transcription factor Bcl-6 and 
are dependent on B-cell interaction for their development. Unlike TFH however, TFR are FOXP3+ and 
originate from Thymic FOXP3+ precursors.  
TFR have been shown in vitro to have suppressive effects and are able to limit the number of TFH and 
GC B cells so controlling the size and rate of the GC reaction. In the absence of TFR, an excess of B cells 
lacking antigen specificity has been observed. The mechanisms through which TFR regulate the GC are 
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not established at present but it is likely that they have a directly suppressive effect on TFH cells 
(Linterman, Pierson et al. 2011).        
1.3.5 TFH in disease states 
As described above, TFH are essential for generating a high affinity antibody response and defects in, 
or absence of TFH cells leads to a dramatically attenuated immune response to infection and ineffective 
vaccination.   
TFH cells have been implicated in a range of autoimmune diseases such as systemic lupus 
erythematosus (SLE), rheumatoid arthritis, Sjogren’s syndrome and other connective tissue disorders. 
In these conditions, increased numbers of circulating TFH cells can be identified in the peripheral blood 
and it is possible that uncontrolled or poorly regulated TFH response leads to autoantibody generation 
in these disorders (Simpson, Gatenby et al. 2010, Ma, Zhu et al. 2012, Ahearne, Allchin et al. 2014).  
In addition to having a role in autoimmune diseases, infection and response to vaccination, TFH cells 
may have a role in allergy and have also been recently reported to be important in some solid organ 
malignancies as well as lymphomas.  
A correlation between the number of TFH cells, an associated gene expression profile of TFH cells and 
good clinical outcome has been reported in breast cancer and colorectal cancer (Bindea, Mlecnik et 
al. 2013, Gu-Trantien, Loi et al. 2013). The reason why enrichment of TFH cells infiltrating the tumour 
of solid organ malignancies should be associated with improved outcome has not been elucidated but 
it is interesting to consider why this may be.  
In research into breast cancer, histopathological studies have revealed the presence of B cell follicle-
like structures, so called ectopic lymphoid infiltrates at the border of the tumour, and the TFH cells are 
found within these structures (Gu-Trantien, Loi et al. 2013). Therefore it may be that the increased 
number of TFH cells identified in patients with good outcome reflects the fact that in those patients, a 
robust anti-tumour immune response has been established rather than that the TFH cells themselves 
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are directly providing anti-tumour signals (Bindea, Mlecnik et al. 2013, Crotty 2014). Further work is 
needed to unravel this interesting finding.    
Conversely, in FL TFH cell infiltration has been associated with adverse outcome (Richendollar, Pohlman 
et al. 2011). This needs to be interpreted with caution due to technical limitations of the research and 
contradictory findings from other groups as described in greater detail below in section 1.6 (Carreras, 
Lopez-Guillermo et al. 2009, Wahlin, Aggarwal et al. 2010, Yang, Grote et al. 2015) but why this should 
be the reverse of the situation observed in breast and colorectal cancer is important to consider.  
Whilst in the solid organ malignancies we can hypothesise that TFH cell infiltration represents part of 
an effective anti-tumour immune response - with TFH cells providing appropriate B cell support to 
mount an immune response to the tumour, in FL, the malignant cells themselves are derived from and 
share many features with GC B cells, and the tumour shares many features of normal GCs.  
TFH cell infiltration in FL may therefore provide FL B cell support as in normal GCs with TFH cell help 
leading to increased proliferation and survival of the malignant B cells. If this theory is correct, 
increased numbers of TFH cells may be associated with adverse outcome in this GC-derived B cell 
malignancy.  
1.3.6 Summary of the role of TFH cells and rationale for studying them in FL: 
Given the similarities between GC and FL follicles, and the central role of TFH cells in the GC reaction, 
this research focussed on the role of TFH cells in FL and investigated similarities and differences 
between the malignant follicles of FL and the GCs of reactive lymph nodes.  
In particular we were interested to determine if there is any evidence that TFH cells provide FL B cells 
with support or a proliferative advantage.   
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1.4 PD1, PD-L1, immune tolerance, immune checkpoints and their role in 
oncogenesis 
Programmed cell death 1 (PD1, PDCD1, CD279) is an immunoglobulin superfamily transmembrane 
protein, expressed by many T cells upon activation (Ishida, Agata et al. 1992, Ahearne, Allchin et al. 
2014, Hawkes, Grigg et al. 2015). The key role of the PD1 pathway in the normal physiological state is 
proposed to be to control the immune response to avoid an excessive, potentially damaging host 
response to antigenic challenge, and to promote self-tolerance and prevent autoimmunity; as such it 
operates as an ‘immune checkpoint’ (Pardoll 2012). Immune checkpoints mainly act through cell 
surface receptors interacting with surface-bound ligands (Zou 2005). There are many other such 
immune checkpoints but, alongside PD1, Cytotoxic T-lymphocyte associated antigen 4 (CTLA4) is the 
other immune checkpoint that is at present most clinically relevant to cancer immune-biology and 
represents a therapeutic target against which drugs are currently available (Pardoll 2012, Eyre and 
Collins 2015).  
As described above in section 1.3.1, PD1 is very highly expressed on TFH cells. It is thought that this is 
to prevent TFH cell proliferation in GCs to control the number of TFH cells in a site where one of their 
key roles is to promote B cell proliferation and to maintain tight control of GC B cell selection (Crotty 
2014). 
In the normal healthy state, in addition to being expressed on TFH cells, PD1 is expressed 
predominantly on antigen presenting cells including B cells and other activated T cells as well as being 
expressed on T cells that have become exhausted or anergic. This phenomenon has especially been 
noted in CD8+ T cells on exposure to chronic viral infection. It is thought that this ‘exhausted’ state 
can be reversed by PD1 inhibition has been proposed that this mechanism is involved in tumour-
induced immune suppression (Barber, Wherry et al. 2006, Eyre and Collins 2015).  
There are two known endogenous ligands for PD-1, PD-L1 (CD274) and PD-L2 (CD273) which are 
variably expressed on antigen presenting cells, including some GC B cells, macrophages, and dendritic 
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cells (Hawkes, Grigg et al. 2015). Upon ligation with PD-L1 or PD-L2, T cells expressing PD1 
downregulate intracellular phosphoinositide-3 kinase activity as well as other stimulatory pathways 
leading to reduced cytokine production, and reduced TCR-mediated T cell proliferation (Eyre and 
Collins 2015, Hawkes, Grigg et al. 2015). 
One of the hallmarks of cancers is their ability to avoid detection and eradication by the immune 
system by evading immune surveillance (Hanahan and Weinberg 2011). There has been a recent 
explosion of interest in how cancers evade immune surveillance which has been fuelled by greater 
understanding of ‘immune checkpoints’ such as PD1 and CTLA4 and the emergence of novel 
therapeutic strategies that seek to unlock these immune checkpoints, co called ‘immune checkpoint 
inhibitors’ (Pardoll and Drake 2012, Eyre and Collins 2015).    
There is now good evidence that in many malignancies the tumour itself is able to influence its 
microenvironment and accordingly the immune landscape in which it is found. One way in which 
cancers are able to influence the immune response is through up-regulation of immune checkpoints 
such as PD1 on the immune cells infiltrating the microenvironment. This renders the CD8+ cytotoxic 
T-cells ineffective and exhausted and so attenuates the anti-tumour immune response.  
Another way that cancers are able manipulate the microenvironment to evade immune surveillance 
is through up-regulation of the PD1 ligands, PD-L1 or PD-L2 on the malignant cells themselves (Blank, 
Gajewski et al. 2005). PD-L1 has been found to be highly overexpressed in many solid organ 
malignancies (Quezada and Peggs 2013, Pyo, Kang et al. 2016). When cytotoxic T cells come into 
contact with the malignant cells expressing a PD1 ligand, signalling through PD1 leads to 
downregulation of phosphoinositide-3 kinase activity and other stimulatory pathways in the T cells 
leading to reduced cytokine production, and reduced TCR-mediated T cell proliferation (Eyre and 
Collins 2015, Hawkes, Grigg et al. 2015). Hence, the tumour downregulates the anti-tumour immune 
response. Increased levels of PD-L1 expression on malignant cells has been associated with adverse 
prognosis in some solid organ malignancies including but not limited to malignant melanoma, breast 
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cancer, and gastric cancer (Wu, Zhu et al. 2006, Nomi, Sho et al. 2007, Hino, Kabashima et al. 2010, 
Hawkes, Grigg et al. 2015).   
1.4.1 PD-L1 expression in lymphoma 
Since lymphomas are malignancies of the immune system, the role of PD1, the expression of its ligands 
PD-L1 and PD-L2 and the effects of its inhibition are different and more complex than in solid organ 
malignancies (Hawkes, Grigg et al. 2015). 
Unlike in many solid organ malignancies, expression of PD-L1 and PD-L2 is less pronounced in 
lymphoma and there is considerable heterogeneity in expression both within and between lymphoma 
sub-types. This heterogeneity and the fact that PD1 may be expressed on ‘normal’ cells of the immune 
system (as found in the normal GC reaction) as well as on lymphoma cells goes some way to explaining 
why there has been considerable variation in the reported influence of PD1 expression on prognosis 
in lymphoma (Eyre and Collins 2015, Hawkes, Grigg et al. 2015).   
In most lymphomas, the malignant cells themselves rarely express PD1, the exceptions being 
angioimmunoblastic T cell lymphoma (AITL) and some cases of CLL (Xerri, Chetaille et al. 2008, 
Ahearne, Allchin et al. 2014). The expression of PD1 on AITL cells is interesting as it has been proposed 
that the cell of origin in AITL is a TFH cell (Xerri, Chetaille et al. 2008).  
Whilst malignant lymphoma cells rarely express PD1, tumour infiltrating T lymphocytes with high 
surface expression of PD1 have been reported in FL, DLBCL, Burkitt lymphoma, primary mediastinal 
DLBCL, and Hodgkin lymphoma, especially the nodular lymphocyte predominant sub-type (Hawkes, 
Grigg et al. 2015). This is an area of considerable interest and complexity. PD1 may be expressed on 
TFH cells as in normal GCs and these certainly represent a significant proportion of PD1+ CD4+ T cells 
infiltrating the microenvironment of GC derived lymphomas including FL, however PD1 can also be 
expressed in other T cell subsets as well as in exhausted T cells (Barber, Wherry et al. 2006), and in 
these cells, PD1 expression may reflect a tumour-driven down-regulation of the anti-tumour immune 
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response (Eyre and Collins 2015, Hawkes, Grigg et al. 2015). Thus, in lymphoma, PD1 may be expressed 
on exhausted, dysfunctional, anergic tumour infiltrating T lymphocytes and also on active CD4+ T cell 
subsets such as TFH cells. This complexity partially explains the difficulties and discrepancies in using 
PD1 as a prognostic biomarker in lymphoma (see section 1.6.2.1 below) and also adds a layer of 
complexity when considering the mechanism of action of PD1 inhibitors in the treatment of 
lymphoma.    
Despite high levels of PD1 expression by tumour infiltrating T lymphocytes in many sub-types of B cell 
NHL, there is only low level of expression of the ligands PD-L1 and PD-L2 in these conditions and the 
ligands have not been identified on the malignant cells themselves (Hawkes, Grigg et al. 2015).  
In Hodgkin lymphoma and primary mediastinal DLBCL however, high levels of PD-L1 have been 
reported on the malignant cells. Expression of PD-L1 in these conditions is proposed to be mediated 
by the 9p24 mutation leading to increased copy numbers of the genes encoding the PD1 ligands. 
Furthermore, EBV-driven lymphomas have been demonstrated to have upregulated PD-L1 expression 
as an aberrant effect of the EBV genome (Green, Monti et al. 2010, Green, Rodig et al. 2012, Chen, 
Chapuy et al. 2013, Hawkes, Grigg et al. 2015). It is proposed that in these conditions the tumour cells 
themselves have upregulated PD-L1 expression to downregulate the anti-tumour immune response 
so conferring a survival advantage for the malignant cells. This is especially interesting in classical 
Hodgkin Lymphoma as it has been appreciated for many years that this condition is typified by 
impaired T cell mediated immunity, and it is now apparent that this may be driven by the tumour cells 
through upregulation of PD-L1 (Ansell, Lesokhin et al. 2015).   
1.5 Immune checkpoint inhibition: PD1 blockade as a therapeutic option in 
malignancy 
Blockade of immune checkpoints with antibodies to PD1 or CTLA4 is an exciting emerging therapeutic 
option in many cancers with particularly marked benefits recorded in non-small cell lung cancer, 
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malignant melanoma, pancreatic cancer and a number of other solid organ malignancies (Pardoll 
2012, Quezada and Peggs 2013, Hawkes, Grigg et al. 2015).  
The effect of blockade of PD1 or PD-L1 is downregulation of PD1 expression on lymphocytes infiltrating 
the tumour with associated improvement in the anti-tumour immune response including slowing of 
tumour growth and tumour ‘rejection’. This has led to marked clinical benefits in a range of solid organ 
malignancies including dramatic prolongation of overall survival in metastatic malignant melanoma 
whether used as a single agent, in combination with chemotherapy or in combination with the anti-
CTLA4 antibody, Ipilimumab, another checkpoint inhibitor (Hamid, Robert et al. 2013, Postow, 
Chesney et al. 2015, Robert, Long et al. 2015).    
At present there are 3 selective, humanised anti-PD1 inhibitors in use and more are in development. 
The PD1 inhibitors currently in use are pidilizumab, nivolumab, and pembrolizomab.    
Side effects of PD1 inhibition are largely predictable given that the role of the PD1 – PD-L1 axis is to 
control the immune response to prevent autoimmunity and excessive response to detected antigens. 
Reported toxicities and side effects include immune-mediated toxicities such as inflammatory colitis, 
hepatitis, dermatitis, uveitis, thyroid disorders and pneumonitis. Although these complications are 
relatively common (up to 41%), they are usually mild (toxicity grade 1-2) and overall these drugs are 
well tolerated (Topalian, Hodi et al. 2012, Hawkes, Grigg et al. 2015). When used in combination with 
an anti-CTLA4 antibody in the treatment of malignant melanoma, there was predictably an increase 
in incidence of these toxicities (Postow, Chesney et al. 2015).   
Whilst the field of PD1 / PD-L1 inhibition is revolutionising the management of many solid-organ 
malignancies, the complexity of PD1 and its ligands’ expression in lymphomas and differences 
compared to solid organ malignancies mean that there has been a lag in testing these agents in 
lymphoma. Nevertheless there is now considerable interest and many clinical trials are either in 
process or have already reported in various lymphoma sub-types.  
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An initial phase 1 clinical trial assessed a single intravenous dose of the PD1 inhibitor Pidilizumab in a 
range of haematological malignancies (Berger, Rotem-Yehudar et al. 2008). The maximum tolerated 
dose (MTD) was not established in this trial, and although this phase 1 trial was not primarily designed 
to assess efficacy there was one patient with advanced stage FL who experienced a CR after a single 
dose of anti-PD1 therapy which was maintained for at least 1 year which is a remarkable response. A 
further phase 1 clinical trial of Nivolumab showed a response rate of 40% amongst patients with FL 
(Hawkes, Grigg et al. 2015).  
Subsequent trials in FL include a phase 2 clinical trial assessing Pidilizumab in combination with 
rituximab in 30 patients with relapsed FL (Westin, Chu et al. 2014, Eyre and Collins 2015). In this single-
arm trial the ORR was 66% with a CR rate of 52%, interestingly some responses were delayed. The 
response rate is impressive but is hard to interpret as single-agent rituximab has a good response rate 
even in previously treated patients. Nevertheless it represents an exciting new therapeutic approach 
that should be evaluated further in randomised trials.    
Anti-PD1 therapy has also been assessed in DLBCL with variable results. Pidilizumab has been assessed 
in a phase 2 clinical trial as consolidation therapy post autologous stem cell transplantation (Armand, 
Nagler et al. 2013). This showed a modest improvement in PFS compared to historical controls and 
50% of patients who had residual disease post-transplant had a further reduction in disease burden 
following anti-PD1 therapy.  
The most exciting results of anti-PD1 therapy in lymphoma reported to date have been in the 
treatment of classical Hodgkin lymphoma (cHL). In a phase 1 clinical trial of Nivolumab in patients with 
heavily pre-treated cHL, an amazingly high rate of response of 87% with 17% of patients achieving CR 
despite the fact that many of these patients had previously relapsed after ASCT (Ansell, Lesokhin et 
al. 2015). Although this is a small data set and the follow-up is short this represents a very high 
response rate in a group of patients with typically very poor prognosis. The higher response rates in 
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cHL than other lymphomas may represent the increased expression of PD-L1 on the malignant cells in 
cHL compared to the low level of expression on the malignant cells of other lymphoma sub-types. 
1.6 The FL microenvironment  
The tumour microenvironment is increasingly appreciated to be of great importance in the 
pathophysiology of many types of malignancy. Interactions between the tumour and the 
microenvironment assist tumour cells to grow, proliferate, and evade immune destruction. This is now 
recognised as one of the key hallmarks of cancer (Hanahan and Weinberg 2011, Hanahan and 
Coussens 2012).  
The cells comprising the microenvironment in FL are a variety of immune regulatory cells including 
subsets of CD4+ T cells, CD8+ T cells, FDCs, tissue macrophages, and mast cells. Non-malignant cells 
account for up to 50% of the tumour mass. It is apparent that the interaction between FL cells and 
their microenvironment is a dynamic two-way process; the microenvironment is able to deliver either 
pro-survival or anti-tumour signals to the FL cells which in turn are also able to influence the 
composition of the microenvironment (Ame-Thomas and Tarte 2014).  
In the normal GC reaction, differentiation, survival and proliferation of B cells is dependent on 
interactions with CD4+ T cells so it can be hypothesised that, since FL arises from GC B cells that reside 
and proliferate in follicles which have some similarities to normal GCs, similar interactions between B 
and T cells are important in the pathogenesis of FL. This hypothesis is supported by the observation 
that FL cells die rapidly by apoptosis in vitro, but can be rescued from apoptosis by the activation of 
CD40 which is present on both GC B cells and malignant FL cells. As the ligand for CD40 is found on T 
cells, it can be speculated that FL B cells are dependent on interaction with T cells in vivo for their 
survival (Johnson, Watt et al. 1993). Further circumstantial evidence that FL is linked to the host 
immune system is gained from the observation that, in a proportion of patients who are managed on 
a ‘watch and wait’ policy, lymph nodes sometimes regress without treatment - the reason for this is 
not clear but it may indicate an immune response against the tumour (Horning and Rosenberg 1984). 
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In DLBCL, gene expression profiling (GEP) has revealed that the malignant cells have distinctive gene 
expression profiles that strongly determines prognosis (Lenz, Wright et al. 2008). It has also been 
demonstrated that GEP of whole tumour specimens can predict prognosis in FL but here it is the 
molecular features of the non-malignant cells infiltrating the tumour that determines prognosis rather 
than genetic signatures intrinsic to the malignant cells. Dave et al performed oligonucleotide micro-
array based GEP on tumour samples from patients with newly diagnosed FL, first using a training set 
of 95 patient samples to identify good and poor prognostic signals, and then testing this on a separate 
cohort of 96 patient samples. They identified 2 different host immune response profiles which were 
predictive of overall survival. Immune response 1 was characterised predominantly by expression of 
T cell genes and was associated with a good prognosis, whereas the immune response 2 profile 
showed over expression of genes expressed by tissue macrophages and or follicular dendritic cells and 
was associated with poor prognosis  (Dave, Wright et al. 2004). This study provided important 
information to support the hypothesis that the microenvironment plays a role in FL and, by sorting 
cells into CD19+ and CD19- populations showed that it was the signal from infiltrating T cells and 
macrophages that was associated with prognosis. This finding was corroborated in work by Glas et al 
who showed that the different immune response profiles could not only predict survival but also the 
risk of transformation (Glas, Knoops et al. 2007). It has also been shown that PCR of selected genes 
could be used as a surrogate for GEP in identifying these prognostic groups (Byers, Sakhinia et al. 
2008). These findings were an important step in understanding that FL is an immunologically active 
disease and that prognosis may be determined by the level of T cell infiltration and the number of 
tumour associated macrophages. However, this has not yet translated into a practical prognostic tool 
due to the cost and complexity of the methods involved. In addition, GEP studies on whole tissues do 
not give information about the specific cell types, their localisation and distribution. 
Subsequent research into the role of the microenvironment in the pathogenesis of FL or investigating 
the prognostic significance of its composition has typically used either immunohistochemistry (IHC) 
on tissue sections or flow cytometry on disaggregated tumour biopsies.  
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To date, studies investigating the prognostic significance of the microenvironment have yielded 
disparate results. There are many reasons for this but chief amongst them are the heterogeneity in 
outcome in patients with FL, the use of different clinical endpoints, and the lack of a standard 
treatment in FL which makes interpreting outcome difficult. Technical issues also underpin the 
disparity in results. Whilst traditional IHC techniques can characterise the cells in the 
microenvironment, their numbers, distribution, and, if dual labelling is performed, their proximity to 
other cells, it is insufficiently sensitive to discriminate between the various complex cell types 
implicated. It has also been shown that there can be poor reliability and inter-user agreement on IHC 
interpretation (Sander, de Jong et al. 2014).  
Multi-parameter flow cytometry on disaggregated lymph node samples overcomes the limitation of 
IHC because many antigens or proteins can be simultaneously labelled and analysis can be 
standardised to a certain extent but it does not allow architectural information to be obtained (e.g. 
the distribution of cell types with regard to the follicles).  
1.6.1 Tumour associated macrophages in the FL microenvironment 
Consistent with the GEP studies described above which identified that a GEP showing increased 
expression of tissue macrophage genes in the tumour was associated with poor prognosis, a number 
of studies using IHC suggested that increased macrophage infiltration was associated with worse 
prognosis. Farinha and colleagues constructed tissue microarrays on 99 biopsy specimens from 
patients treated uniformly in a clinical trial between 1987 and 1993. They found that patients with >15 
CD68+ tumour associated macrophages (TAM) per high power field (hpf) had a significantly shorter 
overall survival than patients with <15 TAMs per hpf (Farinha, Masoudi et al. 2005, Byers, Sakhinia et 
al. 2008). The adverse impact of increased TAMs was also identified in an IHC study of 194 patients 
treated in a randomised trial between 2000 and 2002 (Canioni, Salles et al. 2008). In this study, 
increased TAMs were associated with adverse prognosis, especially if they were localised within the 
follicles (follicular) rather than in interfollicular areas. The patients in this trial were randomised to 
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receive chemotherapy with, or without rituximab. Importantly, in patients treated with rituximab, the 
adverse prognostic impact of increased TAMs was lost. The reason for this is not entirely clear but it 
can be speculated that rituximab reverses the apparent negative effect of increased TAMs because it 
relies on macrophages for tumour cell deletion and therefore is most efficacious when there are more 
macrophages in the tumour microenvironment (de Jong, Koster et al. 2009, de Jong and Fest 2011). 
Treatment received was also found to affect the prognostic significance of TAMs in a study in which 
tissue microarrays were constructed on 61 samples from patients treated between 1993 and 1997 as 
part of a trial comparing two chemotherapy regimens (CVP versus fludarabine). In this study it was 
found that a dense infiltrate of TAMs conferred favourable prognosis if treated with CVP whereas it 
was associated with a worse prognosis in patients treated with fludarabine (de Jong, Koster et al. 
2009). Other studies have concluded that TAMs either have no association with prognosis, or indeed 
have an opposite effect to that described above, or that the association between TAMs and prognosis 
depends on treatment received (Alvaro, Lejeune et al. 2006, Lee, Clear et al. 2006, Taskinen, 
Karjalainen-Lindsberg et al. 2007, de Jong, Koster et al. 2009). 
These conflicting results show the difficulty in correlating markers related to the tissue 
microenvironment to clinical outcome, and the importance of interpreting these findings carefully. 
These studies used different clinical endpoints (OS vs. EFS vs. PFS), and included patients with different 
clinical characteristics who received heterogeneous treatments. IHC also relies on observer 
interpretation and despite efforts to automate image analysis and eliminate bias, it is still shown to 
be unreliable in some instances (Sander, de Jong et al. 2014). Nevertheless, it can be inferred that 
increased TAMs as demonstrated by IHC was a marker of worse clinical outcome in patients treated 
with traditional chemotherapy but, in patients treated with rituximab-containing regimens, this 
adverse effect is overcome, or even reversed. As most patients today are treated with rituximab-based 
therapy, increased TAMs can’t be seen as a valid indicator of poor prognosis.  
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1.6.2 T cells in the FL microenvironment 
It has long been appreciated that T cells infiltrate the tumour in FL, these are predominantly CD4+ 
(75%) with approximately 25% CD8+ and their location is predominantly interfollicular rather than 
follicular. The GEP study described above demonstrated that T cells in the tumour microenvironment 
were an important predictor of prognosis with stronger T cell gene expression (immune response 1) 
associated with better prognosis but this does not account for the types of T cell implicated or their 
distribution (Dave, Wright et al. 2004). As with IHC-based research into TAMs, studies linking the 
numbers and location of various T cell subsets to prognosis have yielded sometimes contradictory 
results.  
1.6.2.1 CD4+ T cells in FL 
CD4+ T cells (T helper cells) have a vital role in protecting GC B cells from apoptosis. This is achieved 
through direct cell contact between the B cells via a number of receptor-ligand interactions including 
CD40 (on B cells) and CD40 ligand (CD154) on CD4+ T cells, and it is apparent that the same process is 
important in FL B cell survival (Carbone, Gloghini et al. 2009).  
Investigating the number and distribution of CD4+ cells in FL has yielded contradictory results in IHC 
based studies with a high number of CD4+ T cells located within follicles associated with either 
prolonged survival (Lee, Clear et al. 2006) or worse survival (Glas, Knoops et al. 2007, Wahlin, Aggarwal 
et al. 2010) in three studies of heterogeneously treated patients. Accordingly, attention has turned to 
investigating the importance of CD4+ T cell subsets. Two classes of CD4+ T cells thought to play an 
important role in the pathogenesis of FL are T follicular helper T cells (TFH) and regulatory T cells (Tregs). 
IHC studies have investigated the significance of PD1+ cells in the FL microenvironment. In a study of 
100 patients with FL, single parameter staining for PD1 was performed and images were quantitatively 
analysed (Carreras, Lopez-Guillermo et al. 2009). They found that PD1+ cells were mainly restricted to 
the follicles, and that the absolute number of PD1+ cells was decreased in grade 3 compared to grade 
1-2 disease. They also reported that an increased number of PD1+ cells was associated with better 
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prognosis. These findings were confirmed in a separate study (Wahlin, Aggarwal et al. 2010), but in 
further work, increased follicular PD1+ cells were associated with inferior outcome (Richendollar, 
Pohlman et al. 2011). These studies all used single parameter staining and therefore were unable to 
identify the different populations of cells expressing PD1. 
Studies on disaggregated FL lymph node specimens have confirmed the presence of TFH in FL. 
Identifying TFH as CD4+, CD25-, PD1+, ICOS+, CXCR5+, Pangault and colleagues found that TFH cells 
accounted for approximately 30-35% of all CD4+ cells in disaggregated FL lymph nodes which was no 
different to tonsils but was significantly higher than in whole disaggregated reactive lymph nodes. 
They went on to characterise these cells in detail and found that they expressed high levels of IL-4 
(higher than tonsil-derived TFH), demonstrated that TFH derived IL-4 was implicated in STAT6-
dependent FL B cell activation, and proposed that this may favour FL B cell survival and proliferation 
(Pangault, Ame-Thomas et al. 2010, Ame-Thomas, Le Priol et al. 2012). In a separate study they were 
able to demonstrate that FL TFH cells express very high levels of PD1, have the capacity to rescue FL B 
cells from apoptosis in vitro, do not have regulatory function, and express a high level of CD40 ligand 
which contributes to the malignant B cell survival (Ame-Thomas, Le Priol et al. 2012).  
By contrast, it has also been proposed that CD4+ PD1+ T cells in FL represent exhausted, anergic T cells 
with defects in function and in vitro studies have demonstrated that T cells in FL have impaired 
immune synapse formation compared to T cells in normal subjects (Ramsay, Clear et al. 2009, 
Myklebust, Irish et al. 2013).  
Thus, CD4+ PD1+ cells infiltrating FL may consist of different populations; functional TFH cells that 
confer an active pro-tumour signal to the FL B cells through expression of CD40L and secretion of IL-
4, and dysfunctional, exhausted PD1+ T cells that lack the function of TFH cells. These dysfunctional 




Regulatory T cells (Tregs) are important in regulating T cell activation and maintaining immune 
tolerance. They are characterised by the expression of CD4, CD25, and the transcription factor FOXP3 
(forkhead box protein 3). In FL, Tregs have been demonstrated to inhibit the anti-tumour immune 
response through suppression of CD4 and CD8 T cell activation and proliferation (Yang, Novak et al. 
2006, Glas, Knoops et al. 2007, Ame-Thomas and Tarte 2014). In reactive lymph nodes, Tregs are mainly 
located outside of the GCs but they have been identified within the follicles in FL. IHC studies have 
assessed the relevance of FOXP3+ cells to prognosis in FL and interestingly it was found in one study 
that it is the distribution of FOXP3 rather than the absolute number that is important with a follicular 
or perifollicular pattern associated with poor prognosis whilst a diffuse pattern was associated with 
improved prognosis (Farinha, Al-Tourah et al. 2010).  
There are various subsets of cells that express FOXP3 and a subset termed T follicular regulatory (TFR) 
cells has recently been identified in FL. These are cells with a phenotype between TFH and Tregs, 
expressing CD4, CD25, ICOS, FOXP3 and CXCR5 which permits their follicular localisation. It is thought 
that they may inhibit the anti-tumour response although the mechanism for this is unclear at present 
(Linterman, Pierson et al. 2011, Ame-Thomas, Le Priol et al. 2012). 
1.6.2.2 CD8+ T cells in FL 
Anti-tumour activity has been demonstrated by cytotoxic CD8+ T cells infiltrating the FL 
microenvironment. Accordingly, increased CD8+ T cell infiltration has been associated with improved 
outcome in IHC studies (Alvaro, Lejeune et al. 2006, Wahlin, Aggarwal et al. 2010, Laurent, Muller et 
al. 2011). In a study using multi-parameter labelling and confocal microscopy on frozen biopsy 
specimens, functional granzyme B containing cytotoxic T cells were found to form lytic synapses with 
FL B cells at the follicular border but were rarely found within the follicles (Laurent, Muller et al. 2011).  
1.6.3 Influence of the tumour on the composition of the microenvironment 
In addition to the effects of the microenvironment on the pathogenesis and prognosis of the tumour, 
it is now clear that this is a two-way process with evidence that the tumour is able to influence the 
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microenvironment in order to escape immune surveillance. Evidence for this includes the findings that 
malignant B cells are able to increase the number of immunosuppressive FOXP3+ Tregs  in the tumour 
environment by chemotaxis and migration through the secretion of CCL22 (Yang, Novak et al. 2006) 
or by inducing the conversion of conventional CD4+ T cells to become functional FOXP3+ Tregs (Ai, Hou 
et al. 2009). It has also been demonstrated that healthy peripheral blood T cells co-cultured in vitro 
with malignant B cells acquire defective immune synapse formation (Ramsay, Clear et al. 2009), and 
that the gene expression profile of healthy T cells is changed on co-culture with FL B cells through both 
direct cellular contact and through soluble factors resulting in T cell functional impairment (Kiaii, Clear 
et al. 2013).  In addition it has been demonstrated that both tumour associated neutrophils and cancer 
associated fibroblasts (CAFs) contribute to the generation of a pro-tumour cell niche in FL and other 
GC-derived lymphomas although the mechanisms by which this is achieved are not yet fully elucidated 
(Gregoire, Guilloton et al. 2015).   
1.6.4 Summary of the FL microenvironment  
It is clear that the microenvironment is important in the pathogenesis of FL, that it can impart pro-
tumour and anti-tumour signals to the malignant B cells, and that the tumour cells themselves are 
able to influence their environment to escape immune surveillance. It is also increasingly clear that 
this is a complex phenomena and it is likely that it is the balance between these pro- and anti-tumour 
factors alongside the intrinsic molecular and genetic features of the malignant cells that ultimately 
determines the behaviour of the disease in a given individual at a particular time point in the disease 
course.  
Some of the techniques used to date to explore this are not sufficiently sensitive on their own to 
understand the interactions between the tumour and the microenvironment. We refined a technique 
using multiparameter immunofluorescent labelling and confocal microscopy on tumour biopsy 
specimens that we believe will help to answer some of these questions. This technique has many 
advantages over traditional IHC which cannot resolve complex cellular subsets and, compared to flow 
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cytometry on disaggregated lymph node samples, this technique permits disease architecture and 
spatial relationships to be explored. These and other advantages of using multiparameter 
immunofluorescent confocal microscopy on FFPE LN samples are described in greater detail below.    
1.7 Immunohistochemistry, multi-colour immunofluorescent labelling and 
confocal microscopy  
Archived formalin fixed paraffin embedded (FFPE) biopsy material is an immensely valuable research 
resource. Some of the benefits of using FFPE material are that it can be stored easily and cheaply for 
a very long period of time, long follow up data for archived samples is often available, and, in patients 
who have relapsed, paired samples from time of diagnosis and relapse can be compared. 
Immunohistochemistry (IHC) is the most commonly used research tool on archived FFPE material, but 
it is also possible to extract RNA and DNA to perform gene expression profiling studies, or sequencing 
of genes implicated in the pathogenesis of the disease. However traditional IHC, using a primary 
antibody followed by a secondary antibody and a peroxidase complex with visualisation by a 
chromogenic substrate under a light microscope, has a number of limitations. Firstly, this technique is 
usually limited to visualising one protein at a time; two antibodies can be used simultaneously but this 
is complex and does not typically yield accurate co-localisation data. Secondly, the resolution of light 
microscopy is limited by the thickness of the sections. Thirdly, the quantitative analysis of images 
obtained from IHC is limited (Robertson, Savage et al. 2008).  
An alternative approach to traditional IHC staining of FFPE tissue sections is to use immunofluorescent 
labelling. When visualised under an epifuorescence microscope, tissue autofluorescence and the 
inability to eliminate light emitted from the entire depth of the specimen can prevent meaningful 
analysis of immunofluorescently labelled FFPE sections especially when staining more than one 
protein simultaneously therefore this technique has not been widely used. However, these problems 
can be overcome by imaging immunofluorescently labelled sections with a confocal laser scanning 
microscope (Conchello and Lichtman 2005, Robertson, Savage et al. 2008).  
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A method of simultaneously staining multiple proteins with primary antibodies and fluorescently 
conjugated secondary antibodies detected with a confocal laser scanning microscope has been 
developed and it has been demonstrated to be able to obtain high quality images from FFPE material 
(Patten, Buggins et al. 2008, Robertson, Savage et al. 2008). This method has been used to detect 3 
antibodies simultaneously with the 4th available channel usually being used for a nuclear stain, 
commonly 4’,6-diamidino-2-phenylindole, dihydrochloride (DAPI). 
Confocal laser scanning microscopes have a number of significant advantages over standard 
epifluorescence microscopes that ultimately result in the generation of images with much reduced 
background fluorescence. The principle benefit of confocal microscopy is the ability to generate 
images from specific focal depths whilst removing or blocking out-of-focus light, this is known as 
optical sectioning. The other key difference of a confocal microscope is that it generates an image by 
scanning, this means that, rather than acquiring all of the image from illuminating a section 
simultaneously (as in a light microscope or wide field epifluorescence microscope), the section is 
scanned by exciting points of the section with each laser in sequence and then building up the image 
from the information gathered at each point whilst blocking or masking light emitted from all other 
parts of the section. 
These two factors combined, optical sectioning and scanning mean that the images generated by a 
confocal microscope are of very high contrast and have a much lower level of background fluorescence 
than conventionally acquired fluorescent images.  
The ability to form optical sections within a tissue section also permits the collection of images in the 
vertical Z axis which can be reconstructed into 3D series known as Z-series or Z-stacks which is 
particularly useful for investigating cellular interactions or the colocalisation of two or more antigens 
within cells (Conchello and Lichtman 2005, Robertson, Savage et al. 2008).  
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Using a laser scanning confocal microscope equipped with lasers emitting light at 4 distinct 
wavelengths permits the development of a staining protocol that uses 3 primary antibodies which are 
then detected with 3 fluorescently labelled secondary antibodies plus a fluorescent nuclear 
counterstain, or, theoretically 4 primary antibodies can be detected with 4 fluorescently labelled 
secondary antibodies if no nuclear counterstain is used. The fluorescently labelled secondary 
antibodies each have an excitation threshold and they should be chosen to match the wavelength of 
the light emitted by the lasers on the microscope. Following excitation by the lasers, the 
fluorochromes emit light at a slightly higher wavelength (emission peak) which is detected by 
photomultiplier tubes (PMTs). A series of filters prevents out-of-focus light, or light that it not within 
the emission spectra of the fluorochromes from reaching the PMTs.  
When designing multiple labelling experiments it is important to consider the excitation and emission 
spectra of the fluorescently labelled secondary antibodies. The excitation spectra of the different 
fluorochromes must be sufficiently different not to be excited by the same laser, and the maximum 
emission wavelengths must be well resolved with minimal spectral overlap, and fall within the 
wavelengths of the filters used with the microscope (see example in Figure 1-5).  
 
Figure 1-5. Example of emission spectra. Approximate emission spectra of DyLight 405 (blue), Alexa Fluor 488 
(green), Alexa Fluor 555 (red), and Alexa Fluor 647 (brown) showing that the emission peaks of these 4 
fluorochromes are well resolved with minimal spectral overlap. Reproduced from Jackson Immuno Research 
Laboratories   
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1.8 T cell receptor repertoire 
The ability of T cells to recognise antigen bound to the major histocompatibility complex (MHC) is 
critical for an effective immune response. T cells recognise antigen through their surface-bound T cell 
receptor (TCR) which forms a complex together with CD3. The TCR is made up of two chains linked 
together by a disulphide bond, the two chains are either alpha and beta (α, β) or less frequently 
gamma and delta (γ,δ).  
In order to be able to recognise near-limitless potential antigens, the TCR genes, like the BCR, diversify 
by random rearrangement and recombination of the variable domains, V, D, and J. The linkage areas 
between these domains are known as hypervariable regions and the greatest diversity is generated in 
the third hypervariable region, CDR3.    
T cells undergo a process of positive or negative selection in the thymus depending on their TCR 
affinity. Up to 95% of T cells are negatively selected either due to either an ineffective, low affinity TCR 
or due to high affinity for auto-antigen. Further selection occurs in the secondary lymphoid tissue by 
interaction with antigen presenting cells.  
Skewing of the repertoire of TCRs occurs as a result of particular TCR V gene usage in response to 
different antigens.  The TCR repertoire of tumour infiltrating T lymphocytes has previously been 
investigated in a number of different solid organ malignancies. This research using high throughput 
sequencing of the TCRs has demonstrated that in some cancers there is relative skewing of the TCRs 
of tumour infiltrating lymphocytes compared to circulating T cells indicating perhaps a local response 
within the tumour to specific, as yet unidentified antigens (Emerson, Sherwood et al. 2013, Sherwood, 





The TCR repertoire of T cells infiltrating the FL tumour microenvironment has not been previously 
investigated, and we hypothesised that, since there are many similarities between the malignant 
follicles of FL and GCs of reactive LNs, the TCR repertoire of intra-follicular FL T cells may be restricted 
in response to a specific antigen.  
  
 
1.9 Aims and Objectives 
The goal of this research is to investigate the hypothesis that interactions in the neoplastic follicles in 
FL mirror those that occur in the normal GC reaction.  
Since CD4+ TFH cells play such a key role in the normal GC reaction, and many of the features of the 
normal GC are retained in FL, in this research we focus on the location, phenotype and possible role 
of TFH cells in the pathogenesis of FL.  
Specific aims of the research are to: 
 Characterise the phenotype and precise location of CD4+ TFH cells infiltrating the 
microenvironment of FL using multi-colour immunofluorescent confocal microscopy in situ in 
formalin fixed paraffin embedded lymph node tissue sections 
 Investigate to what extent the CD4+ T cell subsets and their distribution in FL are similar to 
the normal GC  
 Investigate whether TFH cells are involved in promoting the proliferation of malignant B cells 
 Investigate if TFH cells are associated with induction of AID in malignant B  cells 
 Investigate whether the CD4+ T cells in FL show evidence of antigen specificity 
 Undertake preliminary investigation to determine if the composition of the CD4+ T cell 




Chapter 2 Materials and Methods 
2.1 Ethics 
Ethical approval was applied for and granted for the collection and analysis of archived formalin fixed 
paraffin embedded (FFPE) tissue biopsy specimens from patients with lymphoproliferative disorders 
or reactive lymphadenopathy.  
The histological material was surplus to clinical requirements, anonymised, and linked with a relevant 
clinical dataset.  
The ethics committee determined that individual patient consent was not required for this work on 
archived, anonymised material. The research ethics registration number is 13/NW/0040.  
2.2 Patient samples 
Potential samples were identified from the database of the department of histopathology at King’s 
College Hospital. Patients with a diagnosis of FL, CLL, or reactive lymphadenopathy with adequate 
surplus FFPE tissue blocks were included. Biopsies were either from the time of original diagnosis or 
taken at time of relapse. In cases of relapsed disease, only cases in which no systemic treatment had 
been received for at least 12 months prior to biopsy were included. Linked clinical information was 




Table 2-1 Clinical dataset of information for patients with FL 
Parameter Value / units 
Diagnosis FL / CLL / reactive LN 
Gender Male / Female 
Age at time of biopsy Years 
Biopsy site Cervical / Supraclavicular / Axillary / Mediastinal / 
Mesenteric / Retroperitoneal / Inguinal / Extranodal 
Biopsy taken at diagnosis or relapse? Diagnosis / Relapse 
Histological grade  Grade 1 / 2 / 3a / 3b 
Stage at time of diagnosis I / II / III / IV 
FLIPI score  0-5 
FLIPI 2 score  0-5 
Initial management Observation only / radiotherapy only / chemotherapy / 
immunochemotherapy / other 
Treatment outcome CR / CRu / PR / SD / PD / unknown / other 
Time to event outcome  (next treatment, 
progression, transformation, death) 
Months 
Current disease status Alive in remission / alive with relapse / dead (death due 
to lymphoma) / dead (death not due to lymphoma) 
 
2.3 Sample preparation 
2.3.1 Cutting sections, de-paraffinisation, and antigen retrieval 
FFPE lymph node blocks were cooled on ice for at least 30 minutes prior to sectioning, blocks were 
then cut into sections of either 4µm or 12µm thickness on a rotary microtome (Slee Mainz, Cut 4060). 
Thick sections (12μm) were used for detailed co-localisation studies; for all other studies, thin sections 
(4µm) were used. Sections were floated onto warm water at 40°C and mounted onto Poly-L-Lysine 
coated microscope slides (VWR). Slides were dried on a hotplate at 70°C for 30 minutes before further 
drying at room temperature overnight.  
64 
 
Tissue sections were deparaffinised in two changes of xylene (Fisher scientific) in a fume cupboard for 
five minutes each then rehydrated in changes of graded ethanol. Rehydration was in 100% ethanol for 
10 minutes followed by two changes of 96% ethanol for 10 minutes each, and 10 minutes in each of 
70% and 50% ethanol. After this, the sections were washed in water.  
Heat induced epitope retrieval was performed before immunohistochemical staining to unmask 
epitopes that had been cross linked by the formation of methylene bridges during the fixation of the 
specimens. Antigen retrieval was performed in pH 6.1 citrate buffer with 0.05% Tween 20 or pH 9.0 
Tris-EDTA with 0.05% Tween 20. The antigen retrieval solution was heated to boiling in a pressure 
cooker and the slides were then transferred in a metal rack from water to the boiling solution using 
forceps. The lid of the pressure cooker was locked and, once full pressure had been achieved, 3 
minutes were timed. After this, the pressure was released and the lid removed, the slides were cooled 
by the addition of cool water.  
2.3.2 Multiple immunofluorescent labelling of formalin fixed tissue sections 
After antigen retrieval, slides were washed in water and rehydrated in phosphate buffered saline (PBS) 
for 30 minutes. The slides were removed from the PBS and the tissue sections were circumscribed 
with a hydrophobic barrier pen (ImmEdge) without allowing the tissue to dry out. 
Next, the slides were blocked with 5% normal donkey serum diluted in PBS for 1 hour at room 
temperature. The species of the blocking antibody was the same as the species in which the secondary 
antibodies were raised. In all experiments described in this report, donkey serum was used as all 
secondary antibodies in immunofluorescent labelling experiments were raised in donkey. Blocking 
with serum helps to prevent non-specific secondary antibody binding to the tissue section and reduces 
Fc receptor binding of both primary and secondary antibodies.  
The donkey serum was drained off the slides but not washed and relevant combinations of primary 
antibodies diluted in PBS were carefully pipetted onto the sections within the area circumscribed by 
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the hydrophobic barrier pen. 0.025% Triton X-100 was added to the PBS to reduce surface tension and 
ensure that the tissue sections were completely covered to prevent drying out of the specimens.  
The primary antibodies used, the manufacturers, and the concentrations at which they were used are 
listed in Table 2-2. Numerous combinations of primary antibodies were used but all primary antibodies 
used on each section were raised in different species; no experiments using two primary antibodies 
from the same species were performed.  
The slides were incubated with the primary antibodies for 2 hours at room temperature or overnight 
at 4°C in a humidified chamber. Overnight incubation at low temperature was preferable as it 
permitted the use of a lower concentration of some antibodies and was associated with a lower level 
of non-specific background staining. The concentrations of antibodies listed in Table 2-2 are for 
overnight incubation at 4°C. The total volume of diluted antibody combination depended on the size 
of the tissue section being stained, 100-200µl for small sections and 400µl for large sections was 
adequate; it was important to ensure that the section was completely covered to prevent drying out 




Table 2-2 Primary antibodies for immunofluorescent labelling 
Antigen Species Manufacturer Clonality Clone Product 
code 
Dilution 
CD3 Rat Abcam Monoclonal CD3-12 Ab11089 1:200 
ICOS Rabbit Abcam Monoclonal SP98 Ab105227 1:100 
Ki67 Rabbit Abcam Polyclonal - Ab833 1:100 
PKC-theta Rabbit Abcam Polyclonal - Ab131503 1:100 
T-bet Rabbit Abcam Monoclonal EPR9302 Ab154200 1:200 
pSTAT6 Rabbit Abcam Polyclonal - Ab28829 1:100 
CD8 Rabbit Abcam Monoclonal EP1150Y Ab93278 1:400 
PD1 Goat R&D systems Polyclonal - AF1086 1:50 





CD20cy Mouse Dako Monoclonal L26 M0755 1:400 
BCL-6 Mouse Dako Monoclonal PG-B6p M7211 1:50 





AID Mouse Invitrogen Monoclonal ZA001 39-2500 1:200 
FOXP3 Mouse Abcam Monoclonal 236A/E7 Ab20034 1:100 
PD-L1 Rabbit Spring 
Bioscience 
Monoclonal SP142 M442RUO 1:200 
 
After primary antibody incubation, slides were thoroughly washed in 3 changes of PBS for 10 minutes 
each (30 minutes total). The relevant combination of fluorescently conjugated secondary antibodies 
(total volume 100-400µl depending on section size) was then carefully pipetted onto the tissue within 
the area circumscribed by the hydrophobic barrier pen and the slides were incubated in the dark at 
room temperature for 2 hours. The secondary antibodies used, the manufacturers, and the 
concentrations at which they were used are listed in Table 2-3.  
The secondary antibodies were all raised in donkey and were directed against the species in which the 
primary antibodies were raised. For example, if 3 primary antibodies were used, raised in mouse, goat, 
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and rabbit then the secondary antibodies used were donkey anti-mouse, donkey anti-goat, and 
donkey anti-rabbit. When choosing the secondary antibodies, as well as ensuring that there was no 
species cross reactivity, it was also important to ensure that the fluorochromes were well separated 
to prevent spectral overlap, see section 1.7 above.  
After secondary antibody incubation, slides were thoroughly washed in 3 changes of PBS for 10 
minutes each in the dark. If a nuclear counter stain was required, DAPI (Cell Signalling Technology) 
was diluted to 0.4µg/ml in PBS, pipetted onto the tissue within the area circumscribed by the 
hydrophobic barrier pen and incubated for 10 minutes in the dark before washing in PBS. DAPI could 
not be used in conjunction with any secondary antibody conjugated to the DyLight 405 fluorochrome 
as they are excited by the same laser and their maximum emission wavelengths are similar (DAPI 
emission maximum 461nm, Alexa Fluor 405 emission maximum 420nm).  
Table 2-3 Fluorescently conjugated secondary antibodies 
Host 
species 





Donkey Rat IgG 
(H+L) 
DyLight 405 Jackson  712-475-150 1:200 400 421 
Donkey Rabbit 
IgG (H+L) 





Jackson  711-545-152 1:200 493 519 











A31570 1:200 555 565 




Jackson  705-605-003 1:200 651 667 




Jackson 712-605-150 1:200 651 667 
 
Slides were briefly dried at room temperature in the dark (approximately 10-30 minutes depending 
on tissue size) and then mounted with 0.13-0.16mm thickness coverslips (VWR) using ProLong Gold 
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Antifade (Invitrogen) to reduce the rate of bleaching of the fluorescently conjugated secondary 
antibodies. Slides were cured in the dark for at least 24 hours prior to microscopy.  
It was important to ensure that the tissue sections were not allowed to dry between the start of the 
deparaffinisation process until after DAPI staining. It was also important to protect the slides from 
prolonged light exposure once the immunofluorescent secondary antibodies had been added. Slides 
were stored after microscopy in the dark at 4°C and were imaged within 2 weeks of staining. 
2.3.3 Controls 
Negative controls were run in parallel with all staining experiments. Negative controls were tissue 
sections incubated with PBS without the addition of any primary antibodies but all of the fluorescently 
conjugated secondary antibodies (with or without DAPI) that were used in the positive slides. Negative 
controls were performed to determine whether fluorescence detected in the stained sections was 
genuine or was due to non-specific binding of the fluorescently labelled secondary antibodies or tissue 
autofluorescence.  
Sections for negative controls were cut from the same blocks as the experimental sections and all 
stages of preparation were performed simultaneously with the experimental sections. When testing 
new secondary antibodies, or to determine the level of autofluorescence of the tissue, a double 
negative control slide was prepared which had no primary or secondary antibodies but had otherwise 
been processed in the same way as the stained sections.  
When testing new combinations of antibodies it was important to ensure that there was no cross 
reactivity or spectral overlap by running single stained control slides which were stained with only one 
primary antibody in turn but all relevant secondary antibodies, this allowed us to assess whether the 
primary antibody staining had successfully worked and to determine whether fluorescence was only 
observed in the channel of the species-specific fluorescently conjugated secondary antibody. Where 
necessary, positive control slides were run in parallel. Tissue for positive controls were reactive lymph 
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nodes or tonsil tissue. With the use of blocking antibody of the same species as the secondary 
antibodies and with our rigorous use of negative control slides, it was determined that isotype controls 
were not required in these experiments.     
2.4 Microscopy 
Images were acquired on a Nikon Eclipse Ti-E inverted microscope equipped with the Nikon A1R Si 
confocal imaging system and lasers that emitted light at the following wavelengths: 405nm, 488nm, 
561nm, and 642nm. Low power images were obtained with a Pan Fluor x10 objective and high power 
images with a Pan Apo oil immersion x60 objective. In order to maintain consistency and to permit 
comparative analyses, all images were collected on the same microscope. Positively stained sections 
were imaged first and settings such as laser power, photo multiplier tube (PMT) gain, pixel dwell time, 
pin hole size, optical section thickness, laser offset, and filter settings were kept the same for analysis 
of any paired control slides. As far as possible these settings were maintained for analysis of all 
similarly stained sections but this was not always possible as small differences in thickness of tissue 
sections, the quality of the tissue fixation, the size of the biopsy specimen (which also affects the 
quality of fixation), and the age of the specimen all affect the strength of antibody binding and 
fluorescence. Accordingly, whilst some settings were always maintained the same for all samples (pin 
hole size, pixel dwell time, filter settings, and optical section thickness), the laser power, PMT gain, 
and laser offset had to be optimised for the particular section being imaged. Determining the 
appropriate settings was facilitated using the ‘pixel saturation’ function of the image acquisition 
software. Laser power and PMT gain were adjusted for each channel in turn to obtain the optimal 
image which is indicated when only a few pixels are shown to be over saturated. The laser offset could 
then be reduced until areas of negativity were indicated to be under-saturated. These settings were 
kept consistent for acquisition of separate images obtained from one slide, and for comparison of 
positive and negative controls but, as described above, settings usually had to be optimised for 
different slides.   
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Low power images (x10 objective) were captured first then immersion oil was applied to the coverslip 
for further acquisition of high power (x60 objective) images. In some images, an area of interest was 
digitally magnified. Where this has been performed it is indicated in the figure legend. Large, ‘stitched’ 
images of adjacent low-power fields could be obtained which were ‘stitched’ together by the image 
acquisition software, this was useful for showing a large field for example giving an overview of several 
GCs within one image.  
The PMTs do not detect colour but the image acquisition and analysis software is able to generate 
colour for each channel. Any colour can be chosen for each channel but to maintain consistency the 
colours were kept the same for each channel in all images included in this thesis as detailed in Table 
2-4. As most images were obtained with 4 colours it was necessary to use white to indicate the signal 
in one of the channels (channel 4, wavelength 640nm), this is important to note as an area where blue, 
green, and red overlap are sometimes shown as white in fluorescent microscopy images.  
Table 2-4 Allocation of colours to different channels and the associated fluorochromes  
Channel number  Laser wavelength (nm) Colour allocated Fluorochromes 
1 405 Blue DAPI or Dy Light 405 
2 488 Green FITC or Alexa Fluor 488 
3 561 Red Alexa Fluor 555 
4 640 White Alexa Fluor 647 
 
One of the advantages of using a confocal microscope over a standard fluorescent microscope is that 
the field can be moved in 3 axes, X, Y and Z. By moving the stage vertically in the Z axis and capturing 
images at pre-defined intervals, Z-stacks (or Z-series) can be obtained. Reconstruction of Z-stacks 
permits the visualisation of the specimen in 3D which is particularly useful for investigating cellular 
interactions Figure 2-1. To obtain a Z-stack the focal plane was adjusted until the tissue was out of 
focus at the superior aspect of the tissue, the stage was then lowered until the section was out of 




Figure 2-1 Image indicating how a Z stack is formed.  A Z stack is a series of images taken at different planes in 
the z axis. Taking images through the section at different levels allows the images to be reconstructed in 3 
dimensions.   
The coordinates of the extremes of focal range were used by the operating system to define the upper 
and lower boundaries of the section. The stage was then automatically moved in the Z axis and a 
separate image acquired at each predefined step; a typical Z-stack of a 12µm section would consist of 
15 images. Z-stacks were not routinely acquired for all sections as they were very time consuming and 
expensive to obtain, lead to bleaching of the area of tissue examined, and added little to the analysis 
of the proportions of cells expressing certain antigens in large fields. Z-stacks were acquired to 
investigate areas of cellular interaction especially the interaction between Ki67 positive tumour cells 
and PD1+ T-cells. Video reconstructions of the Z stacks could be generated which helped to appreciate 
the cellular interactions in 3 dimensions.  
2.5 Image analysis 
Images were analysed using Nikon elements NIS Advanced Research version 4.2 software. Images 
presented in this report have been optimised for contrast using Look Up Tables (LUTs) and, where 
appropriate, cropping or magnification has been performed but no further image enhancement or 
manipulation has been implemented. The image acquisition and analysis software stores the image 
files as ND2 files, these have been converted to tiff files and either inserted directly into this report or 
combined into figures using Microsoft PowerPoint.  
72 
 
The automated or semi-automated analysis of images obtained by immunofluorescent confocal 
microscopy forms an important part of this work and is paramount to its success. Since this is not a 
standard analytical technique, a detailed description of the image analysis method used in this report 
follows.   
The first step in analysing images was to generate binary layers for the channels used. Binary layers 
are superimposed over the original image and do not affect the underlying image itself. A binary layer 
is essentially a ‘mask’ laid over the original image that indicates which areas of an image are 
considered as positive and which areas are negative in the channel(s) concerned. Generating binary 
layers for each channel permitted the accurate quantification of the amount of positive signal in an 
image, allowed the counting of cells as ‘objects’, and facilitated the analysis of co-localisation. As well 
as generating single channel binary layers it was possible to create binary layers where the signal in 2 
or more channels overlaps, so-called ‘intersection’ binary layers. Binary layers could be allocated any 
colour and can be applied to standard 2D images as well as to 3D Z-stack reconstructions.  
In most images in this report either 3 or 4 channels were used and binary layers needed to be 
generated for each channel except Channel 1 (405nm) if DAPI was used. A binary layer for DAPI was 
rarely generated as it was used as a nuclear counterstain only.  
To generate a binary layer for a particular channel the thresholds for the image first had to be set. This 
was a crucial step in the image analysis as it determined which areas of the image would be considered 
as positive signal and therefore included in the binary layer, and which areas were negative, or 
background and therefore excluded from the binary layer and not included in analysis. Thresholding 
of an image was performed on the basis of intensity of fluorescence and a number of possible 
restrictions for example size, area, and circularity.  
To set the threshold for a channel, representative areas considered positive were selected as 
reference points, these were selected using a ‘picker’ tool, this highlighted all other areas of the image 
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where the intensity measured in that channel was of the same or higher level, see Figure 2-2. Thresholds 
could also be set using histograms to define the upper and lower limits of the binary very precisely. 
Restrictions could be set to exclude areas below a certain size (e.g. <1.0µm) which were likely to be 
artefact, Figure 2-3, but this could also be performed mathematically on the data generated (by 
excluding all data from individual binary areas (or objects) below a certain size). Areas of 
autofluorescence or artefact such as formalin crystals or autofluorescing blood vessels could be 
deleted manually from the relevant binary layers. The use of a nuclear counterstain such as DAPI was 
helpful in determining whether signal detected was due to autofluorescence as it helped to define 
whether the signal was intracellular or not, areas of fluorescence that were not in a cellular area of 
the section were manually deleted, see Figure 2-4. 
Once the thresholds had been set, the binary layer could be further refined for example to clean the 
binary (remove small objects), smooth (flatten the contours), fill holes (for example fill in a cell where 
its outline has been defined by the binary), or separate the binary where a number of closely packed 
cells had been counted as a single object in the binary layer. It was important to perform the 
separation of objects within the binary carefully when performing cell counts, although there was an 
automatic function for this within NIS Elements, we found that this did not reliably separate individual 
cells in closely packed tissue sections. Therefore, additional manual object separation had to be 
performed; this was very time consuming. Separation of clusters of cells into individual objects was 




Figure 2-2 Example of thresholding and setting binary layers. x60 image of germinal centre labelled with A.i CD4 (red), B.i 
ICOS (green), C.i PD1 (white) and DAPI (blue). D.i All channels combined. To the right of each original image in A.ii-C.ii the 




Figure 2-3 Example of setting restrictions on a binary layer. x60 image of FL labelled with Ki67 (green) (A). In B the threshold 
has been set and the binary is shown in red without restrictions, note multiple small areas of binary (red) within the 2 white 
rectangles which is artefact, not Ki67+ cells. In C size restriction (exclude items <1µm in size) and ‘clean’ x1 have been applied 
and the difference can be seen within the 2 white rectangles 
 
Figure 2-4 Example of manually deleting areas of autofluorescence. This section has been labelled with Ki67 (red) (A) 
which should be nuclear giving a characteristic staining pattern but in this case there are linear structures included in the binary (white 
arrows). By combining this with the DAPI channel image (blue) it can be confirmed that these areas are not cellular and may represent 
collagen or elastin in vessels. Since these are not thought to be Ki67+ cells, they can be manually deleted so giving a clean binary layer for 
Ki67 (C) 
 
Figure 2-5 Example of using automatic object separation. In A, 3 separate Ki67 positive (green) cells can be identified 
(white arrows). In B the binary layer has included these 3 cells as one large object (red). By applying the 'separate' 
modification to the binary layer, the 3 cells are separated (blue arrows). This function can also be performed manually. (x60 
zoomed image). 




The threshold levels, restrictions and refinements, once set for all channels in an image, could be saved 
and the same thresholds applied to other acquired images. Whenever a negative control was 
analysed, the same thresholds were applied to determine whether any fluorescence detected met the 
criteria for being included as positive events. 
To measure only a certain part of an image, a region of interest (ROI) could be set. This was useful for 
example when looking only at cells within, or outside of a GC in an image that contained both areas, 
see Figure 2-6. 
 
Figure 2-6 x60 image of germinal centre (A). In B a region of interest (ROI) has been drawn around the edge of 
the GC so that the binary layers (C) can be measured within and outside of the GC. 
 
ROIs could also be used when measuring the amount of co-expression of antigens within cells, this 
worked best with a nuclear stain (e.g. Ki67 or FOXP3). The binary layer was set as described above and 
then converted into separate regions of interest. Each positive cell is then a separate ROI and 
interrogation of the amount of binary layers in each ROI (i.e. within each cell) could be performed. See 
section 3.4 below.   
It was not possible to use exactly the same thresholds and settings for all images. As described in 
section 2.4 above, differences in thickness of tissue sections, the quality of the tissue fixation, the focal 
plane and other factors affect the strength of fluorescence, therefore whilst every effort was made to 
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keep acquisition and analysis settings the same, it was necessary to make fine adjustments to these 
settings for different specimens.  
Further details about the specific image analysis method used are presented in the relevant sections 
of the results chapter.  
 
2.6 Investigating the TCR repertoire 
In order to investigate the antigen specificity of the CD4+ T cell compartment in FL lymph nodes we 
performed high throughput sequencing of DNA extracted from FFPE tumour samples.  
An initial experiment was performed to determine if sufficient DNA could be extracted from FFPE 
samples to perform high-throughput sequencing of the CDR3 of the TCRβ subunits.  
For this preliminary experiment, 2 separate lymph nodes biopsied simultaneously in the same patient 
at the time of original diagnosis were used.  
For extraction of DNA from whole sections, 5 x 10µm thick ‘rolls’ of tissue were cut from the paraffin 
blocks (as described above) and collected directly into a DNase free Eppendorf tubes.   
The sections were deparaffinised in xylene. Genomic DNA was then extracted from FFPE tissue using 
the QIAGEN miniDNA kit according to the manufacturer’s instructions.  
DNA quantification and quality assessment was performed using the NanoDrop spectrophotometer 
according to the manufacturer’s instructions. The size of extracted DNA fragments was further 
assessed by gel electrophoresis.  
The yield from this preliminary experiment was good and the samples were subsequently frozen and 
shipped to ImmunoSeq in Seattle, USA for high throughput deep sequencing of the CDR3 TCRβ 
subunits. Deep sequencing was successful and analysis revealed that there was overlap in the TCRβ 
repertoire between the two distant lymph nodes, lending support to the hypothesis that T cells 
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infiltrating the FL tumour microenvironment demonstrate antigen specificity, see results in section 3.9 
below for further details.  
This pilot project revealed that DNA could be successfully extracted from FFPE samples, the TCRβ 
repertoires could be sequenced, and that there was overlap between 2 distant lymph nodes biopsied 
at the same time.   
We had previously identified that the phenotype of the T cells in FL depends on their location (whether 
follicular or interfollicular), and demonstrated that the interaction between TFH and proliferating 
neoplastic cells is restricted to the follicles. We therefore determined that to further understand the 
specificity, clonality and spatial heterogeneity of the T cell response in FL, it was necessary to dissect 
LN sections and interrogate the TCR repertoires in different compartments rather than sequencing 
the TCRs from entire LN sections.  
We hypothesised that if CD4+ TFH cells are present in the follicles as a result of a specific response to 
antigen, the TCR repertoire between different follicles within the same LN would be similar. We 
therefore determined that it would be valuable to laser dissect follicles, extract DNA from separate 
follicles and perform comparisons of receptor repertoire between follicles.  
We next performed some preliminary experiments to determine if this approach was feasible. 
Unfortunately, too little DNA could be extracted from individual follicles to permit analysis. We 
therefore experimented with the technique to determine if sequential sections from the same LN 
could be stained and the same follicle dissected from each section according to the schema depicted 




Figure 2-7 Proposed method for comparing the TCRβ repertoire of 2 follicles. Sequential sections of an FFPE 
lymph node biopsy were mounted onto slides. Serial sections of one malignant follicle (A) dissected using a laser 
capture microscope and specimens collected into tube A. Serial sections of a separate malignant follicle (B) from 
the same specimen micro-dissected and captured in tube B. DNA could then be extracted from the tissue in each 
collection tube and the TCRβ repertoire from follicle A could then be compared with that from follicle B 
 
This proved to be technically unfeasible as it was not possible to reliably identify the same follicle in 
sequential sections and the yield of genomic DNA extracted was too low for sequencing even when 
sequential sections of the same follicle were able to be dissected.  
We subsequently refined our approach by investigating if the TCR repertoire from the follicular areas 
of a FL LN was significantly different to the TCR repertoire of interfollicular areas from the same LN – 
see section 2.6.2 below.  
Since we have identified that the T cells within the follicles are phenotypically significantly different to 
the T cells in the interfollicular areas, we hypothesised that the follicular TCR repertoire – where TFH 




2.6.1 Staining of samples for laser dissection 
To distinguish between follicular and inter-follicular areas of tissue, sections were first stained with 
anti-BCL-6 by standard immunohistochemistry using the VECTASTAIN ABC system (Vector 
Laboratories, California, USA). The FFPE tissue block was cooled on ice prior to sectioning, thick 
sections (12µm) were cut from the  block and floated onto sterile water at 40°C before mounting on 
to uncoated slides and drying as described in section 2.3.1 above. To reduce the risk of sample cross-
contamination, all surfaces were cleaned with trisol detergent between specimens, the disposable 
microtome blade was changed after each section had been cut, the first 5 sections from each block 
were discarded, and strict aseptic technique precautions were observed.  
Deparafinisation was carried out as per section 2.3.1 above. Endogenous peroxidase was then blocked 
in 0.5% hydrogen peroxidase (Sigma) for 10 minutes. Heat induced antigen retrieval was performed 
in pH 6.1 citrate buffer as per section 2.3.1 above. Subsequently sections were blocked in 3% horse 
serum with avidin for 1 hour at room temperature before biotin blocking (15 minutes at room 
temperature). Mouse anti-human BCL-6 monoclonal antibody was diluted in PBS to 1:50 and this was 
pipetted onto the specimens, slides were incubated overnight at 4°C. The primary antibody was 
thoroughly washed off and secondary antibody (biotinylated anti-mouse IgG, raised in horse, Vector 
Laboratories) diluted to 1:100 was added for 1 hour at room temperature. After washing, avidin-
biotinylated enzyme complex (ABC) (Vector Laboratories) was prepared and added to the sections for 
30 minutes at room temperature before further washing. The antibody labelling was then visualised 
using ImmPact Diaminobenzidine (DAB, Vector Laboratories). DAB was diluted according to the 
manufacturer’s instructions and added to the tissue section which was observed directly under a light 
microscope until sufficient staining (brown colour) was observed, the slide was then immediately 
washed in water. Nuclear counterstaining was performed with haematoxylin which was added to the 




2.6.2 Laser dissection of follicles and inter-follicular regions 
Laser capture microscopy permits the non-contact capture of particular areas of tissue from samples 
for a variety of downstream applications including extraction and analysis of DNA or RNA from specific 
areas of tissue.    
Laser dissection was performed using a Zeiss microscope fitted with the PALM Zeiss LCM system, see 
Figure 2-8. The PALM laser dissection system is operated according to the following principles. The 
areas to be captured are first highlighted using the software package. The lid of the collection tube is 
held in position by a clamp above the sample. The UV cutting laser is activated below the sample and 
the robotic stage moves the sample so that the areas demarcated by the software are cleanly cut. 
Once all highlighted areas are cut, a second pulse of laser at a different wave length to the cutting 
laser is directed through the sample to ‘catapult’ the dissected tissue into the collection cap which is 
held approximately 1mm above the sample. The collection caps have a self-adhesive coating so that 
areas of tissue catapulted upwards from the specimen are collected directly into the cap, Figure 2-8.  
We experimented with a number of different techniques for the laser dissection and capture of 
follicles and inter-follicular regions of FFPE FL lymph node sections. The optimal yield would have been 
achieved by mounting the samples on to dedicated laser-capture membrane slides. These are slides 
made of a membrane that is easily ‘cut’ by the laser, the sample and the membrane so dissected are 
captured together using this method. Despite many attempts, it was not possible to overcome 
difficulties in fixing the samples to the membranes sufficiently strongly to withstand the IHC labelling 
process. We therefore had to mount the samples on standard glass slides. To optimise the easy cutting 
and catapulting of tissue from the glass slides, uncoated slides were used for this process as the tissue 
is too firmly attached to poly-L-lysine coated slides for capture. Compared to membrane slides, the 
yield of tissue was lower for each specimen as some parts of the demarcated tissue remained firmly 
adherent to the glass slides, nevertheless we had to pursue this technique due to the difficulties 




Figure 2-8 Figure showing set up of laser dissection system. A. The PALM Zeiss system consists of an inverted 
Axiovert Zeiss microscope, PALM robo laser system and stage, and PALM software package. B. Areas to be 
dissected are highlighted using the software system, a laser is then directed through the slide and specimen to 
cut out the area to be dissected. Pulses of laser are then directed through the sample to lift or ‘catapult’ the 
specimen into the collection tube cap (C). Note that samples must not be covered with a cover slip and that the 
sample is facing upwards on the slide with the lens of the inverted microscope below the glass slide. The pathway 
of the laser is through the inverted objective, through the glass slide and into the specimen (B).  Images adapted 
from ZEISS manual.   
 
Dissection and collection of samples was according to the schema depicted in Figure 2-9. Firstly, areas 
identified as follicles – highlighted by BCL6 staining - were demarcated using the software package, 
the follicles were then circumscribed with the cutting laser before being ‘catapulted’ into the caps of 
the collection tubes.  
It was observed that not all of the material ‘cut’ from the specimen and ‘catapulted’ towards the 
adhesive cap of the collection tube was captured in the adhesive material and some microscopic tissue 
fragments fell back onto the slide where it could then erroneously be catapulted into the incorrect 
tube e.g. follicular material could be collected into the interfollicular collection tube and vice versa. It 
was therefore necessary to dissect and collect follicular material from one section, and then collect 
interfollicular material from a separate, sequential section from the same sample to prevent cross-
contamination of material into the relevant collection tubes.  
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To maximise the yield, six sequential sections from the same block were used for each sample. 
Equivalent areas of follicular and interfollicular tissue were collected from sequential sections from 
each of five separate FL LN specimens.  
 
Figure 2-9 Schema demonstrating method for comparing the TCRβ repertoire of follicular verus interfollicular 
T cells. Sections of FFPE lymph node biopsy mounted onto slides. The inter-follicular areas (pink) dissected using 
a laser capture microscope and specimens catapulted into collection tube A. Follicular areas (blue) from the 
same specimen microdissected and catapulted into tube B. To maximise the yield, this was repeated for 6 
sections from each sample (not depicted in this schema) and to minimise cross-contamination of inter-follicular 
and follicular areas, separate sections were used for Tube A and B (not depicted in this schema). The TCRβ 
repertoire of the inter-follicular area (A) was then compared with that of the follicles (B). 
 
2.6.3 DNA extraction 
DNA was extracted from the laser captured tissue using the QIAGEN miniDNA kit following the 
manufacturer’s protocol. The yield of DNA was assessed using the NanoDrop spectrophotometer.  
Strict microbiological aseptic technique was followed at all steps of sample processing, dissection, 
DNA extraction and analysis to prevent sample contamination from external sources or cross-




2.6.4 TCR repertoire sequencing and analysis 
After extraction, the DNA was shipped to Adaptive Biotechnolgies, Seattle, USA where 
TCRsequences were PCR amplified using consensus primers prior to next generation sequencing 
(NGS) using an Illumina platform (Adaptive Biotechnologies, Seattle, WA. USA).  
Results from sequencing were released by Adaptive Biotechnologies through their proprietary 
software package, ImmunoSEQ. The immunoSEQ Platform permits quantification of TCRs, calculation 
of clonality and assessment of degree of overlap between specimens. Further description of the 
analysis of TCR repertoires, clonality and entropy are presented in the relevant results section 3.9.  
 
2.7 Statistical analysis 
Data generated in Nikon Elements NIS advanced research software were exported to Microsoft Excel 
and statistical analysis was performed using Graph Pad prism software version 5.0 (GraphPad 
Software Inc, La Jolla, California, USA).  
Normally distributed values are presented as the mean (SD), non-normally distributed values are 
presented as median (IQR).  
Normally distributed variables were compared using two-tailed Students unpaired t tests, non-
normally distributed data were compared with the Mann Whitney test.  
For comparison of paired data, Wilcoxon or Students paired t tests were used. Statistical significance 
was assumed when P was <0.05.  
Contingency tables were used to determine whether Ki67pos cells were more likely than non-
proliferating cells to be in contact with TFH. Fisher’s exact test was used to compare individual samples, 
for comparing total numbers of cells in multiple samples, Fisher’s exact test was used for GCs, and Chi 
squared for FL.  
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For correlations e.g. between number of Ki67pos cells and number of TFH, Spearman non-parametric 
correlation coefficient was used.   






Chapter 3 Results 
3.1 Specimens and clinical details 
FFPE lymph node biopsy blocks were obtained from the archives of the department of histopathology 
at King’s College Hospital, London from 8 patients with reactive lymphadenopathy, 2 excised tonsils 
(for control tissue only), 7 cases of CLL, and 25 cases of FL.  
The clinical details for the patients with FL are detailed in Table 3-1. Of the FL samples, 18 were from 
biopsies taken at the time of initial presentation before any treatment had been administered, 7 were 
from biopsies taken at relapse, in all of these cases, no treatment had been given for FL for at least 12 
months prior to biopsy. 17 samples were from patients with grade 1-2 FL, 5 samples were from 
patients with grade 3a disease and 3 were from patients with grade 3b disease. 8 patients have not 
received any treatment but are being managed under a ‘watch and wait’ approach which is the current 
standard of care in advanced stage asymptomatic disease.  
Limited clinical details relating to the specimens from patients with reactive lymphadenopathy are 
presented in Table 3-2. Since FL has a mean age of presentation of 64 years and is very rare in 
childhood, and reactive lymphadenopathy can occur at any age, including in childhood, the median 
age of patients with reactive lymphadenopathy was younger than for the FL patients, 33.0 years versus 




Table 3-1: Clinical Characteristics of FL Patients 
Sample Age 
(years) 
Gender Grade Stage Disease status at 
biopsy 
Initial management (after 
current biopsy) 
FL001 68 Female 1 IV relapse R-CVP 
FL002 88 Female 3b I untreated not treated* 
FL003 47 Male 2 IV untreated R-CVP 
FL004 56 Male 2 IV untreated R-CHOP 
FL005 45 Female 2 IV untreated R-CVP 
FL006 41 Male 2 IV untreated R-CHOP + R  
FL007 63 Female 3a III untreated R-CHOP 
FL008 60 Female 1 III untreated W&W 
FL009 34 Female 3b I untreated R-CHOP + RT 
FL010 70 Female 2 III relapse R-CVP + R 
FL011 58 Male 3b III untreated R-CHOP   
FL012 29 Male 2 IV untreated R-CVP 
FL013 47 Female 1 IV relapse R-FC + ASCT 
FL014 54 Male 2 III untreated W&W 
FL015 57 Male 1 IV untreated R-CVP 
FL016 32 Male 3a IV untreated W&W 
FL017 33 Male 1 - 2  IV relapse W&W 
FL018 52 Male 1 - 2  IV untreated W&W  
FL019 58 Male 3a IV relapse R-bendamustine 
FL020 38 Female 1 - 2  III untreated W&W 
FL021 63 Female 1 III untreated W&W 
FL022 88 Female 1 IV relapse R-CVP  
FL023 62 Male 1 - 2 II relapse W&W 
FL024 55 Female 3a III untreated R-bendamustine 
FL025 60 Male 3a III untreated R-bendamustine 
 
* too frail to receive treatment and died due to ischemic heart disease and FL 5 months after diagnosis 
 
R-CVP = rituximab, cyclophosphamide, vincristine, prednisolone. R-CHOP = rituximab, cyclophosphamide, 
doxorubicin, vincristine, prednisolone. W&W = watch and wait. RT = radiotherapy. R-FC = rituximab, 
fludarabine, cyclophosphamide. R = rituximab. CR = complete response. PR = partial response. HSCT = 




Table 3-2 Characteristics of patients with reactive lymphadenopathy 
Sample Age (years) Gender Histological diagnosis 
rLN01 29 Male Reactive hyperplasia 
rLN02 1 Male Reactive hyperplasia 
rLN03 35 Female Reactive lymph node 
rLN04 40 Female Reactive lymph node 
rLN05 27 Male Reactive hyperplasia 
rLN06 53 Female Reactive lymph node 
rLN07 25 Male Reactive hyperplasia 




3.2 Optimising the multiple labelling technique 
Before conducting multiple labelling experiments, it was first necessary to optimise the method of 
antigen retrieval and determine the contribution of tissue autofluorescence to any signal detected. It 
was then necessary to demonstrate that the primary antibodies could be used on FFPE material 
successfully without cross reacting and that they could be detected using fluorescently conjugated 
secondary antibodies without spectral overlap.  
3.2.1 Antigen retrieval 
Heat induced antigen retrieval was initially performed with pH 6.1 citrate buffer. Some primary 
antibodies gave rise to either non-specific labelling or no discernible labelling. In these instances, 
antigen retrieval with pH9.0 Tris-EDTA was attempted but this did not lead to an improvement in 
labelling in any cases and the primary antibodies were concluded to be incompatible with this 
experimental method and alternative antibodies were sourced.  
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Accordingly, all antigen retrieval was subsequently performed in pH 6.1 citrate buffer. The addition of 
Tween 20 to the citrate buffer gave rise to a slightly cleaner signal with less background although the 
difference was small (data not shown). Tween 20 (0.05%) was added to pH 6.1 citrate buffer solution 
in all labelling experiments.  
3.2.2 Reducing autofluorescence and non-specific binding of secondary antibodies 
For most combinations of antibodies, autofluorescence of the tissue sections was not a significant 
problem. Where autofluorescence was observed it was usually detected in channel 405 (blue) or 488 
(green) with very little autofluorescence in the other two channels. It was found that using secondary 
antibodies conjugated to Alexa Fluor 488 rather than FITC gave a higher signal-to-background ratio, 
therefore Alexa Fluor 488 was the fluorochrome of choice for secondary antibodies detected in 
channel 488.  
Blocking with normal serum from the species in which the secondary antibodies were raised reduces 
the cross reaction of the secondary antibody with endogenous immunoglobulins in the tissue and 
reduces Fc receptor binding of both primary and secondary antibodies. Optimal blocking was with 5% 
donkey serum for 1 hour at room temperature. No improvement in staining or reduction in non-
specific secondary antibody staining was observed through additional blocking prior to incubation 
with the secondary antibodies or by diluting the antibodies in PBS with 5% blocking serum rather than 
PBS alone (data not shown).  
Antibodies were diluted in PBS, there was no discernible difference in background staining when 
antibodies were diluted in Tris-buffered saline (TBS). It has been suggested that 0.025% Triton X-100 
added to the PBS in which antibodies are diluted dissolves Fc receptors leading to reduced non-specific 
binding; we observed minimal reduction in background staining through the addition of Triton-X but 
it did reduce the surface tension of the antibody mixture which helped to ensure that the tissue 
sections were completely covered with antibody, this facilitated even staining and prevented areas of 
tissue from drying out during prolonged incubations. 
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3.2.3 Labelling with 3 antibodies simultaneously 
To develop a multi-labelling experiment it was necessary to identify combinations of primary and 
secondary antibodies that would work together.  
To reduce the risk of detecting a false signal through cross reactivity of antibodies, primary antibodies 
from 3 different species were used, mouse, goat, and rabbit, and secondary antibodies were from a 
different species (Donkey).  
The first combinations tested were anti-CD4 (mouse) or anti-Ki67 (mouse), anti-PD1 (goat), and anti-
ICOS (rabbit) antibodies. It was determined in single labelling experiments that the primary antibodies 
worked with this technique, and the optimal concentrations and incubation conditions were 
established. Next it was assessed whether these antibodies could be used in combination without 
cross reacting with each other and whether, when fluorescently labelled, they could be detected 
without significant spectral overlap or secondary antibody species cross reactivity. As shown 
previously in Figure 2-2, primary antibodies raised in mouse, goat and rabbit were successfully labelled 
and detected with the application of species-specific, fluorescently labelled secondary antibodies. This 
combination was successfully used with DAPI as a nuclear stain.  
When slides were stained with only one primary antibody in turn but all secondary antibodies, no 
spectral overlap was detected, Figure 3-1.  
A low level of autofluorescence was observed in most cases; where autofluorescence was detected, it 
was usually in the 488 (green) channel and was mostly identified in blood vessels (where elastin and 
collagen autofluoresce), or in formalin crystals. The level of background autofluorescence was usually 
low and easily distinguished from the positive signal.   
Many different combinations of the primary antibodies listed in Table 2-2 were successfully used 
simultaneously. The primary antibodies used in all combinations were from different species, i.e. 2 or 




Figure 3-1 Figure showing controls in multi-labelling experiments. In A-C, 3 different fluorescently labelled 
donkey antibodies plus DAPI (blue) have been added to the slides. In Ai, Bi, and Ci only 1 primary antibody has 
been added to the slide (red = Ki67, green = ICOS and white = PD1), each one is shown in the channel where the 
signal is anticipated. In the images on the right, the other channels are shown demonstrating that there has 
been no spectral overlap or non-specific secondary antibody binding. There is background fluorescence seen in 
the green channel (488) in images A.ii, C.ii. This is confirmed in the double negative slide in which low-level non-




3.2.4 Labelling with 4 antibodies simultaneously 
In order to further develop the technique and to permit more refined distinction of cell types and their 
associations, a 4-antibody labelling protocol was developed. This was developed in particular so that 
an antibody against a T cell specific antigen (CD3) could be used in conjunction with an antibody 
against a B cell specific antigen (CD20) and 2 further antibodies for example Ki67 and PD1 to allow the 
investigation of co-localisation between proliferating B cells (Ki67, CD20) and PD1+ T-cells.  
In this protocol the 405nm wavelength laser was used to excite a DyLight 405 conjugated secondary 
antibody rather than DAPI. The choice of primary antibodies that could be used in conjunction with 3 
other antibodies raised in mouse, goat, and rabbit was limited, and no suitable anti-CD4 antibody 
could be identified but a monoclonal anti-CD3 antibody raised in rat that did not cross react with the 
other primary antibodies was sourced.  
The antibodies used are listed in Table 3-3. The first attempts at 4-antibody labelling were unsuccessful 
as the level of background fluorescence in the 405 channel was too high to reliably detect the positive 
signal from the CD3 antibody, Figure 3-2A.  
Table 3-3 Initial antibody panel for 4 antibody labelling 
Primary antibody Secondary antibody 
CD3 – rat  Donkey anti-rat DyLight 405 
CD20 – mouse Donkey anti-mouse Alexa Fluor 555 
PD1 – goat Donkey anti-goat Alexa Fluor 647 





Figure 3-2 Difficulties staining CD3 with donkey anti-rat DyLight 405. A: CD3 (blue) has been stained but the 
positive signal is hard to appreciate above the high background signal. B: When the same CD3 antibody is 
detected with donkey anti-rat Alexa Fluor 647, a clean signal is obtained (white). C: The signal obtained in B is 
confirmed to be genuine by co-staining with anti-CD4 which shows a very similar pattern of staining (red). D. 
Double negative control (no primary or secondary antibody). This suggests that the primary anti-CD3 antibody 
works and is specific but it is not well detected above the high background signal in the 405 channel. 
 
Possible causes for the high level of background in the 405 channel were non-specific binding of the 
primary antibody, tissue autofluorescence, non-specific binding of the secondary antibody, or spill-
over (spectral overlap) from the other channels. All of these possibilities were investigated.  
It was found that the primary antibody worked well when detected with alternative secondary 
antibodies (donkey-anti-rat Alexa Fluor 647, or donkey-anti-rat Alexa Fluor 488) and that the 
distribution of CD3+ cells closely matched the distribution of CD4+ cells in the same section, Figure 
3-2B and C. Next it was demonstrated that, in a double negative control slide (no primary or secondary 
antibody), there was very minimal tissue autofluorescence seen in the 405 channel (Figure 3-3A), and 
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in single antibody controls, no spectral overlap from other channels was identified. It was therefore 
most likely that the high level of background fluorescence was due to non-specific binding of the 
secondary antibody to the tissue, indeed in the secondary antibody control slide (no primary antibody, 
donkey anti rat DyLight 405 secondary only) there was a very high background signal in the 405 
channel (Figure 3-3B). To attempt to reduce this, the following steps were introduced: a second 
blocking step with 5% donkey serum prior to secondary antibody incubation, prolonged washing after 
the secondary antibody incubation, and further diluting the secondary antibody to 1:400. However, 
none of these steps led to an appreciable reduction in the high level of background in the 405 channel 
which made interpreting the pattern of CD3 staining very difficult due to the poor signal to background 
ratio.  
 
Figure 3-3 Non-specific staining with DyLight 405 (blue). When no primary or secondary antibodies are used 
there is minimal autofluorescence in the 405 channel (A). When the donkey anti-rat DyLight 405 secondary 
antibody is used alone with no primary antibodies, a high level of background fluorescence is obtained in the 
405 channel (B).  
Since this problem could not be resolved it was decided to change the secondary antibodies so that 
the primary antibody with the strongest and most distinctive pattern of staining (Ki67) was detected 
by labelling with the secondary antibody with the lowest signal to background ratio (DyLight 405) 
whilst the anti-CD3 antibody which does not have such a distinctive or characteristic staining pattern 
was detected with a stronger fluorescently conjugated secondary antibody (donkey anti-rat Alexa 
Fluor 488). This was found to give excellent results with Ki67 (detected with donkey anti-rabbit DyLight 
405) clearly identified above the background signal in the 405 channel and very clear CD3 staining 
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detected in the 488 channel, Figure 3-4. Once this technique had been developed it permitted the 
investigation of further combinations with 4 simultaneously labelled antibodies, see Table 3-4. 
Table 3-4 Potential antibody combinations for 4 colour labelling experiments 
Rat Goat Rabbit Mouse 
CD3 PD1 Ki67 CD20 
CD3 PD1 Ki67 AID 




Figure 3-4 Successful 4 antibody labelling of Ki67 (blue), CD20 (red), CD3 (green), and PD1 (white) in FL. (Image 
acquired with x10 objective). 
97 
 
3.3 Distribution and phenotype of T Follicular Helper Cells in FL, reactive LN, and 
CLL 
The phenotype and function of Follicular helper T cells (TFH) are detailed in section 1.3 above. TFH cells 
have been described in FL by flow cytometry of disaggregated lymph nodes and single parameter IHC 
studies have revealed PD1+ cells to be limited mainly to the follicles where an increased number has 
been reported to be associated with better prognosis (see section 1.6.2). Limitations to previous 
research in this area are related to the methodology used; single parameter IHC is unable to accurately 
identify complex cellular subsets and flow cytometry on disaggregated LNs is unable to provide 
detailed information about the distribution and location of particular cell populations with regards to 
the follicles.  
Thus, one of the key aims of this part of my research was to establish the phenotype and distribution 
of CD4+ T cells in FL and to make direct comparisons to the findings in GCs. This sophisticated method 
of analysing populations of cells in situ has not been previously performed in FL or GCs and accordingly 
novel insights into TFH in both FL and GCs have been attained. 
Since PD1, ICOS, Bcl-6, and CXCR5 can be expressed by various T cell subsets and both Bcl-6 and PD1 
can be identified in FL B cells, no single marker can be used to identify TFH cells and this is a problem 
of single parameter IHC studies that have used PD1 as a surrogate marker for TFH cells.  
In this research we developed a protocol using antibodies against CD4, PD1, and ICOS simultaneously 
to identify TFH cells by confocal immunofluorescent microscopy. As detailed above, this combination 
of antibodies could be used with a nuclear counterstain (DAPI) without cross reaction and with well 
separated fluorescently labelled secondary antibodies. We investigated the proportion of CD4+ cells 
with a TFH phenotype within follicles (follicular) and outside follicles (interfollicular) in FL, within and 
outside of GCs in reactive lymph nodes, and for comparison with another lymphoproliferative 
disorder, in lymph nodes infiltrated with CLL.   
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3.3.1 Distribution and proportion of CD4+ T cells with TFH phenotype in FL 
The distribution of CD4+ T cells in FL is striking; they were identified in all specimens analysed and 
were predominantly located in the interfollicular areas or at the border of the follicles where they 
often form dense infiltrates with relatively few scattered CD4+ T cells within the B cell rich malignant 
follicles. This predominantly interfollicular pattern of CD4+ T cell distribution was identified in 21/25 
(84%) cases examined. In the remaining 4 cases, the pattern of CD4+ T cell infiltration was either 
indistinct (3/25 cases, 12%) or in one case (4%) the pattern appeared predominantly follicular (Case 
004, a previously untreated male patient with Grade 2 FL). There was no clear association between 
histological grade and CD4 pattern of distribution. In the 4 cases not demonstrating the predominantly 
interfollicular CD4 pattern, the follicular structure was indistinct in the biopsy specimen as the follicles 




Figure 3-5 The distribution of CD4+ T cells in FL. CD4 (red) infiltration was interfollicular in 84% of samples (A 
and B) but can be mixed (C), or was predominantly follicular in one case (D). Nuclear counter stain is with DAPI 
(blue). (All images acquired with x10 objective, scale bars represent 100μm) 
 
By measuring the proportion of CD4+ cells that co-expressed the surface antigens PD1 and ICOS it was 
possible to determine the proportion of CD4+ cells with a TFH phenotype in the follicular and 
interfollicular areas of infiltrated lymph nodes.  
CD4+ PD1+ ICOS+ cells were identified within the follicles of all cases of FL examined (n=25).  
Analysis of an average of 5 high power (x60 objective) fields from representative follicular areas per 
specimen revealed that the median proportion of follicular CD4+ cells co-expressing both PD1 and 
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ICOS was 25.0% (18.5-28.7). The CD4+ PD1+ ICOS+ cells were tightly restricted to the follicles with only 
3.63% (1.89-6.15) of interfollicular CD4+ cells co-expressing PD-1 and ICOS. As discussed in section 
3.3.1.3 on page 108 below, it was not possible to generate a reliable, reproducible, automated method 
of calculating the absolute number of CD4+ cells present in any given image. 
The proportion of CD4+ T cells with a TFH phenotype within follicles was significantly higher than the 
proportion in interfollicular areas, p<0.001, (Mann-Whitney test), Figure 3-6. A representative high 
power field of a follicle showing the original image, the intersection of the CD4, PD1 and ICOS binary 
layers and how this relates to the CD4 layer is shown in Figure 3-7. 
Figure 3-6 The proportion of CD4+ cells with a TFH phenotype is significantly higher within FL follicles than in 





Figure 3-7. TFH cells in FL. A. The original image is shown with DAPI (blue) CD4 (red) ICOS (green) and PD1 (white). 
B. The intersection of the binary layers for CD4 PD1 and ICOS is shown in pink highlighting the TFH cells. C. The 
relationship of the intersecting binary layer to the CD4 (red) cells is shown. It can be seen that CD4+ cells (red) 
outside of the follicle (top left of image) do not co-express PD1 and ICOS (All images acquired with x60 objective, 
scale bars represent 25μm) 
 
The distribution of TFH cells with regards to the follicles was variable; in 46% of cases there was a 
predominantly perifollicular distribution of TFH cells forming a ‘halo’ around the edge of the follicles. 
In 38% of cases the TFH cells were mainly concentrated in the centre of the follicles, and in the 
remaining cases (17%), the distribution was diffuse or mixed, 
Figure 3-8. There may be a relationship between the pattern of distribution of TFH cells, histological 
grade and rate of proliferation; 6/9 (66%) of cases with a follicular pattern of TFH distribution were 
grade 3a or 3b disease whereas only 1/11 (9%) of cases with a perifollicular pattern of distribution had 
grade 3a disease. Not enough data has been generated to date to determine the significance of this 





Figure 3-8. Figure showing patterns of TFH location in FL. CD4 (red), ICOS (green), PD1 (white), DAPI (blue). In 
Ai, Bi and Ci the original images are shown. In Aii, Bii and Cii, the DAPI layer (blue) is shown with superimposed 
binary layer of the intersection of CD4, PD1 and ICOS (pink). This highlights the mainly perifollicular location of 
TFH in A and B whilst in C the TFH are centrally located in the follicles. (All images acquired with x10 objective, 




The need for multi parameter labelling to identify the complex T cell subsets present in the FL 
microenvironment is highlighted by the observation that whilst 46.9% (34.7-51.9) of follicular CD4+ 
cells were positive for PD1, only 52.2% (45.7-61.9) of these co-expressed ICOS. In interfollicular areas, 
9.3% (5.1-26.4) of CD4+ cells were positive for PD1 but almost two thirds of these (62% ± 4.8) did not 
co-express ICOS. Therefore, single staining for PD1 (or dual labelling for CD4 and PD1) would 
significantly overestimate the proportion of TFH cells as it would encompass two distinct populations 
of T cells, CD4+/PD1+/ICOS+ and CD4+/PD1+/ICOS- cells, as well as PD1+ B cells. 
3.3.1.1 Confirmation that CD4+ PD1+ ICOS+ cells are TFH.  
The complexity of phenotyping of CD4+ T cell subsets meant that it was necessary to perform further 
experiments to confirm that cells identified as CD4+, PD1+, ICOS+ were indeed TFH.  
A 4-antibody panel comprising CD3, BCL-6, PD1, and ICOS was developed in order to investigate 
whether the PD1+ ICOS+ T-cells expressed BCL-6, the transcription factors essential for TFH 
differentiation. Technical limitations meant that it was not possible to stain simultaneously with CD4, 
BCL6, PD1, and ICOS, hence CD3 was used in place of CD4. 15 images from 5 FL specimens were 
analysed using this technique. As expected, the FL B cells within follicles were strongly positive for 
BCL-6 and it was observed that a population of CD3+ T-cells within the follicles were also positive for 
BCL-6, Figure 3-9 and Figure 3-11. 89.6% (88.3-91.8) of PD-1+ ICOS+ CD3+ cells were BCL-6 positive 
strongly indicating that the majority of PD1+ ICOS+ T cells are TFH. 
This is the first time that BCL6 positive, CD4+ T cells with a TFH phenotype have  been demonstrated in 
situ in FL.  
Interestingly, the level of expression of BCL-6 was intermediate in TFH; lower than in FL B-cells but 




Figure 3-9 BCL-6 is present in PD1+ ICOS+ cells. Follicle in FL showing BCL-6 (red), ICOS (green), PD1 (white) and 
DAPI (blue). The area in the white rectangle has been magnified in the figure on the right and the binary layers 
for BCL6 (turquoise) and PD1/ICOS intersection (pink) are shown. This shows that most PD1+ ICOS+ cells (pink) 
are BCL6 positive. (Magnified area of image acquired with x10 objective, scale bar represents 100μm) 
 
 
Figure 3-10 Intensity of BCL-6 expression in FL: expression is significantly higher in TFH than other T-cells but is 
significantly lower than in the FL B-cells. (Horizontal bars represent mean). Analysis performed on 15 images 
obtained from 5 samples. Individual dots represent intensity of expression on BCL6 in a given cell. Mean intensity 
compared by Mann Whitney Tests.  
The analysis of these images could not be automated and required significant operator input to 
identify the cells in which BCL-6 expression was to be measured. This had the potential to introduce 
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bias to the system which was overcome by verifying the images with a second investigator, and was 
also very time consuming which prevented us from using this assay on more samples. Mean intensity 
of BCL6 expression within a given cell was measured using the automated intensity tool in the image 
analysis software.  
 
Figure 3-11. PD1+ ICOS+ T cells express BCL-6. A. 4 CD3+ T cells (blue) are seen in this highly magnified FL 
section. The 3 T cells labelled with white arrows are positive for BCL-6 (red). There is one T cell that is not positive 
for BCL-6 (green arrow). B. The 3 T cells that are positive for BCL-6 are also ICOS (green) and PD1 (white) positive 
confirming these as TFH cells. The BCL-6 negative T cell (green arrow) expresses neither PD1 or ICOS. The BCL-6+ 
(red) non-T-cells in this image are FL B cells. (Magnified area of image acquired with x60 objective, scale bar 
represents 5μm) 
 
Since technical limitations meant that we had to stain with CD3 instead of CD4 in this panel, it was 
important to ascertain whether this was a valid substitution. In separate experiments we identified 
that there were no CD8+ BCL-6+ T-cells in FL, Figure 3-12, therefore we could assume that all CD3+ 
BCL-6+ T cells are CD4+ and this validated our panel of CD3, BCL-6, PD1 and ICOS for the identification 




Figure 3-12 CD8+ T cells (green) are not BCL-6+ (red) in FL. Image acquired with x60 objective. 
 
Furthermore, in additional staining experiments, we identified that PD1+ ICOS+ cells were CXCR5 
positive, Figure 3-13. However, since most cells within the follicles and GCs are CXCR5+ this did not 
add further clarification that the cells we identified as being CD4+ PD1+ ICOS+ were indeed TFH, CXCR5 




Figure 3-13 PD1+ (white) ICOS+ (green) cells within follicles are also CXCR5+ (red). Representative high power 
image. Note that CXCR5 does not specifically highlight the PD1+ ICOS+ cells but is expressed on many cells within 
the follicles. Magnified image acquired with x60 objective.  
 
3.3.1.2 Intensity of expression of CD4 and PD1 depends on location of T-cells in FL 
It was noted that the intensity of CD4 expression appeared to be lower amongst the follicular CD4+ 
cells than in interfollicular CD4+ cells, meanwhile PD1 appeared to be expressed at a high level in the 
follicular CD4+ cells but was present at a low level in a proportion of interfollicular CD4+ T cells.  
The level of expression of CD4 and PD1 was formally measured in follicular and interfollicular areas in 
5 FL samples. The intensity of CD4 expression was 30.7% lower in follicular CD4+ T-cells than in their 
interfollicular counterparts (mean intensity 846 ± 13.2 versus 1222 ± 17.5, P <0.0001). As CD4 is known 
to be internalised and degraded following activation, this finding suggests that these represent a 
distinct population of more activated T-cells.  
The intensity of expression of PD-1 was significantly higher in follicular PD-1+ T-cells than in the 
interfollicular PD-1+ T-cells (1346 ± 55.2 versus 545 ± 13.7, P <0.0001). The high expression of PD-1 in 
the follicular T-cells is consistent with them being TFH, which are characterized by very high PD-1 
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expression, meanwhile the interfollicular CD4+ PD1low ICOS- cells are unlikely to be TFH (Haynes, Allen 
et al. 2007), Figure 3-14. 
 
Figure 3-14 (A) Mean intensity of CD4 expression was significantly lower in the follicular CD4+ T-cells in FL 
than in interfollicular CD4+ T-cells. (B) Mean intensity of PD-1 in follicular CD4+ PD1+  T-cells is significantly 
higher than in interfollicular CD4+PD1+ T-cells (n= 81 follicular areas and 81 interfollicular areas from n=5 FL 
cases). Horizontal bars represent the mean, error bars = SEM. 
 
As well as indicating that there are distinct populations of CD4+ and PD1+ T cells in the follicular and 
interfollicular regions, this observation highlighted the importance of carefully setting the threshold 
for CD4 and PD1. These thresholds were set on follicular regions and then the same thresholds were 
applied to the interfollicular area analysis so that the correct populations of cells were identified. This 
is similar to the way that gating strategies used in flow cytometry are based on level of expression in 
cells or beads known to be positive or negative for a particular antigen. Furthermore, a high level of 
PD1 expression (PD1Hi) cells was used as a surrogate indicator of TFH in later experiments when ICOS 
or BCL6 could not be used in combination.   
3.3.1.3 Method of analysis for determining the proportion of TFH cells  
Two methods of analysis were developed for determining the proportion of CD4+ T cells with a TFH 
phenotype, ‘object’ analysis and ‘area’ analysis. Object analysis divided the CD4 binary layer into 
‘objects’ which broadly correlated with CD4+ cells. Each CD4+ ‘object’ (i.e. cell) was then interrogated 
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to determine whether it had any overlapping binary areas of PD1 and ICOS positivity so giving a count 
of the number of CD4+ cells that were TFH. This method was severely compromised by the membrane 
pattern of staining of CD4 and the fact that in tissue sections, cells are very tightly packed together 
therefore it was difficult to automatically separate CD4+ cells into discrete objects and this process 
accordingly required a lot of manual object separation which was very time consuming, difficult to do 
accurately and, given that it could not be automated, introduced a possible element of user bias.  
An alternative method of analysis was therefore developed, ‘area’ analysis. In area analysis, each 
binary layer is set as described in section 2.5 above and then the amount of the CD4 binary layer in 
which PD1 and ICOS are co-expressed is calculated as a proportion of this area. Whilst this has the 
advantage of being fully automated (once the thresholds had been set), and is therefore fast and has 
a reduced risk of user bias, it has a disadvantage that it does not give a cell count. Both methods were 
assessed and no significant difference in the percentage of CD4+ cells co-expressing PD1 and ICOS was 
detected between the two techniques (paired t test, p=0.487), Figure 3-15. Therefore, the area 
analysis was adopted for this analysis. 
 
Figure 3-15 Comparison of two different methods of image analysis: There was no significant difference in the 





3.3.2 Distribution and proportion of CD4+ T cells with TFH phenotype in reactive lymph 
nodes 
Similar to FL, CD4+ T cells were also identified in all cases of reactive lymph nodes examined (n = 8). 
As in FL, the T cells were mainly located outside of the follicles and GCs but small distinct populations 
of CD4+ T cells were also present within the GCs.  
TFH cells, identified by CD4, PD1, and ICOS staining were present in all reactive lymph nodes examined 
(n=8). They were very tightly restricted to the GCs where analysis of 5 high power fields (x60 
magnification) per section revealed that a median of 33.05% (24.7-43.7) of CD4+ cells were dually 
positive for PD1 and ICOS with very few identified in the non-GC areas, median 0.34% (0.26-1.13), the 
difference between GCs and non-GCs was highly significant (Mann Whitney test, p = 0.0014), Figure 
3-16. In representative sections from 4 cases of reactive lymphadenopathy, the GC PD1+/ICOS+ cells 
were also demonstrated to be BCL-6 positive and CXCR5 positive - as in FL – and are therefore highly 
likely to represent TFH cells.  
The distribution of TFH cells within the GCs was variable, they were noted to be either centrally located 
or polarised to the light zone of the GC, Figure 3-17. As identified in FL, lower expression of CD4 and 
higher expression of PD1 were noted in the GC T cells than in the non-GC T cells but it has not been 
possible to formally quantify the difference in level of expression in reactive LNs retrospectively as 
adequate numbers of high quality images of non-GC areas of reactive LNs were not obtained at time 




Figure 3-16 Significantly more germinal centre than non-germinal centre CD4+ T cells have a TFH phenotype in 
reactive lymph nodes. (Column height represents mean with error bars indicating SEM).  
 
Figure 3-17 Distribution of TFH cells in germinal centres of reactive lymph nodes. A. Stitched image (4 x 10x 
magnification images joined together, scale bar represents 200μm) showing clear GCs with most CD4+ T cells 
located outside of the GCs, CD4 (red), ICOS (green), PD1 (white),  DAPI (blue). B. The intersection of CD4, PD1 
and ICOS is highlighted in pink showing TFH cells are restricted to the GCs. C. Distribution of TFH cells can be 




3.3.3 Distribution and proportion of CD4+ T cells with TFH phenotype in CLL 
The presence and distribution of TFH cells were investigated in 7 cases of CLL as a comparison to FL and 
reactive lymph nodes. Although many cells in CLL expressed PD1, few were found to be TFH. A median 
of 23% (17.9 – 33.7) of CD4+ cells in CLL expressed PD1, but only 2.8% (1.8 – 6.8) of CD4+ cells co-
expressed PD1 and ICOS and very few BCL-6+ T cells could be identified. The PD1+ CD4+ ICOSneg T cells 
are unlikely to represent TFH cells but could perhaps be exhausted T cells.  The pattern of distribution 
of the few TFH cells in CLL was diffuse and it was beyond the scope of this research to determine 
whether they were present in proliferation centres.  
3.3.4 TFH comparison between FL, reactive GCs and CLL 
There was no significant difference in the proportion of CD4+ T cells with a TFH phenotype in the 
follicles of FL and normal GCs (medians 25.0 versus 33.0 respectively, Mann Whitney test, p = 0.06). 
There were slightly more interfollicular TFH in FL than in reactive lymph nodes but the numbers were 
low in both situations and the slight increase in the interfollicular area of FL may reflect the sometimes 
diffuse nature of the follicles and subsequent difficulty distinguishing the follicular border in FL 
whereas the GCs of reactive LNs were always clearly demarcated (medians 3.63 versus 0.34, Mann 
Whitney test, p = 0.003). The proportion of CD4+ T cells that were TFH in CLL was significantly lower 
than either FL follicles or reactive GCs but was not significantly different to the interfollicular region 
of FL (Mann Whitney test, p = 0.61), Figure 3-18, and Table 3-5. 
 
Table 3-5 Proportion of CD4+ T cells co-expressing PD1 and ICOS in different compartments 
 FL follicles GCs Interfollicular 
area of FL 
Interfollicular area 
of reactive LNs 
CLL 
Median %  
(IQR) 
25  
(18.5 – 28.75) 
33  
(24.7 – 43.7) 
3.63  
(1.89 – 6.15) 
0.34  
(0.26 – 1.13) 
4.14  







Figure 3-18 Graphs showing differences in proportion of TFH between different compartments. A. No difference 
in proportion of TFH between follicles of FL and GCs of reactive LNs. B. A small but significant difference between 
the interfollicular regions of FL and non-GC areas of reactive LNs, and a non-significant difference between the 
interfollicular area of FL and CLL. (n = 115 images from 25 FL samples, n = 39 images from 8 reactive LNs, n = 28 
images from 7 CLL samples). Boxes represent interquartile range, horizontal bars show median, ‘whiskers’ show 
minimum and maximum values.      
 
3.4 Association of TFH cells with proliferating B cells 
It has previously been identified that proliferating B cells in CLL are frequently in close contact with 
CD4+ T cells indicating a role of the CLL microenvironment in influencing proliferation in this disease 
(Patten, Buggins et al. 2008). Such an association has never previously been reported in FL, and whilst 
it is accepted that TFH are important in determining GC size and B cell proliferation within GCs, co-
localisation of GC B cells with TFH has not previously been demonstrated. Here, we investigated 
whether there was any spatial correlation between proliferating B cells in FL and TFH cells and explored 
to what extent this is the same in reactive lymph nodes.  
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3.4.1 Association of TFH cells with proliferating B cells in FL 
Proliferation was identified by Ki67 staining whilst simultaneously co-staining with CD4 and PD1; in 
separate sections Ki67, ICOS and PD1 were co-stained. Later, once a 4-colour staining protocol was 
developed it was possible to simultaneously stain for CD20, Ki67, PD1 and CD3. Ki67 is commonly used 
in IHC to identify cells in cycle. Ki67 expression can be detected by IHC at all stages of cellular 
proliferation, Ki67 expression is highest in G2 but it is not expressed at the protein level in G0 (Williams 
and Stoeber 2007). 
As previously reported by others, proliferation – as identified by Ki67 staining - was found to be highly 
variable both within different follicles of the same section and between cases (Samols, Smith et al. 
2013, Kedmi, Hedvat et al. 2014) but, as expected, Ki67pos cells were more frequent in high grade 
disease samples (Grade 3a and 3b) than in low grade disease (Grade 1-2).  
Ki67 had a similar pattern of distribution as TFH cells; in cases where the TFH cells were located at the 
follicular border, Ki67pos cells were predominantly at the follicular border too, but when TFH cells were 




Figure 3-19 Distribution of Ki67 positive cells is similar to TFH distribution in FL. Ai shows peripheral location of 
TFH (pink intersection binary of CD4/PD1/ICOS) and in a separate section of the same specimen when Ki67 is 
stained (green) (Aii) it is shown to have a similar perifollicular distribution. Bi shows follicular location of TFH 
(pink intersection of CD4/PD1/ICOS) and in the same specimen when Ki67 is stained (Bii) it is shown to have a 
similar follicular distribution. 
 
A high proportion of proliferating cells were found to be in close contact with TFH cells. In 23 FL cases 
examined, a mean of 41% ± 13.6 of Ki67pos cells were in direct contact with CD4+ PD-1Hi cells (n=100 
images from 23 samples). Staining for Ki67 PD-1 and ICOS in separate sections revealed that 84.7% ± 
1.7 (n=43 images from 13 samples) of the PD-1Hi CD4+ cells in contact with Ki67pos cells were dually 




Figure 3-20 Ki67pos cells are in close proximity to CD4+ PD1+ cells in FL. A. low power view showing 
Ki67 (green), CD4 (red) PD1 (white), and DAPI (blue). B. The binary layers of Ki67 (green) and CD4-PD1 
intersections (pink) are shown highlighting the close proximity of Ki67pos cells to PD1Hi T cells. C and 
D. High power views showing the same as A and B. >40% of Ki67pos cells are in direct contact with PD1Hi 
CD4+ cells.  
 
3D reconstruction of Z-stacks allowed closer visualisation of the often intimate interaction of these 
cells and revealed more interactions than were identified in 2D images. It was sometimes found that 





Figure 3-21 PD1Hi cells in contact with Ki67pos cells are ICOS+ A. Ki67 (red), PD1 (white), ICOS (green) z 
series 3D reconstruction. B. When the binary layers are shown (Ki67 green, PD1-ICOS intersection 




The development of a 4-antibody staining method permitted co-staining with CD20 to confirm that 
proliferating cells were B cells whilst still keeping PD1 and a T cell marker (although it was necessary 
to replace CD4 with CD3 for these experiments). A small proportion of Ki67+ cells were found to be 
CD3+/CD20- T-cells (3.5% ± 0.86, n = 12 images from 4 samples), but the majority were B-cells and 





Figure 3-22 Ki67pos cells are CD20+ B-cells. Ki67 = blue, CD20 = red, PD1 = white, CD3 = green. Representative 
low power (A) and magnified high power (B) images of 4 colour labelling in FL. 96% of Ki67pos cells are CD20+ B 
cells. Scale bars, A = 100µm, B = 10µm.    
Another benefit of using this method is that, as CD20 is located in the membrane whereas Ki67 is 
nuclear, it permits further analysis of the close spatial correlation of these cells. This is discussed in 
further detail later and shown in, Figure 3-29 and Figure 3-31.  
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3.4.1.1 Method for analysing co-localisation of Ki67pos cells with TFH cells  
The automated analysis of images was very important to this part of the research as visual analysis 
would be difficult to standardise, overly time consuming, and open to bias.  
To analyse the proportion of Ki67pos cells that were in direct contact with TFH cells the binary layers for 
Ki67, PD1 and CD4 (or ICOS) were set. The binary layer for Ki67 was then carefully ‘cleaned’ so that 
only Ki67pos cells were included in the binary; since Ki67 was usually detected in the 488 channel which 
is where there was most autofluorescence, manual deletion of areas of Ki67 positivity that were not 
cellular was necessary. Since manual deletion was time consuming and open to user variability, a 
mathematical model was also introduced which excluded any object in the Ki67 binary layer with an 
area <10µm2 as analysis revealed that these did not correlate with cells, nevertheless, additional 
manual deletions were still required.  The Ki67 binary layer was then ‘separated’ so that all discrete 
Ki67pos cells were identified in the binary layer as separate ‘objects’, the automated ‘separate’ function 
of the software was not always able to distinguish individual cells when they were closely packed and 
so manual separation was necessary too, cross referencing the DAPI layer was helpful for this. The 
CD4 and PD1 (or PD1 and ICOS) binary layers were combined as an intersection layer to highlight TFH 
cells. Since Ki67 is nuclear and both CD4 and PD1 are located in the membrane it was necessary to 
dilate the Ki67 binary by 1µm in all directions to calculate the number of Ki67 cells in contact with TFH.  
Next, the Ki67 binary layer was converted into individual regions of interest (ROI). It was then possible 
to calculate the number of ROIs (Ki67pos cells measuring >10µm2) that were overlapping with 
CD4+/PD1Hi cells (or PD1Hi/ICOS+). A TFH-Ki67 co-localisation score was generated by dividing the 
number of Ki67 cells touching TFH by the total number of Ki67 cells. This was repeated on 5 high power 
images per section to generate a score for each sample. Correlation with visual analysis confirmed 
that this approach yielded accurate measurement.  
It should be noted that this method only counted Ki67pos cells as being in contact with a TFH if there 
was some overlap between the area of the Ki67 binary layer and the CD4/PD1 or PD1/ICOS 
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intersecting binary layers, many more Ki67pos cells were in very close proximity to TFH but not counted 
as ‘in contact’ by this strict, semi-automated method. Furthermore, as described above, Ki67 can be 
detected by IHC throughout the cell cycle except in G0 and there is little data on how long Ki67 remains 
detectable for after a cell has completed division (Gerdes, Lemke et al. 1984, Williams and Stoeber 
2007).  
3.4.2 Association between Ki67, histological grade, and number of TFH in FL 
Next we investigated if there was any association between the number of TFH cells and the rate of 
cellular proliferation (i.e. the number of Ki67pos B cells) and histological grade, this had not previously 
been investigated in FL or other lymphoproliferative disorders to the best of our knowledge. The 
hypothesis was that there would be more TFH cells in cases where there was higher rate of cellular 
proliferation but that in more aggressive cases, e.g. grade 3a and grade 3b disease, there may be less 
dependence on TFH cells for B cell proliferation so there may be a lower level of TFH-Ki67 co-localisation 
in the highly proliferative cases.  
As expected, the total area of the Ki67 binary layer and the corresponding number of Ki67pos cells 
counted by automated analysis increased with histological grade (Spearman non-parametric 
correlation coefficient r = 0.90, P<0.0001, n=99 images from 23 samples), Figure 3-23 A & B. As well 
as being an expected finding, this further validated the method of semi-automated counting of Ki67+ 
cells.  
The area of the PD-1Hi ICOS+ intersection binary was strongly correlated with the number of Ki67pos 
cells and with grade (Spearman non-parametric correlation coefficient r = 0.79, P<0.0001, n=42 images 
from 13 samples), demonstrating that the absolute number of TFH cells is increased in cases with higher 
proliferation, Figure 3-23C & D.  
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There was only weak correlation between the number of Ki67pos cells and amount of co-localization 
with TFH cells (r = 0.47, p = 0.001, n=42 images from 13 samples) and no significant difference in the 
level of Ki67-TFH co-localization and histological grade.  
Thus, in cases with low Ki67 there were relatively few TFH cells and in cases with high proliferation 
there were more TFH cells but the level of co-localization remained relatively constant regardless of 




   
Figure 3-23 Correlation between number of TFH, histological grade and number of Ki67pos cells in FL. A. The 
area of the Ki67 binary layer correlates closely with the number of Ki67pos cells automatically counted (r = 0.90 
(Spearman correlation), P<0.0001) (n=23 samples, 99 images).  B. The area of the Ki67 binary layer is significantly 
higher in grade 3a or 3b disease than in grade 1-2 disease (n=23 samples, 99 images). C. The number of Ki67pos 
cells correlates closely with the number of PD1Hi/ICOS+ cells (r = 0.79 (Spearman correlation), p < 0.0001) (n=13 
samples, 42 images). D. There are significantly more TFH cells (as represented by increased area of PD1/ICOS) in 
grade 3a and 3b disease than in grade 1-2 disease (n=13 samples, 42 images). E. The degree of TFH – Ki67 
interactions is only weakly associated with the number of Ki67pos cells (r = 0.47, p = 0.001). F. The proportion of 
Ki67pos cells in contact with TFH does not significantly differ according to histological grade disease. 




3.4.3 Are Ki67pos FL B cells in contact with TFH cells by chance? 
Having identified a very close spatial relationship between TFH cells and Ki67pos FL B cells, and a 
correlation between the number of TFH and the rate of B cell proliferation, we next investigated 
whether these cells were in close spatial proximity by chance or because the TFH are involved in 
promoting FL B cell proliferation.  
To investigate this we used the 4-colour labelling technique (see section 3.2.4) to simultaneously stain 
CD20, Ki67, CD3 and PD1. As described previously, it was not possible to simultaneously stain with 
CD20, Ki67, PD1, and CD4 but we determined that CD3 was an acceptable substitute in this situation. 
Furthermore, it was not possible to add a further marker of TFH cells e.g. ICOS or BCL6 but earlier work 
identified that setting a high threshold to include only T cells strongly expressing PD1 (PD1Hi) meant 
that we could be confident that the CD3+ PD1Hi cells in close proximity to B cells were TFH cells.  
The null hypothesis was that if TFH cells were in contact with Ki67pos cells by chance, then the 
proportion of CD20+ Ki67neg cells in contact with TFH cells would not be significantly different to the 
proportion of CD20+ Ki67pos cells in contact with TFH cells.  
Initial observation showed that within follicles there were areas of high proliferation (high number of 
Ki67pos CD20+ B cells) and areas where there were many CD20+ B cells but low numbers of Ki67pos 
cells. It was observed that TFH cells were more frequent within areas of high proliferation, and in areas 
where the proliferation rate was low, few TFH were identified, Figure 3-24. This suggested that TFH are 
not randomly distributed but this observation alone couldn’t exclude the possibility that the spatial 
relationship was due to chance. Further analysis was therefore required to establish if the null 





Figure 3-24 TFH cells are more often located near proliferating CD20+ cells than non-proliferating cells. Ki67 = 
blue, CD20 = red, PD1 = white, CD3 = green. Image showing 4 colour staining to analyse Ki67pos and Ki67neg 
CD20+ B cell co-localisation with PD1Hi CD3+ T cells in FL. A. Low power image (x10), it can be seen that within 
the follicles there are areas of low cellular proliferation (low Ki67 - blue) where there are few PD1Hi (white) CD3+ 
T cells (green) (area highlighted by yellow oval), whereas in areas where there is high Ki67, there are more PD1Hi, 
CD3+ T cells (area highlighted by white circle) and they are frequently in contact with Ki67pos CD20+ FL B cells. B. 
High power image (x60) in which the close correlation of Ki67pos (blue) B cells with PD1Hi (white) CD3+ (green) 
cells can be seen, whilst the CD20+ (red), Ki67neg cells are less frequently in contact with TFH cells. This indicates 




We analysed 25 images from 7 different samples for this analysis. Due to the diffuse pattern of CD20 
staining, the automated analysis software was unable to reliably distinguish CD20+ cells that were not 
Ki67pos. In the automated analyses described earlier, the nuclear pattern of staining of Ki67 permitted 
reliable automated analysis but the membrane pattern of staining of CD20 meant that when there are 
many closely packed CD20+ B cells, as in the follicles of FL, the software could not reliably identify 
individual cells. For this analysis we therefore had to resort to manual, visual assessment. 
To perform this, images were thresholded according to the method described above in section 2.5 
and intersections of the CD3+/PD1Hi binary layer were created. The image was then opened with the 
binary layers hidden from view. A grid was superimposed over the image to assist in visual assessment 
and to help ensure that each area of the image was inspected. A ‘taxonomy tool’ within the NIS 
elements software package was used to facilitate the manual counting of different cells.  
First, Ki67pos CD20+ B cells were marked with the taxonomy tool and the sum of Ki67pos B cells was 
recorded. All Ki67pos B cells in the image that were not touching the edges of the image were marked 
and counted by systematically working through each box in the superimposed grid. Cells touching the 
edge of the image were excluded as it could not be certain if they were or were not in contact with a 
TFH beyond the boundaries of the image. 
The CD3+/PD1Hi intersection binary layer was then shown and the taxonomy tool was used to mark 
each Ki67pos cell if it was assessed as touching an area of CD3/PD1Hi intersection, i.e. if it was touching 
a TFH. The number of Ki67pos B cells touching TFH cells was recorded and from this, the number of Ki67pos 
B cells not in contact with a TFH cell was derived.  
The channels for PD1 and CD3 were then hidden so only Ki67 and CD20 were showing and the 
taxonomy tool was used to mark and count non-proliferating Ki67neg CD20+ B cells. PD1 and CD3 layers 
were hidden from view during this step in the process to prevent inadvertent bias e.g. not including 
CD20+ Ki67neg cells that could be seen to be close to T cells.  
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Finally, the PD1Hi/CD3 intersection binary was again shown and the taxonomy tool was used to 
highlight and count all of the marked Ki67neg CD20+ B cells that were in contact with an area of 
CD3/PD1 positivity i.e. TFH cells. The number of Ki67neg CD20+ B cells not in contact with TFH was derived 
from these numbers.  
The number of Ki67pos B cells contacting TFH cells was then compared with the number of Ki67neg B cells 
contacting TFH cells for each sample and the statistical significance was determined using contingency 
tables and either Chi Squared or Fisher’s exact tests.  
Due to the manual visual assessment of these images rather than the automated image analysis 
employed in the other sections of this thesis, two investigators analysed a subset of these images in 
order to identify and reduce operator bias. The two investigators were blinded to each other’s results. 
We identified no significant difference in number of Ki67pos cells counted by observer, the number of 
cells in contact with TFH was also concordant between operators. Therefore, whilst this visual 
assessment was not considered to be as robust as the automated analysis used elsewhere in this 
research, we are confident that the results presented below are an accurate representation of the co-
localisation of TFH cells to Ki67pos and Ki67neg CD20+ FL B cells as shown in Figure 3-24 above.  
In total, 25 images stained with Ki67, CD20, PD1 and CD3 acquired from 7 FL specimens were analysed, 
1481 Ki67pos B cells were counted and 877 (59%) of these were assessed to be in contact with TFH by 
the method described above. 2597 Ki67neg CD20+ B cells were counted from the same images and 552 
(21%) were in contact with TFH. This difference is highly significant, Chi Squared 595, P<0.0001, see 
Table 3-6.  
For individual samples, Fisher’s exact test was applied as cell numbers were too low for Chi Squared 
test, by Fisher’s exact test, P was <0.0001 for each sample analysed, Table 3-7.  
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Table 3-6 Contingency table for all samples combined. Number of Ki67pos FL B cells in contact with TFH cells are 
compared with the number of Ki67neg B cells. Ki67pos B cell are significantly more likely to be in contact with TFH 
than Ki67neg FL B cells. (n=25 images from n=7 specimens) 
 KI67POS B CELLS KI67NEG B CELLS TOTAL 
IN CONTACT WITH TFH 877 552 1429 
NOT IN CONTACT WITH TFH 604 2045 2649 
TOTAL 1481 2597 4078 
 CHI SQUARED 595, P<0.0001  
Table 3-7 Contingency tables for each FL sample analysed (n=7). Number of Ki67pos FL B cells in contact with TFH 
cells are compared with the number of Ki67neg B cells for each sample. Ki67pos B cell are significantly more likely 
to be in contact with TFH than Ki67neg FL B cells in each sample analysed. 
 
Sample ID FL012 Ki67pos  cells Ki67neg cells Total 
In contact with TFH 83 26 109 
Not in contact with TFH 75 263 338 
Total 158 289 447 
Fisher’s exact test for sample FL012, P < 0.0001 
 
Sample ID FL018 Ki67pos  cells Ki67neg cells Total 
In contact with TFH 76 49 125 
Not in contact with TFH 60 251 311 
Total 136 300 436 
Fisher’s exact test for sample FL018, P < 0.0001 
 
Sample ID FL020 Ki67pos  cells Ki67neg cells Total 
In contact with TFH 168 94 262 
Not in contact with TFH 133 406 539 
Total 301 500 801 




Sample ID FL010 Ki67pos  cells Ki67neg cells Total 
In contact with TFH 229 57 286 
Not in contact with TFH 133 314 447 
Total 362 371 733 
Fisher’s exact test for sample FL010, P < 0.0001 
    
Sample ID FL004 Ki67pos  cells Ki67neg cells Total 
In contact with TFH 113 63 176 
Not in contact with TFH 39 139 178 
Total 152 202 354 
Fisher’s exact test for sample FL004, P < 0.0001 
    
Sample ID FL013 Ki67pos  cells Ki67neg cells Total 
In contact with TFH 17 17 34 
Not in contact with TFH 18 124 142 
Total 35 141 176 
Fisher’s exact test for sample FL013, P < 0.0001 
    
Sample ID FL014 Ki67pos  cells Ki67neg cells Total 
In contact with TFH 191 198 389 
Not in contact with TFH 126 596 722 
Total 317 794 1111 
Fisher’s exact test for sample FL014, P < 0.0001 
 
This finding means that Ki67pos FL B cells are significantly more likely to be in contact with TFH cells than 
non-proliferating FL B cells. It is therefore highly unlikely that the close spatial relationship between 
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Ki67pos FL B cells and TFH cells is due to chance. This is further evidence that FL B cells may be dependent 
on interaction with TFH for inducing or sustaining proliferation.  
Although 21% of Ki67neg FL B cells were in contact with TFH cells, it is possible that this is due to chance. 
As seen in Figure 3-24, the closely packed nature of CD20+ B cells within the FL follicles means that 
any given cell is in contact with approximately 6 other cells and therefore there is a chance of a Ki67neg 
B cell being adjacent to a TFH cell randomly. However, the statistical difference between the proportion 
of Ki67pos and Ki67neg FL B cells in contact with TFH cells is so great that we can infer that the Ki67pos 
cells are not in contact with TFH cells by chance. The null hypothesis was therefore rejected. 
These results confirm the observation in low power images that there were areas of follicles with low 
proliferation (low Ki67), and in these areas there were few TFH cells whereas in areas of high numbers 
of  Ki67pos FL B cells,  there were more TFH, Figure 3-24. This also supports the finding that in cases of 
high proliferation there were higher numbers of TFH, Figure 3-23A & C.  
3.4.4 Association of TFH cells with proliferating B cells in germinal centres 
As in FL, proliferating B cells within the GCs of reactive LNs were frequently found to be in close contact 
with CD4+ PD1Hi T cells. Unlike the follicles of FL there was striking zonal demarcation within the GCs 
and a marked difference between the dark and light zones was observed.  
In the light zones, where proliferation of B cells was relatively low, as in FL, many proliferating cells 
were found to be in close contact with CD4+ PD1Hi cells. In the dark (highly proliferative) zones there 
was substantially less interaction between proliferating B cells and T cells perhaps indicating that B 
cell proliferation in the dark zone does not require TFH help whereas it is required for proliferation in 
the light zone and in FL, Figure 3-25 & Figure 3-26. The distinction between dark and light zones was 
made subjectively based on area of highest number of Ki67pos cells as shown by the superimposed 




Figure 3-25. Proliferation and association with PD1Hicells in a normal germinal centre. Ki67 = red, PD1 = white. 
Proliferation (Ki67, red) can be seen to be considerably higher in the dark zone than the light zone. In the dark 
zone there are very few PD1Hi cells (white). In the light zone proliferation rate is lower but there is a close 
association with PD1Hi cells. (Image acquired with x60 objective, dotted line highlights boundary of dark and light 
zones).  
 
Quantification of the level of co-localisation between TFH cells and Ki67pos B cells in the GCs of reactive 
lymph nodes was challenging because the very high number of closely packed Ki67pos cells made 
identification and separation of the Ki67 binary layer into discrete cells difficult. Accordingly this 
analysis required a time consuming effort to separate the Ki67 binary layer into individual cells. The 
analysis of this was otherwise the same as for the FL samples.  
Analysis of Ki67 – TFH co-localisation within the light zones revealed that 63.1% ± 15.9 Ki67pos cells 
(n=13 images from 4 reactive LN samples) were in direct contact with CD4+ PD-1Hi cells, and visual 
inspection revealed that almost all Ki67pos cells were very close to (within one cell’s width), but not 
touching TFH cells. Many Ki67pos cells were in contact with more than one TFH cell simultaneously, and 
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due to the closely packed nature of proliferating cells and TFH, many TFH were in contact with more 
than one Ki67pos cell simultaneously, Figure 3-27B.  
The majority of the PD-1Hi T cells in close proximity to Ki67pos cells were also ICOS+ with 53.9% ± 14.2 
of Ki67pos cells in contact with PD-1Hi ICOS+ cells (n=12 images from 4 samples).  
 
Figure 3-26 Ki67pos cells co-localise with PD1Hi ICOS+ T Cells within the light zone of GCs. Ki67 = red, PD1 = 
white, ICOS = green, DAPI = blue. A. Low power (x10) image of reactive LN showing six GCs. The GCs can clearly 
be seen to be demarcated into highly proliferative dark zones with high Ki67 (red) and light zones with much 
lower rate of proliferation. B. The GC highlighted by the white rectangle in A is enlarged. Here it can be seen 
that within the light zones, Ki67pos cells are often in contact with PD1Hi ICOS+ cells. In the dark zone there are 
relatively few PD1Hi ICOS+ cells. Scale bar = 100µm 
 
In the highly proliferative dark zones, the level of Ki67 was too high to reliably distinguish individual 
Ki67pos cells even after extensive manual ‘separation’ of the binary layer. Therefore, formal 
quantification of the proportion of Ki67pos cells in contact with TFH in this compartment could not be 
performed but, since the number of Ki67pos cells was higher in the dark zones and few TFH were present 





Figure 3-27 Germinal centres in reactive LN showing proliferation of CD20+ B cells and zonal demarcation. 
Ki67 = blue, CD20 = red, CD3 = green, PD1 = white. A. Low power (x10) image of GCs in a reactive LN, 4 colour 
staining with Ki67, CD20, PD1, and CD3. Scale bar = 100µm. B. Magnification of the area highlighted by the white 
rectangle in A highlighting that most cells within the follicles are CD20+ (red) B cells. In the dark zones where 
there is high proliferation (Ki67, blue) there are few PD1Hi CD3+ T cells (TFH). In the light zones Ki67pos CD20+ B 
cells are frequently in contact with PD1Hi CD3+ T cells.   
 
The high number of TFH cells in the light zones of reactive GCs meant that even Ki67neg CD20+ B cells 
were often in contact with one or more TFH cell. Additionally, the closely packed nature of the cells 
within the GCs, relative scarcity of Ki67neg CD20+ B cells and high number of TFH cells meant that it was 
technically challenging to perform the same analysis as we performed in FL to ascertain if the TFH cells 
were in proximity to CD20+ Ki67pos B cells by chance or not. 
Nevertheless we were able to analyse images acquired from 5 GCs from images of 2 separate reactive 
LNs stained with the 4-antibody labelling method for Ki67, CD20, CD3 and PD1, Table 3-8. These 
images were analysed visually rather than automatically as described for FL above, in section 3.4.3. 
Only the light zones were analysed. Within the dark zones, CD20+ Ki67neg B cells were very few or not 




Table 3-8 Contingency tables for Light Zones of GCs (n=5 GCs from n=2 samples). Number of Ki67pos FL B cells 
in contact with TFH cells are compared with the number of Ki67neg B cells for each sample. Ki67pos B cell are 
significantly more likely to be in contact with TFH than Ki67neg B cells 
Sample ID LN03 Ki67pos  cells Ki67neg cells Total 
In contact with TFH 39 17 56 
Not in contact with TFH 12 23 35 
Total 51 40 91 
Fisher’s exact test for sample LN03, P < 0.0012 
    
Sample ID LN008 Ki67pos  cells Ki67neg cells Total 
In contact with TFH 86 50 136 
Not in contact with TFH 37 49 86 
Total 123 99 222 
Fisher’s exact test for sample LN08, P < 0.0037 
 
Whilst a higher proportion of Ki67neg B cells were in contact with TFH cells in the light zones of GCs than 
in the malignant follicles of FL, there was still a significantly higher chance of Ki67pos cells being in 
contact with one or more TFH cell than the non-proliferating cells. Whilst the numbers of samples 
analysed for this are too low to draw firm conclusions, this is preliminary evidence that the TFH cells 
are not in contact with proliferating B cells in the light zones of GCs by chance.  
Furthermore, analysis of the area of TFH and area of Ki67 positivity – surrogate indicators of the number 
of TFH cells and Ki67pos cells respectively, in GCs revealed a positive correlation in reactive LNs, although 
the correlation was not as strong as that identified in FL, Figure 3-28 (r = 0.55, P = 0.019, n=17 GCs 
from n=4 samples). Again, the number of samples analysed for this is too low to draw firm conclusions 
but this supports the evidence of others that GC size is determined at least in part by the number of 




Figure 3-28 Association between area of Ki67 and TFH in reactive GCs. r = 0.55, P = 0.019, n=17 GCs from n=4 
samples 
 
3.5 Synapse formation between TFH cells and proliferating B cells in FL 
As described above, we found that a high proportion of proliferating B cells are in close contact with 
TFH cells in the follicles of FL and in the light zones of GCs. We also found evidence that it is unlikely 
that this close spatial relationship is due to chance with significantly higher co-localisation of TFH cells 
with Ki67pos B cells than Ki67neg B cells in both the malignant follicles of FL and the light zones of 
reactive GCs. It was also noted that the TFH are often very closely apposed to the proliferating cells. 
This led us to investigate if there is evidence of the formation of immunological synapses between 
these cells.  
Immunological synapses are points of physical contact between a T cell and an antigen presenting cell 
that may serve a number of functions including facilitating T cell activation, T cell signalling, and the 
delivery of secretory granules (e.g. cytotoxic T cells secreting perforin granules).  
The immunological synapse is also known as the supramolecular activation cluster (SMAC) which is 
composed of 2 parts, the central (c-SMAC) and peripheral (p-SMAC) (Dustin 2011). There are a number 
of morphological and molecular features that identify immunological synapses. Morphological 
features include close apposition of cells, the formation of projections that encompass other cells, and 
distortion of the T cell nucleus due to rearrangement of the cytoskeleton. Molecular features are the 
presence of components of the c-SMAC (e.g. components of the TCR, protein kinase C-theta (PKC-θ), 
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CD3, and co-stimulatory receptors) and p-SMAC (e.g. leucocyte function-associated antigen-1 - LFA-
1). The formation of central and peripheral components of the SMAC gives rise to a characteristic bull’s 
eye appearance of the synapse (Kupfer and Kupfer 2003, Barcia, Thomas et al. 2006, Dustin 2011).  
Whilst immunological synapses are well described in vitro they have rarely been visualised in situ. We 
used the multicolour confocal microscopy method described above to investigate whether there was 
evidence of immunological synapse formation between proliferating FL B cells and TFH cells in FL in situ 
in FFPE tissue.  
In FL, it has previously been reported that tumour infiltrating T cells form impaired synapses with FL B 
cells compared to healthy B cells and that PD1+ T cells in FL are globally dysfunctional with impaired 
response to cytokines (Ramsay, Clear et al. 2009, Myklebust, Irish et al. 2013). However, previous work 
on this area has been performed in vitro and this work represents the first time that synapses have 
investigated in situ in FL and our results provide some findings that are counter to the previous work 
in this field.  
We identified features of immunological synapses including the formation of cell membrane 
projections, distortion of the cell nucleus in T cells adherent to proliferating cells, and concentration 
of the membrane antigens PD1, and CD3 at points of contact, Figure 3-29, Figure 3-30, and Figure 
3-31. Staining for components of the c-SMAC and p-SMAC such as PKC-θ, f-actin and LFA-1 were also 




Figure 3-29. Close contact between Ki67pos cells and TFH in FL: Evidence of synapse formation. A & C: Ki67 = 
red, ICOS = green, PD1 = white, and DAPI = blue. B: Ki67 binary layer = red, PD1/ICOS intersecting binary layer 
= pink.  A. A ki67pos cell (red) (dashed arrow) is seen to be in contact with 4 PD1Hi (white) ICOS+ cells (green) 
(white arrows). The PD1Hi ICOS+ cells are closely adherent with the Ki67pos cell B. The binary layers of Ki67 (red) 
and PD1/ICOS intersection (pink) are shown highlighting this close association. C. The TFH cells form projections 
encompassing the Ki67pos cell (white arrows). PD1 and ICOS appear more concentrated at site of cell contact. 





Figure 3-30. Evidence of synapse formation. Ki67 = red, ICOS = green, PD1 = white, and DAPI = blue. A. A Ki67pos 
cell (red) is in contact with a PD1Hi (white) ICOS+ (green) cell; PD1 appears more concentrated at site of cell 
contact and there are projections encompassing the Ki67pos cell. B. Only DAPI and Ki67 are shown and the T cell 
nucleus can be seen to be distorted which is a feature of synapses (white arrow). (3D reconstructions of 
magnified Z-stacks acquired with x60 objective, scale bars = 10µm) 
 
Figure 3-31 Four colour labelling allows better appreciation of cellular contact. Ki67 = blue, CD20 = red, CD3 = 
green, PD1 = white. The proliferating cells are demonstrated to be CD20+ and there is overlap of the B cell and 
T cell membranes with concentration of CD3 at the point of contact (white arrow). (Magnified images acquired 
with x60 objective, scale bars = 10µm) 
 
To formally quantify if there was concentration of T cell membrane proteins at the points of cell 
contact with proliferating B cells, a novel analytical technique was developed. High definition, highly 
magnified images were captured from representative areas of tissue, these images were technically 
difficult to generate and required lengthy acquisition times on the confocal microscope.  
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The images so generated were thresholded and binary layers generated as previously described. The 
T cell membrane was then defined manually on the image and the intensity of fluorescence could then 
be automatically measured at each pixel around the perimeter of the T cell membrane, Figure 3-32.  
A graph representing intensity was generated from this data and the area under the curve for a 
defined length of T cell membrane in contact with a Ki67+ cell was compared to the area under the 
curve for an identical length of cell membrane at the opposite pole of the cell, Figure 3-33. 
 
Figure 3-32 Measuring intensity of expression of cell membrane proteins at immunological synapses. Ki67 = 
red, ICOS = green, PD1 = white, and DAPI = blue. Highly magnified image showing a TFH cell in contact with 
Ki67pos FL cell. The T cell membrane has been delineated manually by the red dotted line. The intensity of 
expression of PD1 and ICOS can then be measured at each pixel around this line.  
  
 
Figure 3-33 Graph showing the level of intensity of PD1 (white line) and ICOS (green line) around the T cell 
membrane. The area under the curve (AUC) for the segment of T cell membrane in contact with the Ki67+ cell 
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(highlighted by the grey box) is compared to the AUC for the opposite pole. In this representative graph the AUC 
for the area of contact was greater than at the opposite pole for both PD1 and ICOS.  
This technique was used to investigate 61 cell contacts in images from 9 FL samples. Results show that 
the intensity of expression of CD3, PD1, and ICOS were all significantly higher at points of cell contact 
than at the opposite pole indicating polarisation of the T cell membrane and the formation of an 
immunological synapse, Figure 3-34.  
 
Figure 3-34 CD4, PD1, and ICOS all have significantly higher intensity of expression at the sites of cell contact 
than at the opposite pole. Paired t tests, n=61 cell contacts, from highly magnified images in 9 FL specimens 
stained with either CD4/PD-1/Ki67, or PD-1/ICOS/Ki67. 
The time consuming nature of the microscopy required to generate appropriate images for this 
analytical technique prevented us from being able to perform this on a greater number of samples 
within the confines of the current research.  
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We attempted to investigate if there was a difference in the number of cell contacts with features 
consistent with synapse formation in FL and GCs however technical difficulties described in the 
paragraph below, precluded this.  
In the reactive LN samples, the number of Ki67pos cells was so high, even in the light zones of the GCs 
that most TFH were found to be in contact with more than one Ki67pos cell simultaneously. It was 
therefore not possible to employ the same analysis technique in the reactive LN specimens as had 
been used in the FL specimens as we could not delineate clear areas of T cell membrane that were not 
in contact with Ki67pos cells.  
Although formal quantitative assessment of the formation of immunological synapses could not be 
performed in GCs, morphological assessment revealed that it appears that the formation of 
immunological synapses between TFH and Ki67pos B cells in FL was at least as good as in GCs.  
3.6 PD-L1 expression in FL and GCs  
As described above in the introduction, section 1.4, there are two known endogenous ligands for PD-
1, PD-L1 (CD274) and PD-L2 (CD273). PD-L1 has previously been reported to be absent from the 
surface of FL B-cells (Andorsky, Yamada et al. 2011), but, given the high level of PD1 expression in 
some T cells in FL, we sought to investigate whether there was any co-localisation between T cells with 
high PD1 expression and cells expressing PD-L1.  
We obtained a monoclonal antibody against PD-L1 raised in rabbit from Spring Bioscience and 
performed multiple-labelling experiments to determine if there was evidence of PD-L1 expression on 
the surface of the proliferating malignant cells in contact with TFH in FL. Additionally, co-staining with 
CD23 was performed by a colleague in the laboratory, Dr Beth Phillips to determine if PD-L1 was 
present on follicular dendritic cells. 
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We found no evidence that PD-L1 was strongly expressed on the Ki67+ cells that were in contact with 
PD-1Hi cells, Figure 3-35. Instead, PD-L1 appeared to be expressed mainly on CD23 negative cells in the 
interfollicular areas, Figure 3-36. 
 
Figure 3-35 PD-L1 staining in FL. PD-L1 = green, Ki67 = red, PD1 = white, DAPI = blue. PD-L1 is not present on 
the Ki67+ cells in contact with PD1Hi cells. Representative low power (A) and high power (B) images of FL showing 
that PD-L1 (green) is not highly expressed on the Ki67+ cells (red) that are in contact with PD-1Hi cells (white). 





Figure 3-36 PD-L1 is mainly found outside of the follicles and is not present on CD23+ follicular dendritic cells. 
PD-L1 = green. CD23 = white. CD20 = red. Scale bar represents 100µm. Staining and image acquisition for this 
image was performed by Dr Beth Philips.  
The pattern of PD-L1 staining in reactive lymph nodes was also investigated and no discernible co-
localisation between PD-L1 expressing cells and PD1Hi, presumed TFH cells could be identified, in 
particular, expression of PD-L1 could not be clearly established on the Ki67pos cells in contact with TFH 
in the light zones of GCs, Figure 3-37.  
 
Figure 3-37 PD-L1 staining in germinal centres. PD-L1 = green, Ki67 = red, PD1 = white, DAPI = blue. PD-L1 is 
not present on the Ki67pos cells in contact with PD1Hi cells in germinal centres. Representative low power (A&B) 
and high power (C) images of GCs showing that PD-L1 (green) is not highly expressed on the Ki67pos cells (red) 




3.7 AID expression in proliferating B cells 
AID is a tightly controlled DNA modifying enzyme required for class switch recombination and somatic 
hypermutation. It is present exclusively in GC B cells as they undergo the processes required to 
generate highly specific BCRs. The expression of AID is induced by T cell – B cell interactions in the GC. 
AID has been implicated in the pathogenesis of GC derived lymphomas such as FL perhaps through 
errors in AID-induced BCR rearrangements in B cells that are protected from apoptosis through the 
upregulation of BCL-2. In mouse models lacking AID, it has been demonstrated that BCL-6 dependent 
GC derived lymphomas do not develop (Pasqualucci, Bhagat et al. 2008), see introduction section 1.2.  
We investigated the expression of AID in FL B cells and the association of AID with proliferation and T 
cells with the hypothesis that AID expression may be induced following interaction with TFH cells and 
there may therefore be a spatial relationship between TFH cells and AIDpos cells.   
Staining for AID was technically difficult and required testing a number of different antibodies at 
different concentrations, different incubation conditions and different antigen retrieval methods. 
Reliable staining was achieved with monoclonal mouse anti-AID clone ZA001 (Invitrogen) at a dilution 
of 1:200 and overnight incubation using citrate antigen retrieval.  
The pattern of staining was predominantly cytoplasmic and there was a high level of background 
staining but positive signal restricted to the GCs in reactive lymph nodes or follicles in FL samples could 
be clearly detected above the background signal.  
3.7.1 Distribution of AID in FL: association with proliferation and TFH  
AID positivity was found to be restricted exclusively to the follicles of 7/7 cases of FL examined and 




Figure 3-38 Expression of AID is restricted to the follicles in FL where it is present only in proliferating cells. 
AID = red, Ki67 = green, PD1 = white, DAPI = blue. A. AID (red) is shown to be limited to the follicle. B and C. co-
staining with Ki67 (green) shows that AID is predominantly expressed in proliferating cells within the follicles. (A 
and B acquired with x10 objective, scale bars = 100µm, C acquired with x60 objective, scale bar = 50µm) 
In FL, 63% ± 8.8 of Ki67POS cells were positive for AID (n=16 images from 6 samples, 1 sample was not 
assessable due to high background staining), Figure 3-38.  
As we had earlier identified that proliferating B cells in FL are frequently found to be in close contact 
with TFH cells, we next investigated whether TFH cells are implicated in regulating AID by assessing 
whether AID expressing cells were in close spatial relationship with TFH cells. Limitations in the 
antibodies available meant that we could only use PD1 to label the T cells.   
We found that 39.8% ±9.7 of AIDposKi67pos cells were in direct contact with PD-1Hi cells, Figure 3-39. As 
we had previously identified that 84.7% ± 1.7 of PD-1Hi cells in direct contact with Ki67+ cells were 
ICOS+, we can predict that the majority of PD-1Hi cells in contact with AIDpos Ki67pos cells were TFH. A 
limited number of 4-colour staining experiments confirmed that the PD1Hi cells in close contact with 




Figure 3-39 Proliferating cells expressing AID are often in contact with PD1+ cells in FL. AID = red, Ki67 = green, 
PD1 = white, DAPI = blue. Highly magnified images showing Ki67+ (green) AID+ (red) cells in close contact with 
PD1+ (white) cells. (Images acquired with x60 objective, scale bars = 10µm) 
 
3.7.2 Distribution of AID in reactive lymph nodes:  association with proliferation and TFH  
As in FL, the AID distribution was limited to proliferating cells in the GCs of reactive lymph nodes, 
Figure 3-40. In contrast to FL, in reactive LNs, there was evidence of polarisation of the GCs; in the 
highly proliferative dark zones there were more Ki67pos cells and corresponding AID staining compared 
to the less proliferative light zones. Whilst it was hard to appreciate any relationship between AID and 
PD1Hi cells in the dark zones, in the light zones there was a similar association to that observed in FL, 
i.e. Ki67pos AIDpos cells were found to be closely associated with PD1Hi cells, which may be TFH,  




Figure 3-40. AID expression is limited to proliferating cells in germinal centres. AID = red, Ki67 = green, PD1 = 
white, DAPI = blue A. AID (red) can be seen to be more prominent at one pole of the GC. B. When Ki67 is 
simultaneously visualised it can be seen that AID is present mainly in proliferating cells and is highest in the dark 




Figure 3-41. 3D reconstruction of Z series showing AID in the proliferating cells of the dark zone and association 
with PD1 in the light zone. A. AID = red, Ki67 = green, PD1 = white, DAPI = blue In the dark zone there are many 
proliferating AIDpos cells but few PD1Hi cells. In the light zone PD1Hi cells (white) can be seen to be in contact with 
proliferating AIDpos cells (the dotted line shows the demarcation between dark and light zone). B. In this image 






3.8 FOXP3+ T cells in reactive LN and FL 
FOXP3 is a transcription factor usually associated with T regulatory cells (Tregs) but it has also recently 
been demonstrated to be present in a subset of cells that express ICOS and have a phenotype between 
TFH and Tregs, so called T follicular regulatory cells (TFR) which have been identified in secondary 
lymphoid tissue and in the FL tumour microenvironment (Ame-Thomas, Le Priol et al. 2012, Sage, 
Francisco et al. 2013).  
Tregs have been associated with adverse outcome in FL especially if distributed in a follicular or peri-
follicular pattern, and it is thought that this may be through inhibition of the anti-tumour response 
(Farinha, Al-Tourah et al. 2010).  
Although the primary aim of our research was to thoroughly investigate the TFH cells present in the FL 
tumour microenvironment, it was important to investigate whether the PD1+ ICOS+ T cells that we 
have identified as TFH express FOXP3. We pursued this line of investigation for two reasons, firstly to 
ensure that the cells we have described as TFH are genuinely TFH, in which case they should not express 
the transcription factor FOXP3, and secondly to explore if there is a subset of FOXP3pos TFH-like cells 
for example TFR that can be identified using the techniques we developed. 
Three different anti-FOXP3 antibodies were assessed; no successful labelling was achieved with the 
first 2 antibodies despite attempting different antigen retrieval and incubation conditions. Finally, 
monoclonal mouse anti-FOXP3 clone 236A/E7 (Abcam) was found to work well with standard pH6.1 
citrate antigen retrieval and overnight incubation at 4°C.  
Since this was a mouse antibody, it could not be used simultaneously with the mouse CD4 antibody 
but could be used with rat anti-CD3 antibody. 
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3.8.1 Distribution and phenotype of FOXP3pos CD3+ T cells in FL 
Nuclear FOXP3 was identified exclusively in CD3+ cells in 4/4 FL cases examined. FOXP3 staining was 
not identified in any non-T cells, Figure 3-42.  
Although apparently lower in number than TFH cells, the distribution of FOXP3 positive T cells within 
the follicles was similar to the pattern of distribution of TFH cells; FOXP3pos cells were found mostly in 
a perifollicular distribution with some scattered through the follicles, Figure 3-42 and Figure 3-43A and 
B. Unlike TFH cells which were rarely identified outside the follicles, FOXP3+ T cells were also found in 
the interfollicular areas of FL. Since this was not the primary focus of the research, limited numbers of 
samples were stained for FOXP3 (n=4) and formal quantification of the number of FOXP3pos cells and 
comparison to number of TFH has not been performed.  
 
Figure 3-42. FOXP3 is limited to T cells. FOXP3 = red, CD3 = green. FOXP3 is identified in a proportion of CD3+ 
T cells (green) at the follicular border and is never identified in non-CD3+ cells. (Image acquired with x60 






Figure 3-43 Distribution and phenotype of FOXP3pos cells in FL. FOXP3 = red, PD1 = white, ICOS = green, DAPI 
= blue. A. FOXP3pos cells are distributed mainly around the border of the follicle in a similar pattern to PD1 and 
ICOS but there are also scattered FOXP3pos cells in the interfollicular areas (acquired with x10 objective). B. The 
area in the white rectangle in A has been enlarged. Some FOXP3pos cells can be seen to express either ICOS or 
PD1.  
 
Co-staining with PD1, ICOS, and FOXP3 was next performed to determine if FOXP3pos cells co-
expressed either or both of PD1 and ICOS. Only 4 samples were stained with this combination and one 
stained sample was not analysable due to a high level of background signal. Results are therefore 
based on analysis of n=12 images from 3 samples. Analysis of FOXP3 images was performed manually.  
 
Figure 3-44 Phenotype of FOXP3pos cells in FL. FOXP3 = red, ICOS = green, PD1 = blue, PD1-ICOS intersection = 
pink. Separate binary layers of the same high power (x60) image of a FL follicle are shown in each panel. A, some 
ICOS+ (green) cells are seen to be FOXP3pos (red). B. some PD1Hi (blue) cells are FOXP3pos, but in C it can be seen 
that few FOXP3pos cells are dually positive for both PD1 and ICOS (pink).  
 
In FL, a median of 25% (6.0-28.0) of ICOS+ cells were positive for FOXP3, and a median of 4.0% (1.0 – 
8.0) of PD1+ cells were FOXP3pos. However, when the intersection binary layer of PD1 and ICOS was 
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created, it was found that only a very small proportion of dual positive PD-1+/ICOS+ cells were 
FOXP3pos, median 5%, (1.0 – 8.0), n= 3 FL samples, 12 images, Figure 3-44.  
Thus, whist PD1Hi FOXP3pos cells and ICOS+ FOXP3pos cells were relatively frequent, the majority of 
PD1Hi/ICOS+ cells were negative for FOXP3. This is supportive of the majority of PD1Hi ICOS+ T cells 
being TFH rather than Tregs.  
In the sections stained for FOXP3, PD1 and ICOS, it was noted there were some PD1+/ICOS+ cells 
adjacent to FOXP3pos cells, Figure 3-44. Too few sections have been stained and analysed with this 
combination to draw conclusions about this and line of enquiry requires further investigation to 
determine if FOXP3pos Tregs, may regulate TFH in FL as discussed in the introductory section 1.3.4. 
Similarly, when staining simultaneously for Ki67, PD1, and FOXP3 in 2 preliminary experiments we 
found that there appear to be some FOXP3pos cells in close proximity to Ki67pos cells, Figure 3-45.  This 
area also requires further investigation for example to determine if the ratio of TFH-Treg, or the 
proportion of Ki67pos cells in contact with TFH cells compared to Tregs is important in predicting 
prognosis in FL. This was beyond the scope of the current research but may be investigated further at 




Figure 3-45 FOXP3pos cells sometimes co-localise with Ki67pos cells in FL. FOXP3 = red, Ki67 = green, PD1 = white, 
DAPI = blue. A, some FOXP3pos cells can be seen to co-localise with Ki67pos cells in the area highlighted by the 
white rectangle. B. This area is magnified in B. C & D show the same images in the binary layers only (FOXP3 = 
red, Ki67 = green, PD1 = blue).  
3.8.2 Distribution and phenotype of FOXP3pos CD3+ T cells in reactive lymph nodes 
There was a notable difference in distribution of FOXP3 between FL and reactive LNs. In reactive LNs 
FOXP3pos cells were almost exclusively located outside of the GCs with very few located within GCs.  
Co-staining with PD1, ICOS, and FOXP3 was next performed to determine if FOXP3pos cells co-
expressed PD1 and ICOS in normal GCs. 3 reactive LNs were stained with this combination. 
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Within the GCs, there were too few FOXP3pos cells to generate meaningful data regarding the 
proportion of FOXP3pos cells co-expressing PD1 and ICOS but visual inspection revealed that no 
FOXP3pos PD1+ ICOS+ cells were identified within GCs, Figure 3-46.  
 
Figure 3-46. FOXP3 in reactive germinal centres. FOXP3 = red, PD1 = white, ICOS = green, DAPI = blue A. FOXP3 
is seen to be located almost exclusively outside the GCs. B. The same image as A showing only the FOXP3 binary 
layer (red) highlighting its exclusion from the GCs. C. Only the FOXP3 (red) binary and the intersection of 
PD1/ICOS (pink) are shown demonstrating their different distributions. D. At the border of this GC it can be seen 
that no PD1+/ICOS+ cells (pink) are FOXP3pos (red). (Images A, B, and C acquired with x10 objective. Image D 




3.9 Investigating the TCR repertoire of T cells in FL 
As described in the introduction, section 1.8, we hypothesised that, if the T cells within the malignant 
follicles of FL are present in response to antigen, there may be skewing of their TCR repertoire 
compared to those in the inter-follicular areas of FFPE LN biopsy specimens. The TCR repertoire of T 
cells in the FL microenvironment has not previously been reported.  
The methods for processing and dissecting sections, DNA extraction and sequencing of the TCRs are 
described in section 2.6. To briefly re-cap, it was first ascertained that genomic DNA could be extracted 
from archived FFPE LN specimens for TCR sequencing. Subsequently, the research question was 
refined to determine whether the TCR repertoire of T cells within the follicles was different to the TCR 
repertoire of interfollicular T cells.  
The methodology was influenced by the results of preliminary experiments and by the practical 
problems encountered in laser dissection as described in the methods chapter.  
3.9.1 Sequencing technique and calculation of clonality 
Next generation sequencing (NGS) of T-cell receptor β (TCR) repertoires and initial data analysis and 
processing were performed by Adaptive Biotechnologies, Seattle, USA (Robins, Campregher et al. 
2009). Additional analyses were performed by Dr Marta Pasikowska and Prof Stephen Devereux at 
KCL.  
Sequence reads were aligned to V, D and J sequences, insertions and deletions were identified and 
productive CDR3 sequences extracted. Clonotypes were considered significant if two or more copies 
of the same sequences were obtained, importantly, no clones of size n=1 (singletons) were reported.  
The degree of restriction of the TCR V repertoires was assessed using a clonality index which derives 
from Shannon’s entropy. This is a measure of the certainty with which the identity of a species selected 
randomly from a population of different species can be predicted, and is normalised for the number 
of productive sequences present. The calculation takes in to consideration, and accounts for 
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differences in the number of cells in different samples. In this research, although there were likely to 
be different numbers of T cells analysed in different areas of tissue dissected from the specimens, this 
is corrected for by expressing diversity as a function of the number of unique sequences present 
(Robins, Campregher et al. 2009, Sherwood, Emerson et al. 2013). 
The entropy calculation is influenced by both the total number of different species and the diversity 
of the population. A population or sample containing only one clone would have an entropy of 0 whilst 
a completely polyclonal population, in which all clones are equally frequent, would have a Shannon’s 
entropy equal to the logarithm of the number of unique sequences. To allow populations containing 
different numbers of unique clones to be compared, the entropy was normalized by dividing by the 
logarithm of the number of unique reads present. The clonality index corresponds to the reciprocal of 
the normalized entropy so that a monoclonal population gives a value of 1 and a polyclonal population 
0. 
3.9.2 TCR sequencing from whole LN sections 
In the preliminary experiment to ascertain the feasibility of DNA extraction and TCR sequencing from 
FFPE tissue (see section 2.6 above), 175ug/ul DNA was extracted from 2 separate FFPE LNs excised 
synchronously from a patient with newly diagnosed, untreated FL. The DNA was frozen and shipped 
to ImmunoSeq in Seattle, USA for NGS sequencing of the CDR3 TCRβ subunits.  
It is important to note that in this preliminary experiment, whole LN sections were used for DNA 
extraction and TCR repertoire analysis with no dissection performed. Analysis revealed 2806 unique 
TCR reads from lymph node 1, and 2989 unique reads from lymph node 2 with 152 sequences common 
to both lymph nodes, this is depicted in Figure 3-47 below. In this figure, sequences unique to LN1 are 
represented as green dots on the Y axis, with the frequency with which each clone occurs displayed 
on a logarithmic scale. Sequences unique to LN2 are represented as red dots on the x axis (with 
frequency of occurrence displayed on a logarithmic scale), and sequences found in both LNs are 
displayed as blue dots.  
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It can be seen that while most clones are unique to one of the LNs (green and red dots), there is a 
population found in both LNs, and many of these shared TCR sequences (blue dots) are present at high 
frequency in both LNs possibly indicating the presence of a population of antigen restricted T cells 
present in 2 separate lymph nodes biopsied simultaneously.   
 
Figure 3-47 Results of TCR sequencing from 2 lymph nodes biopsied simultaneously from a patient with newly 
diagnosed FL. On the Y axis, green dots represent, 2806 TCR sequences unique to LN 1 are shown. On the X axis, 
red dots represent 2989 TCR sequences unique to LN 2. Sequences found in both lymph nodes are represented 
by blue dots. Scales represent frequency of occurrence of sequences, displayed on a log scale.    
 
This provided preliminary evidence to support the theory that there may be TCR restriction in the T 
cells infiltrating lymph nodes in FL. However, as detailed above, this preliminary experiment did not 
distinguish between T cells located in the follicular and interfollicular compartments and led to the 
subsequent experiments examining differences in TCR repertoire between these compartments.      
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3.9.3 Comparison of TCR repertoire between follicular and interfollicular regions of FL 
Since we identified that the phenotype of the T cells within the follicles of FL was markedly different 
to those located in the interfollicular areas, and that interaction between TFH and proliferating FL B 
cells was restricted predominantly to the follicles, we next investigated if there was a difference in the 
TCR repertoire between these different compartments.  
Equivalent areas of tissue were laser dissected from follicular and interfollicular areas of 5 FL LN 
samples. Following refinements of the technique, an adequate yield of DNA was obtained using the 
method described in section 2.6.2 and Figure 2-9.  
There was no significant difference in the quantity of DNA extracted from follicular and interfollicular 
areas, mean 415µg (range 310-764µg). The DNA was frozen and shipped to ImmunoSeq in Seattle, 
USA for NGS of the CDR3 TCRβ subunits. 
The TCR repertoire of tissue dissected from the malignant follicles of FL was more restricted with 
greater clonality than the TCRs of the interfollicular areas in each of the 5 cases examined (median 
clonality of follicular areas 0.062, median clonality of interfollicular areas 0.049, Mann Whitney, p = 
0.0317), Figure 3-48A. This finding was consistent in all cases examined and suggests that the T-cells 
within neoplastic follicles are antigen restricted.  
As expected from their different phenotypes, the clonotypes present in the follicular and interfollicular 
areas of the same sample were markedly different with <20% overlap in all cases (median overlap 
0.16), indicating that the TCR repertoires of the follicular and interfollicular areas are different, Figure 
3-48B.  
When only the top 100 most frequent clones were considered, the difference between the follicular 
and interfollicular regions was especially marked with a predominance of more frequent clones in the 
follicles and very little overlap with the interfollicular areas.  
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These data indicate that high-frequency T-cell clones of restricted repertoire dominate the TCRV 
repertoire of neoplastic follicles in FL whereas the interfollicular regions contain more distinct clones 
occurring at lower frequency Figure 3-48C. 
 
Figure 3-48 Evidence of TCR restriction in FL. (A) The clonality of the TCRs in intrafollicular areas was higher than 
in the interfollicular compartment in all cases examined, horizontal bars represent mean of all samples. (B) The 
level of overlap of clonotypes between follicular and interfollicular compartments for all clonotypes in paired 
samples (overall) and for top 100 clonotypes (top 100), horizontal bars represent mean of all samples. (C) The 
frequency of the top 100 clonotypes in each sample from follicular (green dots) and interfollicular compartments 
(blue dots) are shown highlighting greater restriction in the follicular TCRs. Sequences present in both 
compartments are shown as red dots, very few sequences are present in both follicular and interfollicular areas 
(range 2-15) demonstrating that there is little overlap in repertoire between the two compartments. 
 
In order to look at this data another way, we next calculated the proportion of high frequency 
productive reads/clones in the follicular and interfollicular areas (Nazarov, Pogorelyy et al. 2015). 
Consistent with the previous analysis, this showed that compared to the interfollicular areas, the 
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follicular TCR repertoire was dominated by high frequency clones Figure 3-49. The top 50 most 
frequent clones made up a mean of 19% of all clones in the follicular areas (95% CI 17-21) compared 
to 9.8% (95% CI 6.1-13.4) in the interfollicular region (p=0.0002). 
 
Figure 3-49 Summary of TCR data showing the proportion of the total population accounted for by high 
frequency clones in the follicular (F) and interfollicular (IF) regions of FL lymph nodes. Each case is presented 
as a pair of column representing the follicular (F) and interfollicular regions (IF) side-by-side. In each case it can 
be seen that the follicular regions are dominated by larger populations of more frequently occurring clones 
(orange and red colours) whereas the interfollicular regions have higher proportions of low frequency clones 




Chapter 4 Discussion 
We have revealed a number of important and novel findings in this research that extend our 
understanding of the composition of the FL microenvironment and how a specialised subset of T cells, 
TFH, interact with the malignant cells.  We have also gained greater understanding of TFH in the normal 
GC reaction and in doing so have identified many parallels between FL and GCs.  
In this research we have demonstrated some powerful techniques that can be used on readily 
available, archived, formalin fixed paraffin embedded tissue sections. Coupled with this, we developed 
a unique semi-automated image analysis algorithm that permitted the detailed analysis of multiple 
images with minimal manual interference and therefore with reduced scope for operator error or bias. 
The techniques used in this research overcome some of the limitations of other approaches that have 
previously been used to study the microenvironment in FL and other lymphoproliferative disorders. 
The pivotal new findings generated in this research include the following: 
 TFH have been visualised in situ in FL and GCs for the first time using multi-colour 
immunofluorescent confocal microscopy that included simultaneous co-staining with BCL6, 
PD1, ICOS, and CD3. 
 Many similarities between the phenotype, proportion, and location of TFH were identified in 
FL and GCs indicating that TFH may play a similar role in the FL microenvironment as they do 
in GCs. 
  For the first time, a correlation between the number of TFH and the number of Ki67pos FL B 
cells was identified. Associated with this, a correlation between the number of TFH and 
histological grade was identified.  
 In GCs a very close spatial relationship between Ki67pos B cells and TFH was identified in the 
light zones for the first time and a correlation between number of TFH and number of Ki67pos 
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B cells was revealed supporting the theory that TFH control GC size and rate of B cell 
proliferation. 
 AIDpos Ki67pos B cells were found to be in close proximity to TFH suggesting that TFH may be 
important in regulating AID which could be important in the pathogenesis of FL or the 
development of histological transformation.  
 Contrary to previous reports of impaired synapse formation, we identified in situ evidence 
that TFH form immunological synapses with FL B cells.  
 The TCR repertoire of T cells in the FL microenvironment has not been previously studied. Our 
experiments in this area yielded fascinating insights that show TCR repertoire skewing in the 
follicular areas indicating that T cells within the follicles may be present in response to antigen.  
These and other findings are discussed in more detail below.  
 
4.1 Techniques used in this research: advantages, disadvantages and applicability 
One of the key and most widely applicable findings of this work is that multi-parameter confocal 
immunofluorescent microscopy can be performed on archived FFPE lymph node tissue sections 
without undue autofluorescence, and that quantitative analysis of the images acquired can be 
performed.  
This builds on research techniques developed in our laboratory over a number of years and has been 
refined to allow up to 4 antigens or proteins to be simultaneously labelled (Patten, Buggins et al. 2008). 
The semi-automated quantitative image analysis described in this thesis was developed specifically 
for this research and represents a significant advance over previous work using similar techniques and 
overcomes some of the difficulties of interpreting standard IHC (Sander, de Jong et al. 2014). 
Previous research has demonstrated that the microenvironment has a very important role in the 
pathogenesis of FL but when the composition of the microenvironment has been correlated with 
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prognosis, vastly disparate results have been reported from different groups (Lee, Clear et al. 2006, 
Glas, Knoops et al. 2007, Carreras, Lopez-Guillermo et al. 2009, Wahlin, Aggarwal et al. 2010, 
Richendollar, Pohlman et al. 2011).  
There are many reasons for these discrepant findings. One of the reasons for this disparity is the use 
of single parameter IHC in much of the published research which is not sufficiently sensitive to 
precisely define the subsets of cells implicated in the pathogenesis of the disease (Carreras, Lopez-
Guillermo et al. 2009, Wahlin, Aggarwal et al. 2010, Richendollar, Pohlman et al. 2011). This is 
highlighted in our research where 46.9% (34.7-51.9) of follicular CD4+ cells were positive for PD1, but 
only 52.2% (45.7-61.9) of these co-expressed ICOS. Therefore, if we had used non-quantitative PD1 
positivity as a surrogate marker for TFH cells we would have considerably overestimated the proportion 
of this important T cell subset. We occasionally had to use PD1 and CD4 alone to identify TFH but were 
able to set a very high threshold for PD1 in these instances (PD1Hi) and only used this method when 
specifically investigating T cells in direct contact with FL B cells which we had earlier identified to be 
predominantly TFH. 
One of the many reasons therefore for the disparity in the reported influence of PD1 expression on 
prognosis in FL is that it may be important to know not only how many cells in the microenvironment 
are PD1+, but more precisely, how many PD1Hi TFH are there in relation to incompetent, exhausted 
PD1+ T cells? Additional reasons for discrepant results include heterogeneously treated patient 
populations, and subjective interpretation of IHC (Sander, de Jong et al. 2014).  
Other high quality research into the FL microenvironment has used multiparameter flow cytometry 
on disaggregated lymph node samples (Pangault, Ame-Thomas et al. 2010, Ame-Thomas, Le Priol et 
al. 2012, Ame-Thomas, Hoeller et al. 2015). This powerful technique permits simultaneous labelling of 
numerous cell markers and therefore precise identification of T cell subsets can be performed, but a 
drawback to this approach is that it does not allow architectural information or cellular co-localisations 
to be assessed.  
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The technique that we developed and used therefore offers advantages over both standard IHC on 
tissue sections and flow cytometry on disaggregated LNs for investigating the lymphoma 
microenvironment.  
There were, however, some disadvantages to our technique. Firstly, the antibody panels were more 
limited than if using flow cytometry. Only 3 or 4 antibodies could be used simultaneously and all 
primary antibodies had to be raised in different species. Whilst 3-4 antibodies permits more 
sophisticated investigation of cellular subsets than single parameter IHC, we sometimes had to make 
compromises in selection of antibodies. For example, in some experiments CD3 had to be used as a 
surrogate for CD4, and in some circumstances we had to make assumptions based on earlier 
experiments, for example that PD1Hi cells in contact with FL B cells were TFH.  Again, the quantitative 
approach of the image analysis that we used compared to standard IHC lent validity to this approach. 
It was also found that some antigens were best detected in certain channels which had a bearing on 
which combinations of antibodies could be successfully combined. It was necessary to carry out 
regular control experiments to ensure that there was no tissue autofluorescence that could be 
misinterpreted as positive signal, spectral overlap, or non-specific binding of either primary or 
secondary antibodies.  
Acquisition time on the confocal microscope was long and expensive which is a potential barrier to 
using this technique more widely or on larger cohorts of samples. Similarly, whilst the semi-automated 
image analysis technique that we developed offered many advantages over the subjective analysis of 
IHC images, it was time consuming and labour intensive to set up, and there was still some scope for 
operator-bias for example at the stage of setting the binary layers.  
Another potential disadvantage of the research presented in this thesis is that it was performed on 
archived tissue from patients treated heterogeneously from a single centre over a number of years. 
This prevents meaningful application of the results to the population level. However, it will be possible 
for future research to be performed on tissue samples collected from patients enrolled in large 
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prospective clinical trials which will permit the investigation of correlations between the composition 
of the microenvironment and clinical outcomes in homogenous cohorts of patients treated with the 
same interventions.   
The latter part of this research, focusing on the TCR repertoire of T cells infiltrating the tumour 
microenvironment, also used novel techniques including laser dissection of FFPE samples, extraction 
of DNA from very small amounts of tissue and deep sequencing of the DNA obtained by this method. 
The results of this are further discussed below but, once again, this shows that valuable information 
can be obtained from archived FFPE tissue. This is important as FFPE tissue is the most common form 
in which diagnostic lymphoma biopsies are processed and stored, it is easy to store, does not 
significantly degrade over time, and is often routinely collected in clinical trials.  
It should however be noted that most of the samples that we analysed were from whole lymph node 
excisions. A few core biopsies were analysed by confocal fluorescent microscopy and whilst they 
yielded adequate results they were not as good as whole sections and not as many whole follicles per 
specimen could be inspected. We did not attempt DNA extraction from core biopsies. There is an 
increasing tendency to use core biopsies for the diagnosis of lymphoma in the UK which can have 
significant clinical and patient-centred benefits over whole node excisions but, since they yield smaller 
tissue volumes, they may not be as valuable for correlative translational research. This is an area that 
we need to consider as a research and clinical community.      
4.2 TFH in GCs and the FL microenvironment 
FL is derived from GC B cells and in this research we have demonstrated some important similarities 
between normal GCs and the follicles of FL especially with regards to the presence of TFH cells and 
their close spatial relationship with proliferating B cells.  
We found that 25.0% (18.5-28.7) of CD4+ T cells within the follicles co-express the surface markers 
PD1 and ICOS and, in separate sections have shown that these cells are positive for the transcription 
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factor BCL6, the chemokine receptor CXCR5, and negative for the transcription factors FOXP3 and 
TBET. These can therefore be considered with a high degree of certainty to be TFH cells.  
Their proportion, relative to the total number of CD4+ T cells was not significantly different from GCs 
of reactive lymph nodes where 33.05% (24.7-43.7) CD4+ cells were TFH. In the interfollicular regions, 
where the majority of T cells in a lymph node are located, very few had a TFH phenotype, 3.63% (1.89-
6.15); which was significantly higher than in the non-GC areas of reactive lymph nodes although the 
proportion was very low in both cases. One reason for the slightly higher proportion of inter-follicular 
TFH cells in FL than in reactive LNs may have been because it was sometimes difficult to accurately 
delineate the follicular border in FL whereas the border of GCs was very clear in reactive LNs.  
Of note, we made a comparison with the proportion of TFH in CLL and whilst there were many PD1+ T 
cells in CLL, very few T cells dually expressed ICOS and PD1 and the proportion of TFH was significantly 
lower than in either FL follicles or GCs. This highlights the need to use more than one antibody to 
identify TFH and demonstrates that PD1 expression on T cells in CLL is likely to be due the presence of 
exhausted T cells rather than functional TFH.  
Although the proportion of TFH was not different between FL follicles and GCs, their distribution was 
different; in GCs there was clear demarcation between the dark and light zones with most TFH found 
in the light zones or at the interface between dark and light zones. In FL meanwhile the TFH were often 
in a peri-follicular pattern or sometimes distributed throughout the follicles. The distribution of TFH in 
FL was later shown to mirror the distribution of Ki67pos tumour cells.  
Thus, although are many striking similarities between follicles of FL and normal GCs, the lack of zonal 
demarcation in FL is a clear difference. The reasons for this difference and its implication is not clear 
at present but warrants further investigation.  
TFH have previously been reported to constitute 24-35% of all CD4+ T cells assessed by flow cytometry 
in whole disaggregated FL lymph nodes (Pangault, Ame-Thomas et al. 2010, Ame-Thomas, Le Priol et 
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al. 2012, Myklebust, Irish et al. 2013). Given that we identified that 25% of CD4+ T cells within the 
follicles were TFH and very few TFH were present in interfollicular areas where there are proportionally 
more CD4+ T cells, this translates to a lower proportion of TFH in the lymph node as a whole in our 
research than the previous reports but, the use of different techniques makes it difficult to make direct 
comparisons.  
The authors of previous research identified a significantly lower proportion of TFH in whole reactive 
lymph nodes than in FL lymph nodes which led them to conclude that FL nodes are enriched by TFH 
relative to normal reactive LNs. However, this did not account for the extensive contribution of 
interfollicular tissue in whole disaggregated nodes. In our research, in the interfollicular area of 
reactive nodes <1% of CD4+ T cells were TFH and this area is more extensive than the corresponding 
interfollicular component of FL where the lymph node is effaced by large follicles with relatively less 
interfollicular tissue than reactive LNs. This will therefore have caused an underestimate of the 
proportion of T cells with a TFH phenotype located specifically within the GCs in the previous research 
leading to their conclusion that TFH are enriched in FL compared to reactive LNs (Ame-Thomas, Le Priol 
et al. 2012). Conversely, one of the novel findings of our research, only possible due to the techniques 
used, was the findings that there was no significant difference in the proportion of TFH within FL 
follicles and reactive GCs. This suggests that this important feature of normal GCs is recapitulated in 
the follicles of the FL microenvironment.  
Thus, our findings add to previous research into TFH in both FL and GCs. We confirm their presence 
and phenotype which is broadly in keeping with the studies performed by flow cytometry yet we add 
to these findings by being able to describe their distribution with regard to the follicles and, as 
discussed below, their interactions with other cells. 
4.2.1 Image analysis for identifying TFH 
Although our method of image analysis is robust and has many advantages over traditional IHC image 
analysis, there were disadvantages to it too.  
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We developed a technique that measured the total area of CD4 positivity and then calculated the 
proportion of this area that had co-expression of one or more antigens (e.g. PD1 and ICOS) as defined 
by the binary layers. Once the binary layers were established, this technique was fast and reliable and 
not subject to user bias or interference, but we were limited to describing the proportion of the CD4+ 
area that co-expressed other antigens rather than the absolute number of cells.  
However, we validated this approach by demonstrating that results of the ‘area’ based analysis were 
not significantly different to a semi-automated, cell-based ‘object’ analysis. ‘Object’ analysis was a 
more operator-dependent, time consuming approach that was open to more user bias. One reason 
for the difficulty in using an automated ‘object’ based image analysis approach to define the number 
of CD4+ cells expressing different antigens is the membrane pattern of CD4 staining which makes it 
difficult to automatically count individual cells when packed closely together in a tissue section. This 
problem was not encountered when Ki67pos cells were counted as this is a nuclear stain and it is easier 
for the automated analysis software to count individual cells with a nuclear stain than when they are 
only defined by their membranes.  
Developing the image analysis approach further to include a reliable measure of actual cell counts 
would be an important advance if this approach is to be used in larger cohorts of patients to 
investigate a prognostic tool.  
4.3 Co-localisation between Ki67pos cells and TFH in GCs and FL  
It is known that TFH are vital in providing B cell help in the GC reaction where they are implicated in 
promoting SHM, differentiation to memory or plasma cells, and B cell proliferation (Fazilleau, Mark et 
al. 2009). However there is a scarcity of published research detailing the phenotype and location of 
TFH in situ in normal human GCs. 
Previous studies of TFH in FL have identified that they express high levels of IL-4 which may promote B 
cell survival through phosphorylation of STAT6. Furthermore, in vitro work has demonstrated that co-
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culture of FL B cells with TFH cells rescued them from apoptosis (Pangault, Ame-Thomas et al. 2010, 
Ame-Thomas, Le Priol et al. 2012).  
The interaction of TFH with tumour cells in situ has not previously been investigated.   
In this work we identified that TFH and Ki67pos B cells have a similar pattern of distribution in FL and we 
demonstrated for the first time an extraordinarily close association between Ki67pos B cells and TFH. 
We found that 40% of Ki67pos CD20+ B cells are in direct contact with one or more TFH, and many more 
are in very close proximity to TFH although not in direct contact as calculated using our strict, 
automated image analysis algorithm. This suggests that the TFH may be directly providing a pro-tumour 
signal, perhaps inducing or supporting FL B cell proliferation.  
Interestingly, we found that in cases with high proliferation (Ki67) there were more TFH with a strong 
correlation between the two, and proportionately more TFH were identified as histological grade 
increased. In addition, CD20+ FL B cells were significantly more likely to be in contact with TFH if Ki67pos 
than if Ki67neg in each case examined meaning that the co-localisation between TFH and proliferating 
FL B cells was unlikely to be due to chance. These findings are further evidence to support the theory 
that TFH are important in driving FL B cell proliferation.   
We hypothesised that in higher grade FL (grade 3a / 3b), proliferation would be less dependent on T 
cell help, perhaps due to additional genetic events intrinsic to the tumour cells driving proliferation in 
more aggressive disease. Interestingly however, we identified that the close spatial association 
between Ki67pos cells and TFH was present in grade 3a and 3b FL as well as in grade 1-2 disease. The 
degree of co-localisation between TFH and Ki67pos B cells remained relatively constant as grade and 
Ki67 increased suggesting that support from the microenvironment in the form of TFH help remains 
important even in more histologically aggressive disease. 
Importantly, we also assessed co-localisation between TFH and Ki67pos B cells in GCs and this work 
represents one of the most detailed assessments of such co-localisation in GCs to date. In GCs a 
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marked difference between the light and dark zones was observed. In the dark zones, where 
proliferation is very high, there were few TFH and little interaction or co-localisation was identified. 
However, in the light zones 63.1% of Ki67pos cells were in contact with TFH. As in FL, there was a 
correlation between rate of proliferation and the number of TFH. Similarly, CD20+ B cells were 
significantly more likely to be in contact with TFH if they were Ki67pos. These findings support the theory 
that TFH are vital in the GC reaction and that GC size is determined by the availability of TFH help (Allen, 
Okada et al. 2007, Rolf, Bell et al. 2010).  
If GC B cell proliferation is dependent on TFH help then it is interesting to consider why the spatial 
correlation is limited to the light zones where the rate of cellular proliferation is lower. There is now 
good evidence from multiphoton imaging in live animal models that GCs are dynamic environments 
with movement of B and T cells in and out of the GCs (Victora and Nussenzweig 2012). The images 
presented here are therefore a static representation of this highly dynamic process and it is possible 
that B cells receive their signal to start proliferating in the light zone under the influence of TFH help 
which is then TFH independent when the B cells migrate to the dark zone. This is highly speculative and 
is an area for possible further work especially since we have identified that proliferation – as indicated 
by Ki67 – is not limited to the dark zones.  
Although there has been much work in recent years using very advanced imaging techniques to 
investigate the GC reaction (Victora and Nussenzweig 2012), to the best of our knowledge this is the 
first time that this close association between TFH and Ki67pos B cells has been demonstrated in GCs in 
human tissue.  
The close association between CD20+ GC B cells and TFH in the light zones therefore represents a 
significant finding that supports previous work that suggests TFH are important in driving GC B cell 
proliferation and GC size. 
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4.3.1 Method of analysing co-localisation  
Automated image analysis for assessing co-localisation was essential to the success of this part of the 
research. The nuclear pattern of Ki67 staining made it relatively easy to automatically identify Ki67pos 
cells and we developed a system that automatically calculated the number of Ki67pos cells that 
overlapped with TFH (defined in different experiments as either CD4+/PD1Hi or ICOS+/ PD1Hi). The only 
situation in which this method was not successful was in the dark zones of GCs where there were too 
many tightly packed Ki67pos cells for the software to automatically detect individual cells.   
Whilst quadruple labelling experiments allowed us to confirm that the Ki67pos cells were CD20+, the 
image analysis software was unable to define individual CD20+ cells due to the extraordinarily high 
number of tightly packed CD20+ cells in both FL follicles and GCs and the membrane pattern of CD20 
staining. The assessment of whether CD20+ B cells were more likely to be in direct contact with TFH if 
Ki67pos than if Ki67neg was hampered by this difficulty and we had to resort to manual, visual 
assessment of this according to a strict method and using 2 investigators blinded to each other’s 
results to reduce the influence of operator bias in this analysis.  
4.3.2 Co-localisation between Ki67pos B cells and TFH: interpretations and drawbacks 
These findings highlight that the number of TFH and the availability of TFH help to FL B cells may be 
critical in determining the rate of B cell proliferation in FL as they are in the normal GC reaction.  
Further work is necessary to investigate this important observation in greater detail as it is conceivable 
that accurately assessing the number if TFH in FL may have prognostic importance and interrupting the 
interaction between these cells may be a viable therapeutic target.   
The nature of our research was observational and, whilst one of the strengths is that this is the first 
time that these interactions have been visualised in situ in human tissue, one of the drawbacks is that 
we can’t be sure that TFH are really driving B cell proliferation. An alternative interpretation of these 
findings could be that the number of TFH is determined by the rate of proliferation and that TFH are 
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attracted to proliferating B cells rather than that the rate of proliferation is determined by the 
availability of TFH help as we have hypothesised.  
Given that other groups have reported pSTAT6 expression in FL B-cells following exposure to TFH 
derived IL-4, we performed some experiments to see if we could demonstrate pSTAT6 in FL B cells 
that were in close contact with TFH (Pangault, Ame-Thomas et al. 2010). Unfortunately the pSTAT6 
antibodies available did not work well with the multiple labelling immunofluorescent method and we 
were unable to reliably identify pSTAT6pos cells – data not shown.  
An investigation into the feasibility of performing co-culture studies to research the impact of TFH on 
B cell proliferation and survival was beyond the scope of this research project, available funding, and 
patient material. However, the results of the work presented in this thesis have led to the generation 
of grant income for a subsequent student to perform these further studies.  
4.4 Clinical correlations 
We did not investigate associations between clinical features or outcome and either the proportion 
of TFH or the degree of co-localisation as the small number of patients included in this study and the 
heterogeneous nature of the cohort meant that it was beyond the scope of the current research. 
4.5 Demonstration of synapse formation between TFH and Ki67pos FL B cells 
It has been previously reported that tumour infiltrating T cells in FL form impaired synapses with FL B 
cells compared to healthy B cells and that PD1+ T cells in FL are globally dysfunctional with impaired 
response to cytokines (Ramsay, Clear et al. 2009, Myklebust, Irish et al. 2013).  
Given the close proximity between TFH and proliferating FL B cells and the correlation between them 
that we revealed, we investigated if we could identify evidence of synapse formation between these 
cells in FFPE tissue.  
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We attempted to identify molecular components of the cSMAC or pSMAC that constitute the 
immunological synapse (PKC-θ, f-actin and LFA-1) but this proved technically difficult and staining was 
not of sufficiently good enough standard to enable analysis - data not shown. We did however identify 
morphological features that strongly suggest the formation of immune synapses between TFH and 
proliferating B cells in FL.  
Morphological findings included overlapping of B- and T cell membranes, distortion of the T cell nuclei 
away from the point of cell contact and the presence of T cell ‘processes’ that encompass Ki67pos B 
cells. Furthermore, we developed and employed a highly innovative method of formally quantifying 
cell surface expression of CD4, PD1 and ICOS. This demonstrated significantly higher levels of 
expression at the pole of cell contact than at the opposite pole which strongly suggests polarisation 
of the membrane and synapse formation.  
It is intriguing to consider why our results should be discrepant with previous reports of impaired 
synapse formation (Ramsay, Clear et al. 2009, Myklebust, Irish et al. 2013). One explanation is that, as 
demonstrated in our work there are likely to be at least 2 subsets of CD4+ PD1+ cells; 
CD4+/PD1+/ICOS+ TFH cells and CD4+/PD1+/ICOS- cells, the latter of which may perhaps represent 
dysfunctional or exhausted T cells, this is supported by the work of others (Ame-Thomas, Hoeller et 
al. 2015, Yang, Grote et al. 2015).  It is possible that the TFH are able to form synapses with FL B cells 
and provide them with a survival or proliferative advantage, meanwhile, the exhausted T cells may be 
dysfunctional and unable to form normal synapses.  
Another explanation is that the previous work describing impaired synapses was performed in an 
artificial experimental model that bears little resemblance to the human physiological state. One of 
the advantages of our research is that it was performed in situ on human tissue. The results can’t 
therefore be ignored and the dogma that T cells in the lymphoma microenvironment form impaired 




Unfortunately, one of the disadvantages of the work presented in this thesis is that we were unable 
to undertake the same quantitative analysis of synapse formation in normal GCs due to technical 
difficulties as described in the results section 3.5. Despite being unable to perform quantitative 
assessments in GCs, very similar morphological features suggesting immune synapse formation were 
identified in GCs.  
4.6 Expression of AID in Ki67pos B cells in contact with TFH 
It is known that AID is important in the pathogenesis of the GC derived lymphomas including FL and 
has also been implicated in histological transformation. The mechanism by which AID plays a role in 
lymphomagenesis is thought to be through inducing the accumulation of additional mutations as B 
cells - that are resistant to apoptosis due to the t(14;18) translocation - undergo repeated GC reactions 
during which they are exposed to the DNA modifying enzyme AID (Pasqualucci, Bhagat et al. 2008, 
Roulland, Sungalee et al. 2013, Pasqualucci, Khiabanian et al. 2014).  
In this research we demonstrated that AID is expressed predominantly in proliferating B cells in FL and 
for the first time that these cells are often found to be in close contact with PD1Hi T cells. Limitations 
of our antibody panels meant that we were unable to confirm that the PD1Hi T cells in contact with 
AIDpos Ki67pos were TFH in the same sections but earlier results suggest that these are very likely to be 
TFH. 
Although this aspect of the work is limited by low numbers of specimens assessed with this 
combination of antibodies, the spatial relationship between AIDpos Ki67pos B cells and TFH in FL is striking 
and suggests that TFH may induce AID expression in FL B cells as they are proposed to do in normal GC 
B cells where it is essential for CSR and SHM. 
It can therefore be hypothesised that interaction between TFH cells and B cells is important in the 
pathogenesis of FL by inducing the expression of the DNA modifying enzyme AID, off-target action of 
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which may contribute to the accumulation of additional mutations necessary for the disease to 
develop, progress and undergo histological transformation.   
4.7 FOXP3pos T cells in FL and GCs 
The primary focus of our research was to describe the phenotype, distribution and possible roles of 
TFH in FL. As part of the work to define the phenotype of these cells it was necessary to demonstrate 
that the cells that we identified as TFH did not express FOXP3, the transcription factor associated with 
Tregs. Additionally, since FOXP3+ TFR cells with an immunophenotype between that of TFH and Tregs have 
been described in FL, it was important to ascertain if we could identify these cells using the techniques 
we developed (Linterman, Pierson et al. 2011, Ame-Thomas, Le Priol et al. 2012).  
Whereas TFH distribution was very similar between GCs and FL – with the exception that there was 
zonal demarcation between the dark and light zones in GCs – it was found that FOXP3pos T cell 
distribution was quite different between FL and normal LNs. In FL, FOXP3pos T cells were found within 
the follicles predominantly in a perifollicular distribution similar to TFH, in reactive LNs meanwhile, 
there was a striking absence of FOXP3pos cells from the GCs with the FOXP3pos T cells instead located 
mainly in the interfollicular areas.  
In FL, although a high proportion of FOXP3pos T cells were positive for ICOS (25%), triple positive PD1Hi, 
ICOS+, FOXP3pos that may represent TFR were rare (5% of all CD4+ T cells). This confirms that most 
PD1Hi ICOS+ CD4+ T cells are indeed TFH and that there is a small population of TFR in the FL 
microenvironment, additional antibodies including anti-CD25 would need to be used to further 
characterise and quantify these cells.     
Intriguingly, in the few samples stained with this combination of antibodies (n=3), it was noted that 
FOXP3pos cells were sometimes located in close proximity to PD1Hi ICOS+ T cells, i.e. in close proximity 
to TFH. Additionally, 2 sections were stained with the FOXP3, Ki67, PD1 combination and some FOXP3pos 
cells were noted to be in contact with Ki67pos cells. We were unable to investigate these interesting 
175 
 
findings further but given that TFR cells are reported to regulate TFH function, this is an area that 
requires further study in this disease as well as in other diseases where both TFH and TFR are present.  
Others have proposed that it is the balance of different cells in the tumour microenvironment that 
may impart prognostic significance (Ame-Thomas and Tarte 2014). It is possible that the balance 
between TFH and TFR, or the spatial relationships between these CD4+ T cells subsets with regards to 
each other and in relation to tumour cells is important. This area requires more study and the 
techniques that we have described herein are ideally suited to taking this forward.  
4.8 PD-L1 expression 
Reliable IHC staining for the main ligand of PD1, PD-L1 has been difficult to achieve with reports of 
variable staining in the literature (Hawkes, Grigg et al. 2015, Gibney, Weiner et al. 2016). We sourced 
an anti-PD-L1 antibody that worked reliably with our immunofluorescent technique. Despite PD1 
being expressed highly on the surface of TFH cells in direct contact with tumour cells and evidence of 
concentration of this protein at points of cell contact, we were unable to identify high levels of PD-L1 
expression on the surface of the Ki67pos tumour cells that were in contact with TFH.  
This is in keeping with the findings of others who have not identified PD-L1 expression on FL tumour 
cells unlike in Hodgkin Lymphoma, some subtypes of DLBCL and other EBV-driven lymphoproliferative 
disorders, especially those with the 9p24 mutation, which have high PD-L1 expression on the tumour 
cells (Green, Rodig et al. 2012, Hawkes, Grigg et al. 2015).   
In diseases in which PD-L1 is upregulated on the tumour cells, this is proposed to be a mechanism by 
which the tumour can subvert its microenvironment into suppressing the anti-tumour immune 
response so conferring a survival advantage for the tumour cells (Hawkes, Grigg et al. 2015). In FL 
however, PD1 is expressed highly on TFH as demonstrated in this research. We do not fully understand 
the role of PD1 expression in normal TFH cells at present but it has been speculated that it’s role is to 
regulate the number of TFH as, in the absence of PD1 expression, TFH cells could potentially proliferate 
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uncontrollably on stimulation which could lead to an exaggerated immune response (Crotty 2014). 
Additionally, there are other ligands for PD1 including PD-L2 and, theoretically at least, there may be 
others that are not yet identified to which PD1 may bind.  
Thus PD-L1 may not have been identified on the proliferating cells for a number of reasons: it may 
genuinely not be present, there may be an alternative ligand to PD1 on the proliferating cells, or the 
assay may have been insufficiently sensitive to detect PD-L1 at low levels by the immunofluorescent 
technique.  
Recognising that PD1 is highly expressed on TFH in FL and that PD-L1 is not present on the malignant 
cells with which the TFH are interacting are important observations as we enter the era of immune 
checkpoint inhibition with drugs that block the PD1 PD-L1 axis.  
Whilst blocking PD1 on exhausted tumour infiltrating T cells may reduce or reverse tumour-mediated 
immune suppression, we also need to consider the effect of PD1 blockade on PD1Hi tumour infiltrating 
TFH. There is a lack of experimental data to describe what happens to the number of TFH when PD1 is 
blocked. If, as described above, PD1 expression by TFH reduces their proliferation, blockade of PD1 
may lead to a rise in TFH number in FL which may in turn lead to tumour flare if, as postulated in this 
research, they provide the tumour cells with a proliferative advantage. The techniques described in 
this thesis would be a valuable tool to investigate this.   
This hypothesis (that PD1 inhibition may in some instances lead to tumour progression through 
expansion of TFH number) is not supported by the provisional early phase clinical trial data that 
demonstrated some evidence of activity of PD1 inhibition in FL (Westin, Chu et al. 2014). Correlative 
studies using biopsies pre- and during treatment will be essential to answer this question. Intriguingly, 
new data on the drug Pidilizumab now suggests that it does not in fact act by blocking PD1, and 
development of this drug is on hold while its mechanism of action is further defined, there is therefore 
very little clinical data on the use of PD1 inhibition in FL. Furthermore, given the lack of PD-L1 
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expression on the tumour cells, it is uncertain whether PD-L1 inhibition – which has been 
demonstrated to be a useful therapeutic approach in some solid organ malignancies and in Hodgkin 
Lymphoma (Hawkes, Grigg et al. 2015, Ansell 2016) - will be beneficial in FL although it should be 
noted that PD-L1 expression does not always correlate with the clinical efficacy of these drugs (Gibney, 
Weiner et al. 2016).     
4.9 The T cell receptor repertoire in FL 
We have demonstrated that the TCR repertoire of T-cells within the follicles of FL is significantly more 
restricted than that of interfollicular T-cells and that, as expected from their different phenotypes, 
there is little repertoire overlap between these two compartments. These findings suggest that, within 
the neoplastic FL follicles there is an antigen-driven oligoclonal expansion of T-cells. There is no 
published literature on the TCR repertoire in FL, however, restricted repertoires have been reported 
in colonic cancer where little overlap between normal and neoplastic tissue was identified (Sherwood, 
Emerson et al. 2013). 
This part of the work suffered from technical challenges that firstly had to be overcome. The main 
challenge was in capturing adequate amounts of tissue using the laser capture microscope. As a result 
of the difficulties experienced with this we had to adapt our research questions and techniques. It 
would have been informative to compare the TCR repertoire of two distinct follicles within the same 
LNs for example but it wasn’t possible to extract sufficient DNA from individual follicles to do this. 
Furthermore, we captured areas of tissue containing many different subtypes of T cells rather than 
selecting only TFH. This was a limitation of the technique that we used but it would be possible to form 
cell suspensions from fresh LN biopsies or FNAs and perform cell sorting to investigate the TCR 
repertoire of the TFH only. If we used this technique however, it would be difficult to investigate 
differences in clonality between follicles unless a patient had more than one lesion amenable to biopsy 
at the same time.  
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Another limitation of the TCR repertoire studies is that, although we compared similar areas of tissue 
in each comparison, the number of T cells, and in particular the number of TFH will have varied between 
samples. This was accounted for in the calculations used to determine clonality and although cell 
numbers analyzed differed between samples, the fact that follicles contained consistently fewer, 
larger clones and inter-follicular areas contained a larger number of smaller clones suggests that these 
differences were real.  
PCR-based analysis of TCR repertoire also suffers from the limitation that errors introduced during 
amplification may lead to apparent skewing of the repertoire (Best, Oakes et al. 2015). Whilst it is not 
possible to completely exclude this possibility, we minimized the risk by direct, intra-patient 
comparison in the same assay runs, and our findings were consistent in all cases studied. 
This is the first time that the TCR repertoire of T cells infiltrating the FL microenvironment has been 
studied and as such represents preliminary evidence that there is an antigen-driven T-cell response in 
FL. This is a novel finding that poses many questions about the pathogenesis of the disease.  Further 




4.10 Final summary and implications  
In summary, we used multicolour confocal immunofluorescent microscopy to define CD4+ T cell 
subsets in the FL microenvironment and made comparisons with GCs in reactive lymph nodes.  
TFH cells were present in equal proportions in the follicles of FL as in GCs and were tightly restricted to 
the follicles and GCs. There was marked zonal demarcation in GCs with the TFH cells mostly present in 
the light zones, in FL follicles however this zonal demarcation was lost.  
We identified a remarkable co-localisation between TFH and Ki67pos B cells in both the follicles of FL 
and light zones of GCs. The observation that CD20+ B cells were significantly more likely to be in 
contact with a TFH if Ki67pos means that this co-localisation is unlikely to be due to chance, and together 
with the evidence that the number of TFH is correlated with Ki67 in both FL and GCs, suggests that TFH 
have a pivotal role in supporting B cell proliferation in both situations. In addition, we identified that 
TFH are co-localised with AIDpos B cells in FL suggesting that they may also contribute to 
lymphomagenesis through the induction of AID which may lead to the acquisition of additional 
mutations. Finally, we revealed for the first time provisional evidence of antigen restriction amongst 
the tumour infiltrating T cells.  
The results of this research come at an important time. There is much interest in immune checkpoints 
and their inhibition in the treatment of solid organ malignancies and lymphomas. Our findings 
highlight the complexity of PD1 expression in FL. To understand how best to use new treatments that 
block PD1 in FL, a greater understanding of which cells express it and its ligands is required This 
research goes some way to understanding why PD1 inhibition in FL may be more complex than in 
other malignancies. 
There is an unmet need for novel biomarkers in FL to allow us to better predict outcome and to identify 
which patients stand to benefit most from particular therapeutic strategies. Whilst we have not 
identified a prognostic biomarker in the research performed to date, we have developed a technique 
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that may be used to do so in future studies. Given their apparent importance in FL as in GCs, accurate 
quantification of TFH, their location and proportion relative to other T cell subsets (e.g. TFR) may have 
prognostic value and interrupting the interaction between TFH and FL B cells may be a useful 




4.11 Areas for future work 
Building on the work presented in this thesis, suggested areas for future work include the following: 
 Conduct similar work on a larger cohort of patients treated homogeneously in a clinical trial 
and develop the image analysis protocol to calculate actual cell counts (rather than 
proportions) and compare numbers of TFH with Tregs in the same specimens to ascertain if this 
has prognostic significance.  
o This could be performed on samples from patients enrolled in the UK ‘Watch and 
Wait’ trial in which patients were randomised to rituximab only or observation.  
o It would be informative to investigate differences in composition of the CD4+ 
compartment of patients in the observation arm who never required treatment 
compared to patients who progressed rapidly. 
 Further analyse interaction of FOXP3pos T cells with TFH and with proliferating B cells in FFPE 
tissue using the techniques described in this thesis.  
 In trials of PD1 / PD-L1 inhibitors,  utilise the experimental approach detailed in this thesis to 
investigate pre- and post- (or during) therapy co-localisation of PD1+ cells to malignant cells 
and ascertain if TFH number changes while on PD1 inhibitor therapy 
o These experiments will be necessary to determine which patients stand to benefit 
most from immune checkpoint inhibition 
o This is important given the theoretical possibility of causing an expansion in TFH 
number through PD1 inhibition which could in turn lead to tumour flare in some cases.  
 It would be very informative to validate the findings presented in this thesis by investigating 
in in vitro co-culture systems whether rate of FL B cell proliferation is determined by the 
presence of TFH.  




o Is the TCR repertoire of GCs more restricted than that of the inter-follicular area of 
reactive LNs as we found in FL? 
o Compare the TCR repertoire of PB with that of the follicular and interfollicular areas 
in FL.  
o Identify patients who have had multiple biopsies during the course of their disease 
and investigate if the TCR repertoire changes over time. Make simultaneous 
comparisons with peripheral blood TCR repertoire.  
o Future work could also make use of fine needle aspirates or fresh disaggregated lymph 
nodes which would permit the sorting of cells according to phenotype and may permit 
specific assessment of the TCR repertoire of TFH cells to determine if it is these cells 
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